# Hormonal systems: All cancers



| | | | | Overactive thyroid (E.1/E.1)[1] | | Underactive thyroid (E.2/E.2)[1] | | Thyroid nodules (E.3/E.3)[1] | | Thyroid enlargement (E.4/E.4)[1] | | Diabetes-diet (E.5/E.5)[1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **25725** | **459** | **1.8** | **2648** | **10.4** | **600** | **2.4** | **624** | **2.4** | **330** | **1.3** |
| | **Age at baseline** | <18 | 5688 | 44 | 0.8 | 382 | 6.8 | 32 | 0.6 | 45 | 0.8 | 33 | 0.6 |
| | | 18-19 | 2152 | 24 | 1.1 | 162 | 7.6 | 27 | 1.3 | 32 | 1.5 | 15 | 0.7 |
| | | 20-24 | 6024 | 87 | 1.5 | 523 | 8.8 | 91 | 1.5 | 120 | 2.0 | 63 | 1.1 |
| | | 25-29 | 5571 | 110 | 2.0 | 613 | 11.1 | 130 | 2.4 | 162 | 2.9 | 86 | 1.6 |
| | | 30-34 | 3885 | 121 | 3.1 | 539 | 14.0 | 157 | 4.1 | 128 | 3.3 | 73 | 1.9 |
| | | 35+ | 2405 | 73 | 3.1 | 429 | 18.0 | 163 | 6.9 | 137 | 5.8 | 60 | 2.5 |
| | **Years since diagnosis** | 5-9 | 2592 | 25 | 1.0 | 176 | 6.8 | 10 | 0.4 | 25 | 1.0 | 14 | 0.5 |
| | | 10-14 | 8345 | 123 | 1.5 | 820 | 9.9 | 107 | 1.3 | 133 | 1.6 | 81 | 1.0 |
| | | 15-19 | 8211 | 156 | 1.9 | 858 | 10.5 | 193 | 2.4 | 209 | 2.6 | 86 | 1.1 |
| | | 20+ | 6577 | 155 | 2.4 | 794 | 12.2 | 290 | 4.5 | 257 | 4.0 | 149 | 2.3 |
| | **Age at diagnosis** | <1 | 1933 | 13 | 0.7 | 105 | 5.5 | 17 | 0.9 | 17 | 0.9 | 24 | 1.2 |
| | | 1-4 | 8297 | 96 | 1.2 | 620 | 7.5 | 118 | 1.4 | 138 | 1.7 | 71 | 0.9 |
| | | 5-9 | 5790 | 102 | 1.8 | 591 | 10.3 | 133 | 2.3 | 149 | 2.6 | 70 | 1.2 |
| | | 10-14 | 5453 | 135 | 2.5 | 645 | 11.9 | 168 | 3.1 | 167 | 3.1 | 88 | 1.6 |
| | | 15-20 | 4252 | 113 | 2.7 | 687 | 16.2 | 164 | 3.9 | 153 | 3.6 | 77 | 1.8 |
| | **Treatment** | Surgery only | 2169 | 25 | 1.2 | 70 | 3.2 | 11 | 0.5 | 24 | 1.1 | 16 | 0.7 |
| | | Chemotherapy, no radiation | 8166 | 77 | 0.9 | 302 | 3.7 | 79 | 1.0 | 115 | 1.4 | 97 | 1.2 |
| | | Radiation, no chemotherapy | 2086 | 63 | 3.1 | 474 | 23.0 | 112 | 5.4 | 86 | 4.2 | 12 | 0.6 |
| | | Chemotherapy and radiation | 10806 | 243 | 2.3 | 1611 | 15.0 | 358 | 3.3 | 357 | 3.3 | 177 | 1.6 |
| | | Unknown | 2498 | 51 | 2.1 | 191 | 7.7 | 40 | 1.6 | 42 | 1.7 | 28 | 1.1 |
| **Males** | **All cases** | | **13753** | **224** | **1.6** | **1212** | **8.9** | **175** | **1.3** | **215** | **1.6** | **134** | **1.0** |
| | **Age at baseline** | <18 | 3065 | 33 | 1.1 | 224 | 7.4 | 15 | 0.5 | 24 | 0.8 | 15 | 0.5 |
| | | 18-19 | 1122 | 8 | 0.7 | 91 | 8.2 | 14 | 1.3 | 14 | 1.3 | 9 | 0.8 |
| | | 20-24 | 3170 | 40 | 1.3 | 260 | 8.2 | 28 | 0.9 | 39 | 1.2 | 23 | 0.7 |
| | | 25-29 | 3091 | 59 | 1.9 | 291 | 9.5 | 47 | 1.5 | 63 | 2.1 | 33 | 1.1 |
| | | 30-34 | 2072 | 47 | 2.3 | 203 | 9.8 | 37 | 1.8 | 40 | 1.9 | 29 | 1.4 |
| | | 35+ | 1233 | 37 | 3.0 | 143 | 11.7 | 34 | 2.8 | 35 | 2.9 | 25 | 2.0 |
| | **Years since diagnosis** | 5-9 | 1455 | 10 | 0.7 | 94 | 6.5 | 5 | 0.3 | 11 | 0.8 | 5 | 0.3 |
| | | 10-14 | 4468 | 69 | 1.6 | 413 | 9.3 | 39 | 0.9 | 57 | 1.3 | 32 | 0.7 |
| | | 15-19 | 4314 | 72 | 1.7 | 377 | 8.8 | 54 | 1.3 | 73 | 1.7 | 34 | 0.8 |
| | | 20+ | 3516 | 73 | 2.1 | 328 | 9.4 | 77 | 2.2 | 74 | 2.1 | 63 | 1.8 |
| | **Age at diagnosis** | <1 | 987 | 6 | 0.6 | 56 | 5.7 | 5 | 0.5 | 6 | 0.6 | 14 | 1.4 |
| | | 1-4 | 4344 | 51 | 1.2 | 328 | 7.6 | 45 | 1.0 | 52 | 1.2 | 32 | 0.7 |
| | | 5-9 | 3263 | 56 | 1.7 | 314 | 9.7 | 50 | 1.5 | 57 | 1.8 | 25 | 0.8 |
| | | 10-14 | 2887 | 55 | 1.9 | 273 | 9.5 | 37 | 1.3 | 47 | 1.6 | 28 | 1.0 |
| | | 15-20 | 2272 | 56 | 2.5 | 241 | 10.6 | 38 | 1.7 | 53 | 2.3 | 35 | 1.5 |
| | **Treatment** | Surgery only | 1070 | 13 | 1.2 | 26 | 2.4 | 2 | 0.2 | 6 | 0.6 | 8 | 0.8 |
| | | Chemotherapy, no radiation | 4299 | 36 | 0.8 | 115 | 2.7 | 18 | 0.4 | 29 | 0.7 | 42 | 1.0 |
| | | Radiation, no chemotherapy | 1086 | 31 | 2.9 | 216 | 20.0 | 37 | 3.4 | 29 | 2.7 | 2 | 0.2 |
| | | Chemotherapy and radiation | 5825 | 114 | 2.0 | 768 | 13.3 | 109 | 1.9 | 136 | 2.4 | 74 | 1.3 |
| | | Unknown | 1473 | 30 | 2.1 | 87 | 5.9 | 9 | 0.6 | 15 | 1.0 | 8 | 0.5 |
| **Females** | **All cases** | | **11972** | **235** | **2.0** | **1436** | **12.1** | **425** | **3.6** | **409** | **3.4** | **196** | **1.6** |
| | **Age at baseline** | <18 | 2623 | 11 | 0.4 | 158 | 6.1 | 17 | 0.7 | 21 | 0.8 | 18 | 0.7 |
| | | 18-19 | 1030 | 16 | 1.6 | 71 | 7.0 | 13 | 1.3 | 18 | 1.8 | 6 | 0.6 |
| | | 20-24 | 2854 | 47 | 1.7 | 263 | 9.3 | 63 | 2.2 | 81 | 2.9 | 40 | 1.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

# Hormonal systems: All cancers

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **25725** | **266** | **1.1** | **399** | **1.6** | **1996** | **7.9** | **1190** | **4.7** | **5752** | **22.9** |
| | **Age at baseline** | <18 | 5688 | 17 | 0.3 | 54 | 1.0 | 654 | 11.6 | 207 | 3.7 | 1038 | 18.5 |
| | | 18-19 | 2152 | 9 | 0.4 | 20 | 0.9 | 243 | 11.6 | 109 | 5.1 | 430 | 20.6 |
| | | 20-24 | 6024 | 44 | 0.7 | 86 | 1.4 | 560 | 9.5 | 282 | 4.7 | 1226 | 20.9 |
| | | 25-29 | 5571 | 74 | 1.4 | 102 | 1.8 | 397 | 7.3 | 294 | 5.3 | 1321 | 24.4 |
| | | 30-34 | 3885 | 58 | 1.5 | 76 | 2.0 | 114 | 3.0 | 188 | 4.9 | 987 | 26.2 |
| | | 35+ | 2405 | 64 | 2.7 | 61 | 2.5 | 28 | 1.2 | 110 | 4.6 | 750 | 31.9 |
| | **Years since diagnosis** | 5-9 | 2592 | 8 | 0.3 | 43 | 1.7 | 211 | 8.3 | 110 | 4.3 | 469 | 18.6 |
| | | 10-14 | 8345 | 39 | 0.5 | 113 | 1.4 | 710 | 8.7 | 399 | 4.8 | 1784 | 21.9 |
| | | 15-19 | 8211 | 77 | 1.0 | 111 | 1.4 | 623 | 7.8 | 361 | 4.4 | 1814 | 22.7 |
| | | 20+ | 6577 | 142 | 2.2 | 132 | 2.0 | 452 | 7.0 | 320 | 4.9 | 1685 | 26.3 |
| | **Age at diagnosis** | <1 | 1933 | 9 | 0.5 | 21 | 1.1 | 133 | 7.0 | 51 | 2.7 | 265 | 13.9 |
| | | 1-4 | 8297 | 72 | 0.9 | 82 | 1.0 | 967 | 11.8 | 337 | 4.1 | 1659 | 20.5 |
| | | 5-9 | 5790 | 49 | 0.9 | 73 | 1.3 | 641 | 11.3 | 317 | 5.5 | 1353 | 24.0 |
| | | 10-14 | 5453 | 65 | 1.2 | 132 | 2.4 | 221 | 4.1 | 307 | 5.7 | 1336 | 25.1 |
| | | 15-20 | 4252 | 71 | 1.7 | 91 | 2.1 | 34 | 0.8 | 178 | 4.2 | 1139 | 27.6 |
| | **Treatment** | Surgery only | 2169 | 11 | 0.5 | 12 | 0.6 | 40 | 1.9 | 38 | 1.8 | 181 | 8.5 |
| | | Chemotherapy, no radiation | 8166 | 79 | 1.0 | 115 | 1.4 | 182 | 2.3 | 334 | 4.1 | 1014 | 12.7 |
| | | Radiation, no chemotherapy | 2086 | 21 | 1.1 | 20 | 1.0 | 282 | 14.2 | 85 | 4.1 | 804 | 40.1 |
| | | Chemotherapy and radiation | 10806 | 136 | 1.3 | 215 | 2.0 | 1324 | 12.6 | 638 | 5.9 | 3285 | 31.3 |
| | | Unknown | 2498 | 19 | 0.8 | 37 | 1.5 | 168 | 6.8 | 95 | 3.8 | 468 | 19.0 |
| **Males** | **All cases** | | **13753** | **122** | **0.9** | **180** | **1.3** | **1183** | **8.8** | **516** | **3.8** | **2735** | **20.4** |
| | **Age at baseline** | <18 | 3065 | 8 | 0.3 | 23 | 0.8 | 397 | 13.0 | 115 | 3.8 | 609 | 20.1 |
| | | 18-19 | 1122 | 4 | 0.4 | 11 | 1.0 | 143 | 13.1 | 62 | 5.6 | 233 | 21.4 |
| | | 20-24 | 3170 | 17 | 0.5 | 39 | 1.2 | 326 | 10.5 | 128 | 4.1 | 604 | 19.6 |
| | | 25-29 | 3091 | 31 | 1.0 | 45 | 1.5 | 235 | 7.8 | 122 | 4.0 | 624 | 20.8 |
| | | 30-34 | 2072 | 30 | 1.5 | 36 | 1.8 | 69 | 3.4 | 53 | 2.6 | 387 | 19.3 |
| | | 35+ | 1233 | 32 | 2.6 | 26 | 2.1 | 13 | 1.1 | 36 | 2.9 | 278 | 23.1 |
| | **Years since diagnosis** | 5-9 | 1455 | 3 | 0.2 | 21 | 1.4 | 133 | 9.4 | 59 | 4.1 | 269 | 19.0 |
| | | 10-14 | 4468 | 18 | 0.4 | 50 | 1.1 | 431 | 9.8 | 193 | 4.3 | 913 | 20.9 |
| | | 15-19 | 4314 | 31 | 0.7 | 48 | 1.1 | 364 | 8.6 | 149 | 3.5 | 839 | 20.0 |
| | | 20+ | 3516 | 70 | 2.0 | 61 | 1.7 | 255 | 7.4 | 115 | 3.3 | 714 | 20.8 |
| | **Age at diagnosis** | <1 | 987 | 6 | 0.6 | 10 | 1.0 | 75 | 7.7 | 25 | 2.6 | 133 | 13.7 |
| | | 1-4 | 4344 | 31 | 0.7 | 34 | 0.8 | 574 | 13.4 | 160 | 3.7 | 866 | 20.3 |
| | | 5-9 | 3263 | 20 | 0.6 | 33 | 1.0 | 368 | 11.5 | 157 | 4.8 | 715 | 22.5 |
| | | 10-14 | 2887 | 31 | 1.1 | 57 | 2.0 | 147 | 5.2 | 115 | 4.0 | 572 | 20.3 |
| | | 15-20 | 2272 | 34 | 1.5 | 46 | 2.0 | 19 | 0.9 | 59 | 2.6 | 449 | 20.5 |
| | **Treatment** | Surgery only | 1070 | 6 | 0.6 | 7 | 0.7 | 27 | 2.6 | 20 | 1.9 | 86 | 8.3 |
| | | Chemotherapy, no radiation | 4299 | 34 | 0.8 | 57 | 1.3 | 103 | 2.4 | 137 | 3.2 | 438 | 10.4 |
| | | Radiation, no chemotherapy | 1086 | 10 | 1.0 | 6 | 0.6 | 150 | 14.4 | 35 | 3.2 | 376 | 36.2 |
| | | Chemotherapy and radiation | 5825 | 62 | 1.1 | 95 | 1.6 | 788 | 13.8 | 283 | 4.9 | 1595 | 28.1 |
| | | Unknown | 1473 | 10 | 0.7 | 15 | 1.0 | 115 | 7.9 | 41 | 2.8 | 240 | 16.5 |
| **Females** | **All cases** | | **11972** | **144** | **1.2** | **219** | **1.8** | **813** | **6.9** | **674** | **5.7** | **3017** | **25.9** |
| | **Age at baseline** | <18 | 2623 | 9 | 0.3 | 31 | 1.2 | 257 | 9.9 | 92 | 3.5 | 429 | 16.6 |
| | | 18-19 | 1030 | 5 | 0.5 | 9 | 0.9 | 100 | 9.9 | 47 | 4.6 | 197 | 19.8 |
| | | 20-24 | 2854 | 27 | 1.0 | 47 | 1.7 | 234 | 8.4 | 154 | 5.4 | 622 | 22.5 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1)[1] | | Underactive thyroid (E.2/E.2)[1] | | Thyroid nodules (E.3/E.3)[1] | | Thyroid enlargement (E.4/E.4)[1] | | Diabetes-diet (E.5/E.5)[1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 2480 | 51 | 2.1 | 322 | 13.1 | 83 | 3.4 | 99 | 4.0 | 53 | 2.1 |
| | | 30-34 | 1813 | 74 | 4.1 | 336 | 18.7 | 120 | 6.7 | 88 | 4.9 | 44 | 2.4 |
| | | 35+ | 1172 | 36 | 3.1 | 286 | 24.6 | 129 | 11.1 | 102 | 8.8 | 35 | 3.0 |
| | **Years since diagnosis** | 5-9 | 1137 | 15 | 1.3 | 82 | 7.2 | 5 | 0.4 | 14 | 1.2 | 9 | 0.8 |
| | | 10-14 | 3877 | 54 | 1.4 | 407 | 10.6 | 68 | 1.8 | 76 | 2.0 | 49 | 1.3 |
| | | 15-19 | 3897 | 84 | 2.2 | 481 | 12.4 | 139 | 3.6 | 136 | 3.5 | 52 | 1.3 |
| | | 20+ | 3061 | 82 | 2.7 | 466 | 15.4 | 213 | 7.0 | 183 | 6.0 | 86 | 2.8 |
| | **Age at diagnosis** | <1 | 946 | 7 | 0.7 | 49 | 5.2 | 12 | 1.3 | 11 | 1.2 | 10 | 1.1 |
| | | 1-4 | 3953 | 45 | 1.1 | 292 | 7.5 | 73 | 1.9 | 86 | 2.2 | 39 | 1.0 |
| | | 5-9 | 2527 | 46 | 1.8 | 277 | 11.1 | 83 | 3.3 | 92 | 3.7 | 45 | 1.8 |
| | | 10-14 | 2566 | 80 | 3.1 | 372 | 14.6 | 131 | 5.1 | 120 | 4.7 | 60 | 2.4 |
| | | 15-20 | 1980 | 57 | 2.9 | 446 | 22.7 | 126 | 6.4 | 100 | 5.1 | 42 | 2.1 |
| | **Treatment** | Surgery only | 1099 | 12 | 1.1 | 44 | 4.0 | 9 | 0.8 | 18 | 1.6 | 8 | 0.7 |
| | | Chemotherapy, no radiation | 3867 | 41 | 1.1 | 187 | 4.9 | 61 | 1.6 | 86 | 2.2 | 55 | 1.4 |
| | | Radiation, no chemotherapy | 1000 | 32 | 3.3 | 258 | 26.2 | 75 | 7.6 | 57 | 5.8 | 10 | 1.0 |
| | | Chemotherapy and radiation | 4981 | 129 | 2.6 | 843 | 17.1 | 249 | 5.1 | 221 | 4.5 | 103 | 2.1 |
| | | Unknown | 1025 | 21 | 2.1 | 104 | 10.2 | 31 | 3.0 | 27 | 2.6 | 20 | 2.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem[2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 2480 | 43 | 1.8 | 57 | 2.3 | 162 | 6.7 | 172 | 7.0 | 697 | 28.8 |
| | | 30-34 | 1813 | 28 | 1.6 | 40 | 2.2 | 45 | 2.6 | 135 | 7.5 | 600 | 34.1 |
| | | 35+ | 1172 | 32 | 2.8 | 35 | 3.0 | 15 | 1.3 | 74 | 6.3 | 472 | 41.1 |
| | **Years since diagnosis** | 5-9 | 1137 | 5 | 0.4 | 22 | 1.9 | 78 | 7.0 | 51 | 4.5 | 200 | 18.0 |
| | | 10-14 | 3877 | 21 | 0.5 | 63 | 1.6 | 279 | 7.3 | 206 | 5.4 | 871 | 23.0 |
| | | 15-19 | 3897 | 46 | 1.2 | 63 | 1.6 | 259 | 6.8 | 212 | 5.5 | 975 | 25.7 |
| | | 20+ | 3061 | 72 | 2.4 | 71 | 2.3 | 197 | 6.6 | 205 | 6.8 | 971 | 32.6 |
| | **Age at diagnosis** | <1 | 946 | 3 | 0.3 | 11 | 1.2 | 58 | 6.2 | 26 | 2.8 | 132 | 14.2 |
| | | 1-4 | 3953 | 41 | 1.1 | 48 | 1.2 | 393 | 10.1 | 177 | 4.5 | 793 | 20.6 |
| | | 5-9 | 2527 | 29 | 1.2 | 40 | 1.6 | 273 | 11.0 | 160 | 6.4 | 638 | 25.9 |
| | | 10-14 | 2566 | 34 | 1.4 | 75 | 2.9 | 74 | 3.0 | 192 | 7.6 | 764 | 30.5 |
| | | 15-20 | 1980 | 37 | 1.9 | 45 | 2.3 | 15 | 0.8 | 119 | 6.0 | 690 | 35.8 |
| | **Treatment** | Surgery only | 1099 | 5 | 0.5 | 5 | 0.5 | 13 | 1.2 | 18 | 1.6 | 95 | 8.8 |
| | | Chemotherapy, no radiation | 3867 | 45 | 1.2 | 58 | 1.5 | 79 | 2.1 | 197 | 5.1 | 576 | 15.2 |
| | | Radiation, no chemotherapy | 1000 | 11 | 1.2 | 14 | 1.4 | 132 | 13.9 | 50 | 5.1 | 428 | 44.4 |
| | | Chemotherapy and radiation | 4981 | 74 | 1.5 | 120 | 2.4 | 536 | 11.0 | 355 | 7.2 | 1690 | 35.0 |
| | | Unknown | 1025 | 9 | 0.9 | 22 | 2.2 | 53 | 5.2 | 54 | 5.3 | 228 | 22.6 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **7908** | **87** | **1.1** | **423** | **5.4** | **92** | **1.2** | **127** | **1.6** | **134** | **1.7** |
| | **Age at baseline** | <18 | 2236 | 14 | 0.6 | 98 | 4.4 | 6 | 0.3 | 14 | 0.6 | 19 | 0.9 |
| | | 18-19 | 844 | 6 | 0.7 | 44 | 5.3 | 9 | 1.1 | 13 | 1.6 | 10 | 1.2 |
| | | 20-24 | 1970 | 20 | 1.0 | 111 | 5.7 | 22 | 1.1 | 29 | 1.5 | 21 | 1.1 |
| | | 25-29 | 1608 | 25 | 1.6 | 91 | 5.7 | 27 | 1.7 | 39 | 2.4 | 41 | 2.6 |
| | | 30-34 | 847 | 18 | 2.1 | 50 | 5.9 | 15 | 1.8 | 17 | 2.0 | 23 | 2.7 |
| | | 35+ | 403 | 4 | 1.0 | 29 | 7.3 | 13 | 3.3 | 15 | 3.8 | 20 | 5.0 |
| | **Years since diagnosis** | 5-9 | 981 | 4 | 0.4 | 15 | 1.5 | 5 | 0.5 | 8 | 0.8 | 8 | 0.8 |
| | | 10-14 | 2637 | 22 | 0.8 | 139 | 5.3 | 11 | 0.4 | 29 | 1.1 | 33 | 1.3 |
| | | 15-19 | 2441 | 31 | 1.3 | 131 | 5.4 | 26 | 1.1 | 36 | 1.5 | 34 | 1.4 |
| | | 20+ | 1849 | 30 | 1.6 | 138 | 7.5 | 50 | 2.7 | 54 | 3.0 | 59 | 3.2 |
| | **Age at diagnosis** | <1 | 242 | 2 | 0.8 | 33 | 13.8 | 5 | 2.1 | 3 | 1.3 | 10 | 4.2 |
| | | 1-4 | 3735 | 34 | 0.9 | 194 | 5.2 | 39 | 1.1 | 50 | 1.3 | 36 | 1.0 |
| | | 5-9 | 1931 | 20 | 1.0 | 89 | 4.6 | 20 | 1.0 | 35 | 1.8 | 32 | 1.7 |
| | | 10-14 | 1313 | 20 | 1.5 | 74 | 5.7 | 19 | 1.5 | 20 | 1.5 | 34 | 2.6 |
| | | 15-20 | 687 | 11 | 1.6 | 33 | 4.8 | 9 | 1.3 | 19 | 2.8 | 22 | 3.2 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 3383 | 22 | 0.7 | 129 | 3.8 | 19 | 0.6 | 36 | 1.1 | 37 | 1.1 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 3775 | 53 | 1.4 | 265 | 7.1 | 71 | 1.9 | 83 | 2.2 | 88 | 2.3 |
| | | Unknown | 743 | 12 | 1.6 | 29 | 3.9 | 2 | 0.3 | 8 | 1.1 | 9 | 1.2 |
| **Males** | **All cases** | | **4218** | **41** | **1.0** | **194** | **4.6** | **32** | **0.8** | **44** | **1.1** | **53** | **1.3** |
| | **Age at baseline** | <18 | 1222 | 11 | 0.9 | 57 | 4.7 | 4 | 0.3 | 9 | 0.7 | 4 | 0.3 |
| | | 18-19 | 454 | 1 | 0.2 | 28 | 6.2 | 2 | 0.4 | 5 | 1.1 | 6 | 1.3 |
| | | 20-24 | 997 | 5 | 0.5 | 44 | 4.4 | 5 | 0.5 | 8 | 0.8 | 8 | 0.8 |
| | | 25-29 | 870 | 16 | 1.9 | 40 | 4.6 | 11 | 1.3 | 13 | 1.5 | 21 | 2.4 |
| | | 30-34 | 449 | 5 | 1.1 | 15 | 3.4 | 5 | 1.1 | 5 | 1.1 | 6 | 1.3 |
| | | 35+ | 226 | 3 | 1.3 | 10 | 4.5 | 5 | 2.3 | 4 | 1.8 | 8 | 3.6 |
| | **Years since diagnosis** | 5-9 | 557 | 2 | 0.4 | 8 | 1.4 | 2 | 0.4 | 4 | 0.7 | 1 | 0.2 |
| | | 10-14 | 1415 | 12 | 0.9 | 74 | 5.3 | 5 | 0.4 | 13 | 0.9 | 12 | 0.8 |
| | | 15-19 | 1252 | 12 | 1.0 | 52 | 4.2 | 6 | 0.5 | 13 | 1.0 | 14 | 1.1 |
| | | 20+ | 994 | 15 | 1.5 | 60 | 6.1 | 19 | 1.9 | 14 | 1.4 | 26 | 2.6 |
| | **Age at diagnosis** | <1 | 113 | 1 | 0.9 | 16 | 14.3 | 2 | 1.8 | . | . | 6 | 5.4 |
| | | 1-4 | 1998 | 16 | 0.8 | 98 | 4.9 | 14 | 0.7 | 19 | 1.0 | 16 | 0.8 |
| | | 5-9 | 1041 | 10 | 1.0 | 49 | 4.7 | 7 | 0.7 | 11 | 1.1 | 9 | 0.9 |
| | | 10-14 | 650 | 9 | 1.4 | 21 | 3.3 | 3 | 0.5 | 6 | 0.9 | 13 | 2.0 |
| | | 15-20 | 416 | 5 | 1.2 | 10 | 2.4 | 6 | 1.4 | 8 | 1.9 | 9 | 2.2 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 1694 | 9 | 0.5 | 51 | 3.0 | 6 | 0.4 | 9 | 0.5 | 18 | 1.1 |
| | | Radiation, no chemotherapy | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 2076 | 25 | 1.2 | 127 | 6.2 | 26 | 1.3 | 33 | 1.6 | 33 | 1.6 |
| | | Unknown | 444 | 7 | 1.6 | 16 | 3.6 | . | . | 2 | 0.5 | 2 | 0.5 |
| **Females** | **All cases** | | **3690** | **46** | **1.3** | **229** | **6.2** | **60** | **1.6** | **83** | **2.3** | **81** | **2.2** |
| | **Age at baseline** | <18 | 1014 | 3 | 0.3 | 41 | 4.1 | 2 | 0.2 | 5 | 0.5 | 15 | 1.5 |
| | | 18-19 | 390 | 5 | 1.3 | 16 | 4.2 | 7 | 1.8 | 8 | 2.1 | 4 | 1.0 |
| | | 20-24 | 973 | 15 | 1.6 | 67 | 7.0 | 17 | 1.8 | 21 | 2.2 | 13 | 1.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **7908** | **97** | **1.2** | **213** | **2.7** | **548** | **7.1** | **464** | **5.9** | **1494** | **19.4** |
| | **Age at baseline** | <18 | 2236 | 8 | 0.4 | 31 | 1.4 | 196 | 8.8 | 109 | 4.9 | 371 | 16.8 |
| | | 18-19 | 844 | 5 | 0.6 | 11 | 1.3 | 90 | 11.0 | 57 | 6.8 | 168 | 20.7 |
| | | 20-24 | 1970 | 12 | 0.6 | 48 | 2.4 | 139 | 7.3 | 105 | 5.4 | 349 | 18.4 |
| | | 25-29 | 1608 | 35 | 2.2 | 60 | 3.8 | 98 | 6.2 | 109 | 6.8 | 351 | 22.4 |
| | | 30-34 | 847 | 15 | 1.8 | 33 | 3.9 | 16 | 1.9 | 58 | 6.9 | 157 | 19.1 |
| | | 35+ | 403 | 22 | 5.6 | 30 | 7.5 | 9 | 2.3 | 26 | 6.5 | 98 | 25.1 |
| | **Years since diagnosis** | 5-9 | 981 | 2 | 0.2 | 34 | 3.5 | 46 | 4.7 | 53 | 5.4 | 144 | 15.0 |
| | | 10-14 | 2637 | 14 | 0.5 | 65 | 2.5 | 203 | 7.8 | 173 | 6.6 | 494 | 19.1 |
| | | 15-19 | 2441 | 27 | 1.1 | 53 | 2.2 | 173 | 7.3 | 137 | 5.6 | 436 | 18.5 |
| | | 20+ | 1849 | 54 | 3.0 | 61 | 3.3 | 126 | 6.9 | 101 | 5.5 | 420 | 23.4 |
| | **Age at diagnosis** | <1 | 242 | 5 | 2.1 | 11 | 4.6 | 41 | 17.2 | 18 | 7.5 | 70 | 29.3 |
| | | 1-4 | 3735 | 35 | 0.9 | 40 | 1.1 | 340 | 9.3 | 165 | 4.4 | 663 | 18.2 |
| | | 5-9 | 1931 | 18 | 0.9 | 36 | 1.9 | 126 | 6.7 | 119 | 6.2 | 332 | 17.8 |
| | | 10-14 | 1313 | 19 | 1.5 | 82 | 6.3 | 36 | 2.8 | 113 | 8.7 | 288 | 22.4 |
| | | 15-20 | 687 | 20 | 3.0 | 44 | 6.4 | 5 | 0.8 | 49 | 7.2 | 141 | 21.3 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 3383 | 30 | 0.9 | 73 | 2.2 | 90 | 2.7 | 196 | 5.8 | 474 | 14.3 |
| | | Radiation, no chemotherapy | 4 | . | . | 1 | 25.0 | . | . | 1 | 25.0 | 2 | 50.0 |
| | | Chemotherapy and radiation | 3775 | 59 | 1.6 | 119 | 3.2 | 403 | 11.0 | 232 | 6.2 | 895 | 24.6 |
| | | Unknown | 743 | 8 | 1.1 | 20 | 2.7 | 55 | 7.5 | 35 | 4.7 | 123 | 16.8 |
| **Males** | **All cases** | | **4218** | **41** | **1.0** | **98** | **2.3** | **356** | **8.6** | **222** | **5.3** | **753** | **18.3** |
| | **Age at baseline** | <18 | 1222 | 2 | 0.2 | 14 | 1.1 | 135 | 11.1 | 69 | 5.7 | 230 | 19.0 |
| | | 18-19 | 454 | 3 | 0.7 | 6 | 1.3 | 61 | 13.8 | 34 | 7.6 | 99 | 22.5 |
| | | 20-24 | 997 | 5 | 0.5 | 22 | 2.2 | 83 | 8.5 | 52 | 5.2 | 169 | 17.5 |
| | | 25-29 | 870 | 14 | 1.6 | 27 | 3.1 | 64 | 7.5 | 44 | 5.1 | 159 | 18.8 |
| | | 30-34 | 449 | 6 | 1.4 | 16 | 3.6 | 10 | 2.3 | 13 | 2.9 | 53 | 12.1 |
| | | 35+ | 226 | 11 | 5.0 | 13 | 5.8 | 3 | 1.4 | 10 | 4.5 | 43 | 19.6 |
| | **Years since diagnosis** | 5-9 | 557 | . | . | 18 | 3.2 | 32 | 5.8 | 28 | 5.0 | 87 | 15.8 |
| | | 10-14 | 1415 | 5 | 0.4 | 28 | 2.0 | 142 | 10.2 | 95 | 6.7 | 276 | 19.8 |
| | | 15-19 | 1252 | 11 | 0.9 | 24 | 1.9 | 102 | 8.4 | 58 | 4.6 | 198 | 16.4 |
| | | 20+ | 994 | 25 | 2.6 | 28 | 2.8 | 80 | 8.2 | 41 | 4.2 | 192 | 19.9 |
| | **Age at diagnosis** | <1 | 113 | 2 | 1.8 | 4 | 3.6 | 25 | 22.5 | 11 | 9.9 | 35 | 31.5 |
| | | 1-4 | 1998 | 16 | 0.8 | 20 | 1.0 | 225 | 11.4 | 95 | 4.8 | 367 | 18.7 |
| | | 5-9 | 1041 | 5 | 0.5 | 16 | 1.5 | 80 | 7.9 | 62 | 6.0 | 177 | 17.6 |
| | | 10-14 | 650 | 10 | 1.6 | 33 | 5.1 | 22 | 3.4 | 35 | 5.4 | 106 | 16.5 |
| | | 15-20 | 416 | 8 | 2.0 | 25 | 6.0 | 4 | 1.0 | 19 | 4.6 | 68 | 16.9 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 1694 | 11 | 0.7 | 39 | 2.3 | 51 | 3.0 | 89 | 5.3 | 219 | 13.2 |
| | | Radiation, no chemotherapy | 3 | . | . | . | . | . | . | 1 | 33.3 | 1 | 33.3 |
| | | Chemotherapy and radiation | 2076 | 27 | 1.3 | 51 | 2.5 | 263 | 13.0 | 115 | 5.6 | 463 | 23.0 |
| | | Unknown | 444 | 3 | 0.7 | 8 | 1.8 | 42 | 9.5 | 17 | 3.8 | 70 | 15.9 |
| **Females** | **All cases** | | **3690** | **56** | **1.5** | **115** | **3.1** | **192** | **5.3** | **242** | **6.6** | **741** | **20.7** |
| | **Age at baseline** | <18 | 1014 | 6 | 0.6 | 17 | 1.7 | 61 | 6.1 | 40 | 4.0 | 141 | 14.1 |
| | | 18-19 | 390 | 2 | 0.5 | 5 | 1.3 | 29 | 7.7 | 23 | 6.0 | 69 | 18.6 |
| | | 20-24 | 973 | 7 | 0.7 | 26 | 2.7 | 56 | 5.9 | 53 | 5.5 | 180 | 19.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | All cases | Overactive thyroid (E.1/E.1)[1] | | Underactive thyroid (E.2/E.2)[1] | | Thyroid nodules (E.3/E.3)[1] | | Thyroid enlargement (E.4/E.4)[1] | | Diabetes-diet (E.5/E.5)[1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 738 | 9 | 1.2 | 51 | 6.9 | 16 | 2.2 | 26 | 3.5 | 20 | 2.7 |
| | | 30-34 | 398 | 13 | 3.3 | 35 | 8.8 | 10 | 2.5 | 12 | 3.0 | 17 | 4.3 |
| | | 35+ | 177 | 1 | 0.6 | 19 | 10.9 | 8 | 4.7 | 11 | 6.3 | 12 | 6.9 |
| | **Years since diagnosis** | 5-9 | 424 | 2 | 0.5 | 7 | 1.7 | 3 | 0.7 | 4 | 0.9 | 7 | 1.7 |
| | | 10-14 | 1222 | 10 | 0.8 | 65 | 5.4 | 6 | 0.5 | 16 | 1.3 | 21 | 1.7 |
| | | 15-19 | 1189 | 19 | 1.6 | 79 | 6.7 | 20 | 1.7 | 23 | 2.0 | 20 | 1.7 |
| | | 20+ | 855 | 15 | 1.8 | 78 | 9.2 | 31 | 3.7 | 40 | 4.7 | 33 | 3.9 |
| | **Age at diagnosis** | <1 | 129 | 1 | 0.8 | 17 | 13.3 | 3 | 2.3 | 3 | 2.3 | 4 | 3.1 |
| | | 1-4 | 1737 | 18 | 1.0 | 96 | 5.6 | 25 | 1.5 | 31 | 1.8 | 20 | 1.2 |
| | | 5-9 | 890 | 10 | 1.1 | 40 | 4.5 | 13 | 1.5 | 24 | 2.7 | 23 | 2.6 |
| | | 10-14 | 663 | 11 | 1.7 | 53 | 8.0 | 16 | 2.4 | 14 | 2.1 | 21 | 3.2 |
| | | 15-20 | 271 | 6 | 2.2 | 23 | 8.6 | 3 | 1.1 | 11 | 4.1 | 13 | 4.8 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 1689 | 13 | 0.8 | 78 | 4.6 | 13 | 0.8 | 27 | 1.6 | 19 | 1.1 |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 1699 | 28 | 1.7 | 138 | 8.2 | 45 | 2.7 | 50 | 3.0 | 55 | 3.2 |
| | | Unknown | 299 | 5 | 1.7 | 13 | 4.4 | 2 | 0.7 | 6 | 2.0 | 7 | 2.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 738 | 21 | 2.9 | 33 | 4.5 | 34 | 4.7 | 65 | 8.8 | 192 | 26.8 |
| | | 30-34 | 398 | 9 | 2.3 | 17 | 4.3 | 6 | 1.6 | 45 | 11.5 | 104 | 27.2 |
| | | 35+ | 177 | 11 | 6.4 | 17 | 9.7 | 6 | 3.5 | 16 | 9.1 | 55 | 32.2 |
| | **Years since diagnosis** | 5-9 | 424 | 2 | 0.5 | 16 | 3.8 | 14 | 3.4 | 25 | 6.0 | 57 | 13.9 |
| | | 10-14 | 1222 | 9 | 0.7 | 37 | 3.0 | 61 | 5.1 | 78 | 6.4 | 218 | 18.3 |
| | | 15-19 | 1189 | 16 | 1.4 | 29 | 2.4 | 71 | 6.2 | 79 | 6.7 | 238 | 20.8 |
| | | 20+ | 855 | 29 | 3.5 | 33 | 3.9 | 46 | 5.5 | 60 | 7.1 | 228 | 27.6 |
| | **Age at diagnosis** | <1 | 129 | 3 | 2.3 | 7 | 5.5 | 16 | 12.5 | 7 | 5.4 | 35 | 27.3 |
| | | 1-4 | 1737 | 19 | 1.1 | 20 | 1.2 | 115 | 6.7 | 70 | 4.1 | 296 | 17.6 |
| | | 5-9 | 890 | 13 | 1.5 | 20 | 2.3 | 46 | 5.3 | 57 | 6.4 | 155 | 18.0 |
| | | 10-14 | 663 | 9 | 1.4 | 49 | 7.4 | 14 | 2.2 | 78 | 11.9 | 182 | 28.4 |
| | | 15-20 | 271 | 12 | 4.6 | 19 | 7.1 | 1 | 0.4 | 30 | 11.2 | 73 | 28.1 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 1689 | 19 | 1.1 | 34 | 2.0 | 39 | 2.3 | 107 | 6.4 | 255 | 15.4 |
| | | Radiation, no chemotherapy | 1 | . | . | 1 | 100.0 | . | . | . | . | 1 | 100.0 |
| | | Chemotherapy and radiation | 1699 | 32 | 1.9 | 68 | 4.0 | 140 | 8.6 | 117 | 6.9 | 432 | 26.6 |
| | | Unknown | 299 | 5 | 1.7 | 12 | 4.0 | 13 | 4.4 | 18 | 6.1 | 53 | 18.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **6646** | **66** | **1.0** | **280** | **4.2** | **55** | **0.8** | **95** | **1.4** | **96** | **1.4** |
| | **Age at baseline** | <18 | 1941 | 10 | 0.5 | 61 | 3.2 | 4 | 0.2 | 12 | 0.6 | 17 | 0.9 |
| | | 18-19 | 730 | 5 | 0.7 | 27 | 3.7 | 5 | 0.7 | 9 | 1.2 | 6 | 0.8 |
| | | 20-24 | 1693 | 14 | 0.8 | 79 | 4.7 | 11 | 0.7 | 23 | 1.4 | 14 | 0.8 |
| | | 25-29 | 1338 | 21 | 1.6 | 60 | 4.5 | 15 | 1.1 | 26 | 2.0 | 28 | 2.1 |
| | | 30-34 | 657 | 13 | 2.0 | 35 | 5.4 | 12 | 1.8 | 15 | 2.3 | 17 | 2.6 |
| | | 35+ | 287 | 3 | 1.1 | 18 | 6.3 | 8 | 2.8 | 10 | 3.5 | 14 | 4.9 |
| | **Years since diagnosis** | 5-9 | 844 | 4 | 0.5 | 11 | 1.3 | 3 | 0.4 | 6 | 0.7 | 8 | 1.0 |
| | | 10-14 | 2222 | 16 | 0.7 | 79 | 3.6 | 3 | 0.1 | 19 | 0.9 | 27 | 1.2 |
| | | 15-19 | 2024 | 22 | 1.1 | 91 | 4.5 | 14 | 0.7 | 29 | 1.4 | 19 | 0.9 |
| | | 20+ | 1556 | 24 | 1.6 | 99 | 6.4 | 35 | 2.3 | 41 | 2.7 | 42 | 2.7 |
| | **Age at diagnosis** | <1 | 134 | 1 | 0.8 | 16 | 12.0 | 4 | 3.0 | 3 | 2.3 | 7 | 5.3 |
| | | 1-4 | 3322 | 26 | 0.8 | 143 | 4.3 | 27 | 0.8 | 40 | 1.2 | 25 | 0.8 |
| | | 5-9 | 1696 | 15 | 0.9 | 59 | 3.5 | 9 | 0.5 | 26 | 1.5 | 23 | 1.4 |
| | | 10-14 | 1027 | 16 | 1.6 | 42 | 4.1 | 10 | 1.0 | 13 | 1.3 | 24 | 2.3 |
| | | 15-20 | 467 | 8 | 1.7 | 20 | 4.3 | 5 | 1.1 | 13 | 2.8 | 17 | 3.6 |
| | **Treatment** | Chemotherapy, no radiation | 2699 | 16 | 0.6 | 71 | 2.6 | 8 | 0.3 | 24 | 0.9 | 26 | 1.0 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 3306 | 41 | 1.2 | 187 | 5.7 | 45 | 1.4 | 65 | 2.0 | 66 | 2.0 |
| | | Unknown | 637 | 9 | 1.4 | 22 | 3.5 | 2 | 0.3 | 6 | 0.9 | 4 | 0.6 |
| **Males** | **All cases** | | **3576** | **33** | **0.9** | **132** | **3.7** | **21** | **0.6** | **33** | **0.9** | **35** | **1.0** |
| | **Age at baseline** | <18 | 1061 | 8 | 0.8 | 37 | 3.5 | 2 | 0.2 | 7 | 0.7 | 2 | 0.2 |
| | | 18-19 | 397 | 1 | 0.3 | 16 | 4.1 | 1 | 0.3 | 3 | 0.8 | 4 | 1.0 |
| | | 20-24 | 858 | 5 | 0.6 | 35 | 4.1 | 3 | 0.4 | 8 | 0.9 | 6 | 0.7 |
| | | 25-29 | 736 | 13 | 1.8 | 28 | 3.8 | 8 | 1.1 | 9 | 1.2 | 14 | 1.9 |
| | | 30-34 | 354 | 3 | 0.9 | 8 | 2.3 | 4 | 1.1 | 4 | 1.1 | 4 | 1.1 |
| | | 35+ | 170 | 3 | 1.8 | 8 | 4.7 | 3 | 1.8 | 2 | 1.2 | 5 | 3.0 |
| | **Years since diagnosis** | 5-9 | 480 | 2 | 0.4 | 6 | 1.3 | 1 | 0.2 | 2 | 0.4 | 1 | 0.2 |
| | | 10-14 | 1201 | 10 | 0.8 | 46 | 3.9 | 2 | 0.2 | 8 | 0.7 | 8 | 0.7 |
| | | 15-19 | 1052 | 10 | 1.0 | 36 | 3.4 | 2 | 0.2 | 12 | 1.1 | 7 | 0.7 |
| | | 20+ | 843 | 11 | 1.3 | 44 | 5.3 | 16 | 1.9 | 11 | 1.3 | 19 | 2.3 |
| | **Age at diagnosis** | <1 | 65 | 1 | 1.5 | 8 | 12.3 | 1 | 1.5 | . | . | 3 | 4.6 |
| | | 1-4 | 1769 | 13 | 0.7 | 69 | 3.9 | 10 | 0.6 | 17 | 1.0 | 11 | 0.6 |
| | | 5-9 | 924 | 7 | 0.8 | 38 | 4.1 | 6 | 0.7 | 8 | 0.9 | 8 | 0.9 |
| | | 10-14 | 527 | 7 | 1.3 | 11 | 2.1 | 2 | 0.4 | 4 | 0.8 | 8 | 1.5 |
| | | 15-20 | 291 | 5 | 1.7 | 6 | 2.1 | 2 | 0.7 | 4 | 1.4 | 5 | 1.7 |
| | **Treatment** | Chemotherapy, no radiation | 1349 | 7 | 0.5 | 26 | 1.9 | 5 | 0.4 | 5 | 0.4 | 11 | 0.8 |
| | | Radiation, no chemotherapy | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 1839 | 21 | 1.1 | 93 | 5.1 | 16 | 0.9 | 27 | 1.5 | 22 | 1.2 |
| | | Unknown | 385 | 5 | 1.3 | 13 | 3.4 | . | . | 1 | 0.3 | 2 | 0.5 |
| **Females** | **All cases** | | **3070** | **33** | **1.1** | **148** | **4.8** | **34** | **1.1** | **62** | **2.0** | **61** | **2.0** |
| | **Age at baseline** | <18 | 880 | 2 | 0.2 | 24 | 2.7 | 2 | 0.2 | 5 | 0.6 | 15 | 1.7 |
| | | 18-19 | 333 | 4 | 1.2 | 11 | 3.3 | 4 | 1.2 | 6 | 1.8 | 2 | 0.6 |
| | | 20-24 | 835 | 9 | 1.1 | 44 | 5.3 | 8 | 1.0 | 15 | 1.8 | 8 | 1.0 |
| | | 25-29 | 602 | 8 | 1.3 | 32 | 5.3 | 7 | 1.2 | 17 | 2.8 | 14 | 2.3 |
| | | 30-34 | 303 | 10 | 3.3 | 27 | 8.9 | 8 | 2.7 | 11 | 3.6 | 13 | 4.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **6646** | **62** | **0.9** | **168** | **2.5** | **414** | **6.4** | **350** | **5.3** | **1123** | **17.4** |
| | **Age at baseline** | <18 | 1941 | 5 | 0.3 | 25 | 1.3 | 150 | 7.8 | 96 | 5.0 | 291 | 15.2 |
| | | 18-19 | 730 | 3 | 0.4 | 7 | 1.0 | 74 | 10.5 | 47 | 6.5 | 132 | 18.8 |
| | | 20-24 | 1693 | 7 | 0.4 | 37 | 2.2 | 102 | 6.2 | 83 | 4.9 | 265 | 16.3 |
| | | 25-29 | 1338 | 24 | 1.8 | 49 | 3.7 | 74 | 5.7 | 80 | 6.0 | 262 | 20.2 |
| | | 30-34 | 657 | 12 | 1.9 | 29 | 4.4 | 11 | 1.7 | 33 | 5.1 | 110 | 17.4 |
| | | 35+ | 287 | 11 | 3.9 | 21 | 7.4 | 3 | 1.1 | 11 | 3.9 | 63 | 22.4 |
| | **Years since diagnosis** | 5-9 | 844 | 2 | 0.2 | 30 | 3.6 | 38 | 4.5 | 46 | 5.5 | 121 | 14.6 |
| | | 10-14 | 2222 | 10 | 0.5 | 51 | 2.3 | 144 | 6.6 | 132 | 6.0 | 359 | 16.5 |
| | | 15-19 | 2024 | 17 | 0.9 | 42 | 2.1 | 133 | 6.8 | 106 | 5.3 | 330 | 17.0 |
| | | 20+ | 1556 | 33 | 2.2 | 45 | 2.9 | 99 | 6.5 | 66 | 4.3 | 313 | 20.8 |
| | **Age at diagnosis** | <1 | 134 | 2 | 1.5 | 7 | 5.3 | 28 | 21.1 | 11 | 8.2 | 42 | 31.6 |
| | | 1-4 | 3322 | 25 | 0.8 | 29 | 0.9 | 279 | 8.6 | 142 | 4.3 | 535 | 16.5 |
| | | 5-9 | 1696 | 9 | 0.5 | 26 | 1.5 | 87 | 5.3 | 99 | 5.9 | 255 | 15.6 |
| | | 10-14 | 1027 | 13 | 1.3 | 71 | 6.9 | 16 | 1.6 | 70 | 6.9 | 197 | 19.6 |
| | | 15-20 | 467 | 13 | 2.9 | 35 | 7.5 | 4 | 0.9 | 28 | 6.0 | 94 | 20.8 |
| | **Treatment** | Chemotherapy, no radiation | 2699 | 21 | 0.8 | 51 | 1.9 | 51 | 1.9 | 154 | 5.7 | 327 | 12.4 |
| | | Radiation, no chemotherapy | 4 | . | . | 1 | 25.0 | . | . | 1 | 25.0 | 2 | 50.0 |
| | | Chemotherapy and radiation | 3306 | 38 | 1.2 | 101 | 3.1 | 317 | 9.9 | 169 | 5.1 | 692 | 21.7 |
| | | Unknown | 637 | 3 | 0.5 | 15 | 2.4 | 46 | 7.3 | 26 | 4.1 | 102 | 16.2 |
| **Males** | **All cases** | | **3576** | **27** | **0.8** | **75** | **2.1** | **284** | **8.1** | **183** | **5.1** | **590** | **16.9** |
| | **Age at baseline** | <18 | 1061 | . | . | 9 | 0.8 | 103 | 9.8 | 58 | 5.5 | 179 | 17.1 |
| | | 18-19 | 397 | 3 | 0.8 | 6 | 1.5 | 53 | 13.7 | 29 | 7.4 | 80 | 20.8 |
| | | 20-24 | 858 | 4 | 0.5 | 16 | 1.9 | 67 | 8.1 | 43 | 5.0 | 135 | 16.3 |
| | | 25-29 | 736 | 8 | 1.1 | 21 | 2.9 | 52 | 7.2 | 38 | 5.2 | 126 | 17.6 |
| | | 30-34 | 354 | 6 | 1.7 | 14 | 4.0 | 7 | 2.0 | 10 | 2.8 | 40 | 11.6 |
| | | 35+ | 170 | 6 | 3.6 | 9 | 5.3 | 2 | 1.2 | 5 | 3.0 | 30 | 18.1 |
| | **Years since diagnosis** | 5-9 | 480 | . | . | 17 | 3.5 | 26 | 5.4 | 24 | 5.0 | 71 | 14.9 |
| | | 10-14 | 1201 | 3 | 0.3 | 20 | 1.7 | 107 | 9.0 | 79 | 6.6 | 211 | 17.9 |
| | | 15-19 | 1052 | 7 | 0.7 | 18 | 1.7 | 84 | 8.3 | 49 | 4.7 | 160 | 15.8 |
| | | 20+ | 843 | 17 | 2.1 | 20 | 2.4 | 67 | 8.1 | 31 | 3.7 | 148 | 18.0 |
| | **Age at diagnosis** | <1 | 65 | . | . | 1 | 1.5 | 16 | 25.0 | 5 | 7.7 | 20 | 31.3 |
| | | 1-4 | 1769 | 12 | 0.7 | 13 | 0.7 | 186 | 10.7 | 83 | 4.7 | 295 | 17.0 |
| | | 5-9 | 924 | 3 | 0.3 | 13 | 1.4 | 67 | 7.4 | 55 | 6.0 | 149 | 16.7 |
| | | 10-14 | 527 | 8 | 1.5 | 29 | 5.5 | 12 | 2.3 | 25 | 4.8 | 78 | 15.0 |
| | | 15-20 | 291 | 4 | 1.4 | 19 | 6.5 | 3 | 1.1 | 15 | 5.2 | 48 | 16.9 |
| | **Treatment** | Chemotherapy, no radiation | 1349 | 7 | 0.5 | 25 | 1.9 | 32 | 2.4 | 76 | 5.7 | 153 | 11.6 |
| | | Radiation, no chemotherapy | 3 | . | . | . | . | . | . | 1 | 33.3 | 1 | 33.3 |
| | | Chemotherapy and radiation | 1839 | 18 | 1.0 | 42 | 2.3 | 215 | 12.0 | 92 | 5.0 | 374 | 21.0 |
| | | Unknown | 385 | 2 | 0.5 | 8 | 2.1 | 37 | 9.7 | 14 | 3.6 | 62 | 16.2 |
| **Females** | **All cases** | | **3070** | **35** | **1.2** | **93** | **3.0** | **130** | **4.3** | **167** | **5.5** | **533** | **17.9** |
| | **Age at baseline** | <18 | 880 | 5 | 0.6 | 16 | 1.8 | 47 | 5.4 | 38 | 4.3 | 112 | 12.9 |
| | | 18-19 | 333 | . | . | 1 | 0.3 | 21 | 6.5 | 18 | 5.4 | 52 | 16.4 |
| | | 20-24 | 835 | 3 | 0.4 | 21 | 2.5 | 35 | 4.3 | 40 | 4.8 | 130 | 16.3 |
| | | 25-29 | 602 | 16 | 2.7 | 28 | 4.7 | 22 | 3.8 | 42 | 7.0 | 136 | 23.3 |
| | | 30-34 | 303 | 6 | 2.1 | 15 | 5.0 | 4 | 1.4 | 23 | 7.7 | 70 | 24.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 117 | . | . | 10 | 8.7 | 5 | 4.4 | 8 | 7.0 | 9 | 7.8 |
| | Years since diagnosis | 5-9 | 364 | 2 | 0.5 | 5 | 1.4 | 2 | 0.5 | 4 | 1.1 | 7 | 1.9 |
| | | 10-14 | 1021 | 6 | 0.6 | 33 | 3.2 | 1 | 0.1 | 11 | 1.1 | 19 | 1.9 |
| | | 15-19 | 972 | 12 | 1.2 | 55 | 5.7 | 12 | 1.3 | 17 | 1.8 | 12 | 1.2 |
| | | 20+ | 713 | 13 | 1.8 | 55 | 7.8 | 19 | 2.7 | 30 | 4.2 | 23 | 3.2 |
| | Age at diagnosis | <1 | 69 | . | . | 8 | 11.8 | 3 | 4.4 | 3 | 4.4 | 4 | 5.9 |
| | | 1-4 | 1553 | 13 | 0.8 | 74 | 4.8 | 17 | 1.1 | 23 | 1.5 | 14 | 0.9 |
| | | 5-9 | 772 | 8 | 1.0 | 21 | 2.7 | 3 | 0.4 | 18 | 2.3 | 15 | 1.9 |
| | | 10-14 | 500 | 9 | 1.8 | 31 | 6.2 | 8 | 1.6 | 9 | 1.8 | 16 | 3.2 |
| | | 15-20 | 176 | 3 | 1.7 | 14 | 8.0 | 3 | 1.7 | 9 | 5.2 | 12 | 6.9 |
| | Treatment | Chemotherapy, no radiation | 1350 | 9 | 0.7 | 45 | 3.3 | 3 | 0.2 | 19 | 1.4 | 15 | 1.1 |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 1467 | 20 | 1.4 | 94 | 6.5 | 29 | 2.0 | 38 | 2.6 | 44 | 3.0 |
| | | Unknown | 252 | 4 | 1.6 | 9 | 3.6 | 2 | 0.8 | 5 | 2.0 | 2 | 0.8 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 117 | 5 | 4.3 | 12 | 10.3 | 1 | 0.9 | 6 | 5.2 | 33 | 28.7 |
| | **Years since diagnosis** | 5-9 | 364 | 2 | 0.6 | 13 | 3.6 | 12 | 3.3 | 22 | 6.1 | 50 | 14.1 |
| | | 10-14 | 1021 | 7 | 0.7 | 31 | 3.0 | 37 | 3.7 | 53 | 5.2 | 148 | 14.8 |
| | | 15-19 | 972 | 10 | 1.1 | 24 | 2.5 | 49 | 5.3 | 57 | 5.9 | 170 | 18.3 |
| | | 20+ | 713 | 16 | 2.3 | 25 | 3.5 | 32 | 4.6 | 35 | 5.0 | 165 | 24.0 |
| | **Age at diagnosis** | <1 | 69 | 2 | 2.9 | 6 | 8.8 | 12 | 17.4 | 6 | 8.7 | 22 | 31.9 |
| | | 1-4 | 1553 | 13 | 0.8 | 16 | 1.0 | 93 | 6.1 | 59 | 3.8 | 240 | 15.9 |
| | | 5-9 | 772 | 6 | 0.8 | 13 | 1.7 | 20 | 2.7 | 44 | 5.7 | 106 | 14.2 |
| | | 10-14 | 500 | 5 | 1.0 | 42 | 8.4 | 4 | 0.8 | 45 | 9.1 | 119 | 24.6 |
| | | 15-20 | 176 | 9 | 5.3 | 16 | 9.1 | 1 | 0.6 | 13 | 7.5 | 46 | 27.2 |
| | **Treatment** | Chemotherapy, no radiation | 1350 | 14 | 1.0 | 26 | 1.9 | 19 | 1.4 | 78 | 5.8 | 174 | 13.1 |
| | | Radiation, no chemotherapy | 1 | . | . | 1 | 100.0 | . | . | . | . | 1 | 100.0 |
| | | Chemotherapy and radiation | 1467 | 20 | 1.4 | 59 | 4.0 | 102 | 7.3 | 77 | 5.3 | 318 | 22.7 |
| | | Unknown | 252 | 1 | 0.4 | 7 | 2.8 | 9 | 3.6 | 12 | 4.8 | 40 | 16.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **930** | **19** | **2.1** | **112** | **12.2** | **26** | **2.8** | **21** | **2.3** | **26** | **2.8** |
| | **Age at baseline** | <18 | 231 | 4 | 1.7 | 27 | 11.8 | 2 | 0.9 | 2 | 0.9 | 2 | 0.9 |
| | | 18-19 | 89 | 1 | 1.2 | 13 | 15.1 | 3 | 3.5 | 3 | 3.5 | 3 | 3.5 |
| | | 20-24 | 199 | 6 | 3.0 | 29 | 14.7 | 9 | 4.5 | 4 | 2.0 | 6 | 3.0 |
| | | 25-29 | 201 | 3 | 1.5 | 21 | 10.5 | 7 | 3.5 | 7 | 3.5 | 7 | 3.5 |
| | | 30-34 | 134 | 4 | 3.0 | 11 | 8.2 | 2 | 1.5 | 2 | 1.5 | 4 | 3.0 |
| | | 35+ | 76 | 1 | 1.4 | 11 | 14.9 | 3 | 4.2 | 3 | 4.1 | 4 | 5.4 |
| | **Years since diagnosis** | 5-9 | 85 | . | . | 4 | 4.8 | 2 | 2.4 | 1 | 1.2 | . | . |
| | | 10-14 | 320 | 6 | 1.9 | 42 | 13.3 | 6 | 1.9 | 8 | 2.5 | 2 | 0.6 |
| | | 15-19 | 323 | 8 | 2.5 | 33 | 10.2 | 10 | 3.1 | 5 | 1.6 | 13 | 4.0 |
| | | 20+ | 202 | 5 | 2.5 | 33 | 16.6 | 8 | 4.1 | 7 | 3.5 | 11 | 5.6 |
| | **Age at diagnosis** | <1 | 93 | 1 | 1.1 | 15 | 16.3 | 1 | 1.1 | . | . | 3 | 3.3 |
| | | 1-4 | 315 | 8 | 2.6 | 40 | 12.8 | 9 | 2.9 | 7 | 2.2 | 10 | 3.2 |
| | | 5-9 | 172 | 4 | 2.3 | 22 | 13.0 | 8 | 4.7 | 6 | 3.5 | 5 | 2.9 |
| | | 10-14 | 199 | 3 | 1.5 | 23 | 11.7 | 5 | 2.6 | 4 | 2.0 | 4 | 2.1 |
| | | 15-20 | 151 | 3 | 2.0 | 12 | 8.0 | 3 | 2.0 | 4 | 2.7 | 4 | 2.7 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 558 | 6 | 1.1 | 50 | 9.0 | 10 | 1.8 | 11 | 2.0 | 8 | 1.4 |
| | | Chemotherapy and radiation | 296 | 11 | 3.8 | 56 | 19.2 | 16 | 5.5 | 8 | 2.7 | 15 | 5.1 |
| | | Unknown | 73 | 2 | 2.8 | 6 | 8.3 | . | . | 2 | 2.8 | 3 | 4.2 |
| **Males** | **All cases** | | **456** | **7** | **1.6** | **49** | **10.9** | **9** | **2.0** | **7** | **1.5** | **11** | **2.4** |
| | **Age at baseline** | <18 | 126 | 3 | 2.4 | 15 | 12.0 | 2 | 1.6 | 2 | 1.6 | 2 | 1.6 |
| | | 18-19 | 45 | . | . | 10 | 23.3 | 1 | 2.3 | 1 | 2.3 | 1 | 2.3 |
| | | 20-24 | 95 | . | . | 9 | 9.5 | 2 | 2.1 | . | . | 2 | 2.1 |
| | | 25-29 | 90 | 2 | 2.3 | 7 | 7.9 | 2 | 2.2 | 2 | 2.2 | 2 | 2.2 |
| | | 30-34 | 65 | 2 | 3.1 | 6 | 9.2 | 1 | 1.6 | 1 | 1.6 | 2 | 3.1 |
| | | 35+ | 35 | . | . | 2 | 5.9 | 1 | 3.0 | 1 | 2.9 | 2 | 5.9 |
| | **Years since diagnosis** | 5-9 | 50 | . | . | 2 | 4.1 | 1 | 2.0 | 1 | 2.0 | . | . |
| | | 10-14 | 160 | 2 | 1.3 | 20 | 12.6 | 2 | 1.3 | 3 | 1.9 | 1 | 0.6 |
| | | 15-19 | 149 | 1 | 0.7 | 13 | 8.8 | 4 | 2.7 | 1 | 0.7 | 5 | 3.4 |
| | | 20+ | 97 | 4 | 4.3 | 14 | 14.7 | 2 | 2.1 | 2 | 2.1 | 5 | 5.3 |
| | **Age at diagnosis** | <1 | 40 | . | . | 7 | 17.9 | 1 | 2.6 | . | . | 3 | 7.7 |
| | | 1-4 | 172 | 3 | 1.8 | 24 | 14.1 | 4 | 2.3 | 2 | 1.2 | 4 | 2.3 |
| | | 5-9 | 79 | 3 | 3.8 | 8 | 10.3 | 1 | 1.3 | 2 | 2.5 | . | . |
| | | 10-14 | 82 | 1 | 1.2 | 6 | 7.4 | . | . | 1 | 1.3 | 1 | 1.3 |
| | | 15-20 | 83 | . | . | 4 | 4.8 | 3 | 3.7 | 2 | 2.4 | 3 | 3.6 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 269 | 2 | 0.7 | 24 | 9.0 | 1 | 0.4 | 3 | 1.1 | 4 | 1.5 |
| | | Chemotherapy and radiation | 146 | 3 | 2.1 | 23 | 16.0 | 8 | 5.6 | 3 | 2.1 | 7 | 4.9 |
| | | Unknown | 40 | 2 | 5.1 | 2 | 5.1 | . | . | 1 | 2.6 | . | . |
| **Females** | **All cases** | | **474** | **12** | **2.5** | **63** | **13.4** | **17** | **3.6** | **14** | **3.0** | **15** | **3.2** |
| | **Age at baseline** | <18 | 105 | 1 | 1.0 | 12 | 11.5 | . | . | . | . | . | . |
| | | 18-19 | 44 | 1 | 2.3 | 3 | 7.0 | 2 | 4.7 | 2 | 4.7 | 2 | 4.7 |
| | | 20-24 | 104 | 6 | 5.8 | 20 | 19.6 | 7 | 6.7 | 4 | 3.8 | 4 | 3.8 |
| | | 25-29 | 111 | 1 | 0.9 | 14 | 12.6 | 5 | 4.5 | 5 | 4.5 | 5 | 4.5 |
| | | 30-34 | 69 | 2 | 2.9 | 5 | 7.2 | 1 | 1.4 | 1 | 1.4 | 2 | 2.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **930** | **27** | **3.0** | **27** | **2.9** | **96** | **10.5** | **80** | **8.7** | **262** | **28.9** |
| | **Age at baseline** | <18 | 231 | 3 | 1.3 | 5 | 2.2 | 31 | 13.6 | 12 | 5.2 | 60 | 26.4 |
| | | 18-19 | 89 | 2 | 2.4 | 1 | 1.2 | 14 | 16.3 | 8 | 9.3 | 28 | 32.9 |
| | | 20-24 | 199 | 5 | 2.5 | 8 | 4.1 | 27 | 13.6 | 13 | 6.5 | 61 | 30.8 |
| | | 25-29 | 201 | 10 | 5.1 | 6 | 3.0 | 17 | 8.7 | 20 | 10.0 | 58 | 29.7 |
| | | 30-34 | 134 | . | . | 1 | 0.8 | 3 | 2.2 | 16 | 11.9 | 31 | 23.3 |
| | | 35+ | 76 | 7 | 9.9 | 6 | 8.1 | 4 | 5.6 | 11 | 15.1 | 24 | 34.3 |
| | **Years since diagnosis** | 5-9 | 85 | . | . | . | . | 4 | 5.0 | 6 | 7.1 | 14 | 17.7 |
| | | 10-14 | 320 | 4 | 1.3 | 10 | 3.2 | 41 | 13.0 | 31 | 9.8 | 96 | 30.5 |
| | | 15-19 | 323 | 10 | 3.1 | 8 | 2.5 | 34 | 10.6 | 18 | 5.6 | 80 | 25.0 |
| | | 20+ | 202 | 13 | 6.6 | 9 | 4.5 | 17 | 8.6 | 25 | 12.6 | 72 | 37.1 |
| | **Age at diagnosis** | <1 | 93 | 3 | 3.3 | 3 | 3.3 | 11 | 12.1 | 6 | 6.6 | 24 | 26.4 |
| | | 1-4 | 315 | 9 | 2.9 | 9 | 2.9 | 45 | 14.4 | 18 | 5.8 | 95 | 30.7 |
| | | 5-9 | 172 | 7 | 4.1 | 6 | 3.5 | 26 | 15.1 | 14 | 8.1 | 55 | 32.2 |
| | | 10-14 | 199 | 3 | 1.5 | 4 | 2.0 | 13 | 6.6 | 29 | 14.8 | 57 | 29.4 |
| | | 15-20 | 151 | 5 | 3.5 | 5 | 3.4 | 1 | 0.7 | 13 | 8.7 | 31 | 21.7 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 558 | 8 | 1.5 | 12 | 2.2 | 30 | 5.4 | 32 | 5.8 | 117 | 21.4 |
| | | Chemotherapy and radiation | 296 | 16 | 5.6 | 13 | 4.4 | 61 | 21.3 | 41 | 14.0 | 130 | 45.5 |
| | | Unknown | 73 | 3 | 4.2 | 2 | 2.8 | 5 | 6.9 | 7 | 9.6 | 15 | 21.1 |
| **Males** | **All cases** | | **456** | **13** | **2.9** | **12** | **2.7** | **49** | **10.9** | **31** | **6.9** | **115** | **25.7** |
| | **Age at baseline** | <18 | 126 | 2 | 1.6 | 4 | 3.2 | 20 | 15.9 | 10 | 7.9 | 39 | 31.2 |
| | | 18-19 | 45 | . | . | . | . | 7 | 16.3 | 5 | 11.4 | 17 | 39.5 |
| | | 20-24 | 95 | 1 | 1.1 | 3 | 3.2 | 11 | 11.6 | 6 | 6.3 | 24 | 25.3 |
| | | 25-29 | 90 | 6 | 6.8 | 2 | 2.2 | 8 | 9.1 | 5 | 5.6 | 18 | 20.7 |
| | | 30-34 | 65 | . | . | 1 | 1.6 | 3 | 4.6 | 2 | 3.1 | 10 | 15.4 |
| | | 35+ | 35 | 4 | 12.5 | 2 | 5.9 | . | . | 3 | 9.1 | 7 | 21.9 |
| | **Years since diagnosis** | 5-9 | 50 | . | . | . | . | 3 | 6.1 | 4 | 8.0 | 11 | 22.9 |
| | | 10-14 | 160 | 2 | 1.3 | 5 | 3.1 | 23 | 14.6 | 14 | 8.8 | 46 | 29.1 |
| | | 15-19 | 149 | 4 | 2.7 | 3 | 2.0 | 15 | 10.1 | 5 | 3.4 | 28 | 18.9 |
| | | 20+ | 97 | 7 | 7.5 | 4 | 4.2 | 8 | 8.4 | 8 | 8.5 | 30 | 32.3 |
| | **Age at diagnosis** | <1 | 40 | 2 | 5.1 | 2 | 5.1 | 7 | 17.9 | 5 | 13.2 | 12 | 30.8 |
| | | 1-4 | 172 | 4 | 2.3 | 5 | 2.9 | 25 | 14.5 | 10 | 5.8 | 55 | 32.2 |
| | | 5-9 | 79 | 2 | 2.5 | 1 | 1.3 | 10 | 12.7 | 5 | 6.3 | 21 | 26.9 |
| | | 10-14 | 82 | 2 | 2.5 | 1 | 1.3 | 6 | 7.5 | 9 | 11.3 | 15 | 18.8 |
| | | 15-20 | 83 | 3 | 3.8 | 3 | 3.6 | 1 | 1.3 | 2 | 2.4 | 12 | 15.2 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 269 | 4 | 1.5 | 7 | 2.6 | 14 | 5.2 | 10 | 3.7 | 52 | 19.5 |
| | | Chemotherapy and radiation | 146 | 8 | 5.6 | 5 | 3.4 | 32 | 22.5 | 18 | 12.5 | 57 | 40.4 |
| | | Unknown | 40 | 1 | 2.6 | . | . | 3 | 7.5 | 3 | 7.5 | 6 | 15.4 |
| **Females** | **All cases** | | **474** | **14** | **3.0** | **15** | **3.2** | **47** | **10.1** | **49** | **10.4** | **147** | **31.9** |
| | **Age at baseline** | <18 | 105 | 1 | 1.0 | 1 | 1.0 | 11 | 10.8 | 2 | 1.9 | 21 | 20.6 |
| | | 18-19 | 44 | 2 | 4.7 | 1 | 2.3 | 7 | 16.3 | 3 | 7.1 | 11 | 26.2 |
| | | 20-24 | 104 | 4 | 3.8 | 5 | 4.9 | 16 | 15.4 | 7 | 6.7 | 37 | 35.9 |
| | | 25-29 | 111 | 4 | 3.7 | 4 | 3.6 | 9 | 8.4 | 15 | 13.5 | 40 | 37.0 |
| | | 30-34 | 69 | . | . | . | . | . | . | 14 | 20.3 | 21 | 30.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 41 | 1 | 2.5 | 9 | 22.5 | 2 | 5.1 | 2 | 5.0 | 2 | 5.0 |
| | **Years since diagnosis** | 5-9 | 35 | . | . | 2 | 5.9 | 1 | 2.9 | . | . | . | . |
| | | 10-14 | 160 | 4 | 2.5 | 22 | 14.0 | 4 | 2.5 | 5 | 3.1 | 1 | 0.6 |
| | | 15-19 | 174 | 7 | 4.0 | 20 | 11.5 | 6 | 3.4 | 4 | 2.3 | 8 | 4.6 |
| | | 20+ | 105 | 1 | 1.0 | 19 | 18.3 | 6 | 5.8 | 5 | 4.8 | 6 | 5.8 |
| | **Age at diagnosis** | <1 | 53 | 1 | 1.9 | 8 | 15.1 | . | . | . | . | . | . |
| | | 1-4 | 143 | 5 | 3.5 | 16 | 11.3 | 5 | 3.5 | 5 | 3.5 | 6 | 4.2 |
| | | 5-9 | 93 | 1 | 1.1 | 14 | 15.4 | 7 | 7.5 | 4 | 4.3 | 5 | 5.4 |
| | | 10-14 | 117 | 2 | 1.7 | 17 | 14.7 | 5 | 4.3 | 3 | 2.6 | 3 | 2.6 |
| | | 15-20 | 68 | 3 | 4.5 | 8 | 11.9 | . | . | 2 | 3.0 | 1 | 1.5 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 289 | 4 | 1.4 | 26 | 9.1 | 9 | 3.1 | 8 | 2.8 | 4 | 1.4 |
| | | Chemotherapy and radiation | 150 | 8 | 5.4 | 33 | 22.3 | 8 | 5.4 | 5 | 3.4 | 8 | 5.4 |
| | | Unknown | 33 | . | . | 4 | 12.1 | . | . | 1 | 3.0 | 3 | 9.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 41 | 3 | 7.7 | 4 | 10.0 | 4 | 10.3 | 8 | 20.0 | 17 | 44.7 |
| | **Years since diagnosis** | 5-9 | 35 | . | . | . | . | 1 | 3.2 | 2 | 5.9 | 3 | 9.7 |
| | | 10-14 | 160 | 2 | 1.3 | 5 | 3.2 | 18 | 11.5 | 17 | 10.8 | 50 | 31.8 |
| | | 15-19 | 174 | 6 | 3.5 | 5 | 2.9 | 19 | 10.9 | 13 | 7.5 | 52 | 30.2 |
| | | 20+ | 105 | 6 | 5.8 | 5 | 4.8 | 9 | 8.8 | 17 | 16.3 | 42 | 41.6 |
| | **Age at diagnosis** | <1 | 53 | 1 | 1.9 | 1 | 1.9 | 4 | 7.7 | 1 | 1.9 | 12 | 23.1 |
| | | 1-4 | 143 | 5 | 3.5 | 4 | 2.8 | 20 | 14.3 | 8 | 5.7 | 40 | 29.0 |
| | | 5-9 | 93 | 5 | 5.4 | 5 | 5.4 | 16 | 17.2 | 9 | 9.7 | 34 | 36.6 |
| | | 10-14 | 117 | 1 | 0.9 | 3 | 2.6 | 7 | 6.0 | 20 | 17.2 | 42 | 36.8 |
| | | 15-20 | 68 | 2 | 3.2 | 2 | 3.0 | . | . | 11 | 16.4 | 19 | 29.7 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 289 | 4 | 1.4 | 5 | 1.8 | 16 | 5.6 | 22 | 7.7 | 65 | 23.0 |
| | | Chemotherapy and radiation | 150 | 8 | 5.5 | 8 | 5.4 | 29 | 20.0 | 23 | 15.5 | 73 | 50.3 |
| | | Unknown | 33 | 2 | 6.1 | 2 | 6.1 | 2 | 6.3 | 4 | 12.1 | 9 | 28.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **4498** | **113** | **2.5** | **851** | **19.1** | **76** | **1.7** | **82** | **1.8** | **41** | **0.9** |
| | **Age at baseline** | <18 | 953 | 16 | 1.7 | 193 | 20.4 | 8 | 0.8 | 6 | 0.6 | 7 | 0.7 |
| | | 18-19 | 376 | 8 | 2.1 | 74 | 19.8 | 7 | 1.9 | 6 | 1.6 | 1 | 0.3 |
| | | 20-24 | 1182 | 29 | 2.5 | 241 | 20.6 | 15 | 1.3 | 22 | 1.9 | 6 | 0.5 |
| | | 25-29 | 1086 | 31 | 2.9 | 200 | 18.7 | 22 | 2.1 | 24 | 2.2 | 10 | 0.9 |
| | | 30-34 | 625 | 20 | 3.2 | 105 | 16.9 | 16 | 2.6 | 14 | 2.3 | 8 | 1.3 |
| | | 35+ | 276 | 9 | 3.3 | 38 | 14.0 | 8 | 3.0 | 10 | 3.7 | 9 | 3.3 |
| | **Years since diagnosis** | 5-9 | 464 | 9 | 2.0 | 92 | 20.0 | 1 | 0.2 | 1 | 0.2 | 3 | 0.7 |
| | | 10-14 | 1540 | 33 | 2.2 | 294 | 19.2 | 18 | 1.2 | 20 | 1.3 | 13 | 0.8 |
| | | 15-19 | 1416 | 34 | 2.4 | 267 | 19.1 | 27 | 1.9 | 30 | 2.1 | 6 | 0.4 |
| | | 20+ | 1078 | 37 | 3.5 | 198 | 18.7 | 30 | 2.8 | 31 | 2.9 | 19 | 1.8 |
| | **Age at diagnosis** | <1 | 219 | 2 | 0.9 | 41 | 19.0 | . | . | . | . | 3 | 1.4 |
| | | 1-4 | 1323 | 30 | 2.3 | 254 | 19.4 | 24 | 1.8 | 24 | 1.8 | 6 | 0.5 |
| | | 5-9 | 1407 | 35 | 2.5 | 311 | 22.4 | 30 | 2.2 | 27 | 1.9 | 11 | 0.8 |
| | | 10-14 | 1069 | 37 | 3.5 | 189 | 17.8 | 13 | 1.2 | 22 | 2.1 | 14 | 1.3 |
| | | 15-20 | 480 | 9 | 1.9 | 56 | 11.8 | 9 | 1.9 | 9 | 1.9 | 7 | 1.5 |
| | **Treatment** | Surgery only | 1275 | 20 | 1.6 | 60 | 4.7 | 8 | 0.6 | 15 | 1.2 | 10 | 0.8 |
| | | Chemotherapy, no radiation | 355 | 10 | 2.9 | 49 | 13.9 | 3 | 0.9 | 6 | 1.7 | 7 | 2.0 |
| | | Radiation, no chemotherapy | 1170 | 21 | 1.8 | 213 | 18.5 | 22 | 1.9 | 22 | 1.9 | 8 | 0.7 |
| | | Chemotherapy and radiation | 1256 | 52 | 4.2 | 470 | 38.1 | 39 | 3.2 | 34 | 2.7 | 12 | 1.0 |
| | | Unknown | 442 | 10 | 2.3 | 59 | 13.5 | 4 | 0.9 | 5 | 1.1 | 4 | 0.9 |
| **Males** | **All cases** | | **2455** | **65** | **2.7** | **478** | **19.6** | **29** | **1.2** | **29** | **1.2** | **16** | **0.7** |
| | **Age at baseline** | <18 | 529 | 13 | 2.5 | 117 | 22.2 | 4 | 0.8 | 3 | 0.6 | 5 | 1.0 |
| | | 18-19 | 191 | 4 | 2.1 | 37 | 19.5 | 4 | 2.1 | 3 | 1.6 | 1 | 0.5 |
| | | 20-24 | 634 | 16 | 2.6 | 143 | 22.8 | 5 | 0.8 | 8 | 1.3 | 1 | 0.2 |
| | | 25-29 | 619 | 21 | 3.4 | 109 | 17.8 | 5 | 0.8 | 8 | 1.3 | 2 | 0.3 |
| | | 30-34 | 333 | 6 | 1.8 | 57 | 17.2 | 4 | 1.2 | 3 | 0.9 | 4 | 1.2 |
| | | 35+ | 149 | 5 | 3.4 | 15 | 10.2 | 7 | 4.8 | 4 | 2.7 | 3 | 2.0 |
| | **Years since diagnosis** | 5-9 | 264 | 4 | 1.5 | 57 | 21.8 | . | . | 1 | 0.4 | 2 | 0.8 |
| | | 10-14 | 832 | 24 | 2.9 | 175 | 21.1 | 7 | 0.8 | 5 | 0.6 | 7 | 0.8 |
| | | 15-19 | 772 | 17 | 2.2 | 144 | 18.9 | 12 | 1.6 | 13 | 1.7 | 1 | 0.1 |
| | | 20+ | 587 | 20 | 3.5 | 102 | 17.6 | 10 | 1.7 | 10 | 1.7 | 6 | 1.0 |
| | **Age at diagnosis** | <1 | 128 | 1 | 0.8 | 28 | 22.2 | . | . | . | . | 1 | 0.8 |
| | | 1-4 | 699 | 21 | 3.0 | 140 | 20.2 | 11 | 1.6 | 12 | 1.7 | 2 | 0.3 |
| | | 5-9 | 786 | 21 | 2.7 | 179 | 23.0 | 8 | 1.0 | 10 | 1.3 | 6 | 0.8 |
| | | 10-14 | 571 | 18 | 3.2 | 106 | 18.7 | 3 | 0.5 | 3 | 0.5 | 3 | 0.5 |
| | | 15-20 | 271 | 4 | 1.5 | 25 | 9.3 | 7 | 2.6 | 4 | 1.5 | 4 | 1.5 |
| | **Treatment** | Surgery only | 650 | 9 | 1.4 | 24 | 3.7 | 1 | 0.2 | 2 | 0.3 | 4 | 0.6 |
| | | Chemotherapy, no radiation | 191 | 9 | 4.8 | 30 | 15.9 | 1 | 0.5 | 2 | 1.1 | 3 | 1.6 |
| | | Radiation, no chemotherapy | 616 | 11 | 1.8 | 110 | 18.0 | 10 | 1.6 | 8 | 1.3 | 1 | 0.2 |
| | | Chemotherapy and radiation | 744 | 29 | 4.0 | 282 | 38.4 | 15 | 2.1 | 13 | 1.8 | 6 | 0.8 |
| | | Unknown | 254 | 7 | 2.8 | 32 | 12.7 | 2 | 0.8 | 4 | 1.6 | 2 | 0.8 |
| **Females** | **All cases** | | **2043** | **48** | **2.4** | **373** | **18.5** | **47** | **2.3** | **53** | **2.6** | **25** | **1.2** |
| | **Age at baseline** | <18 | 424 | 3 | 0.7 | 76 | 18.2 | 4 | 1.0 | 3 | 0.7 | 2 | 0.5 |
| | | 18-19 | 185 | 4 | 2.2 | 37 | 20.2 | 3 | 1.7 | 3 | 1.6 | . | . |
| | | 20-24 | 548 | 13 | 2.4 | 98 | 18.1 | 10 | 1.8 | 14 | 2.6 | 5 | 0.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **4498** | **52** | **1.2** | **35** | **0.8** | **977** | **22.2** | **276** | **6.2** | **1549** | **35.3** |
| | **Age at baseline** | <18 | 953 | 5 | 0.5 | 8 | 0.8 | 306 | 32.4 | 45 | 4.8 | 388 | 41.5 |
| | | 18-19 | 376 | 2 | 0.5 | 2 | 0.5 | 106 | 29.3 | 27 | 7.2 | 141 | 39.1 |
| | | 20-24 | 1182 | 11 | 0.9 | 8 | 0.7 | 281 | 24.3 | 81 | 6.9 | 417 | 36.0 |
| | | 25-29 | 1086 | 19 | 1.8 | 6 | 0.6 | 206 | 19.4 | 75 | 7.0 | 363 | 34.2 |
| | | 30-34 | 625 | 8 | 1.3 | 5 | 0.8 | 67 | 11.0 | 36 | 5.8 | 171 | 28.4 |
| | | 35+ | 276 | 7 | 2.6 | 6 | 2.2 | 11 | 4.0 | 12 | 4.4 | 69 | 25.7 |
| | **Years since diagnosis** | 5-9 | 464 | 3 | 0.7 | 4 | 0.9 | 127 | 28.0 | 25 | 5.4 | 174 | 38.6 |
| | | 10-14 | 1540 | 10 | 0.7 | 8 | 0.5 | 346 | 23.0 | 97 | 6.4 | 538 | 35.7 |
| | | 15-19 | 1416 | 13 | 0.9 | 12 | 0.9 | 307 | 22.1 | 77 | 5.5 | 476 | 34.4 |
| | | 20+ | 1078 | 26 | 2.5 | 11 | 1.0 | 197 | 18.7 | 77 | 7.2 | 361 | 34.6 |
| | **Age at diagnosis** | <1 | 219 | 1 | 0.5 | 1 | 0.5 | 55 | 25.5 | 13 | 6.0 | 75 | 35.0 |
| | | 1-4 | 1323 | 14 | 1.1 | 7 | 0.5 | 387 | 29.8 | 77 | 5.9 | 510 | 39.5 |
| | | 5-9 | 1407 | 16 | 1.2 | 14 | 1.0 | 378 | 27.5 | 100 | 7.2 | 544 | 39.7 |
| | | 10-14 | 1069 | 12 | 1.1 | 6 | 0.6 | 137 | 13.0 | 66 | 6.2 | 326 | 31.0 |
| | | 15-20 | 480 | 9 | 2.0 | 7 | 1.5 | 20 | 4.3 | 20 | 4.2 | 94 | 20.5 |
| | **Treatment** | Surgery only | 1275 | 7 | 0.6 | 7 | 0.6 | 33 | 2.6 | 32 | 2.5 | 139 | 11.1 |
| | | Chemotherapy, no radiation | 355 | 5 | 1.4 | 1 | 0.3 | 45 | 12.9 | 12 | 3.4 | 90 | 25.9 |
| | | Radiation, no chemotherapy | 1170 | 14 | 1.2 | 8 | 0.7 | 272 | 24.0 | 69 | 6.0 | 432 | 38.3 |
| | | Chemotherapy and radiation | 1256 | 22 | 1.8 | 16 | 1.3 | 551 | 44.9 | 144 | 11.7 | 762 | 62.2 |
| | | Unknown | 442 | 4 | 0.9 | 3 | 0.7 | 76 | 17.4 | 19 | 4.3 | 126 | 28.8 |
| **Males** | **All cases** | | **2455** | **18** | **0.7** | **10** | **0.4** | **583** | **24.2** | **134** | **5.5** | **847** | **35.4** |
| | **Age at baseline** | <18 | 529 | 3 | 0.6 | 2 | 0.4 | 178 | 33.8 | 21 | 4.0 | 228 | 43.7 |
| | | 18-19 | 191 | . | . | 1 | 0.5 | 59 | 32.2 | 15 | 7.9 | 74 | 40.4 |
| | | 20-24 | 634 | 2 | 0.3 | 2 | 0.3 | 176 | 28.3 | 42 | 6.7 | 239 | 38.5 |
| | | 25-29 | 619 | 8 | 1.3 | 2 | 0.3 | 121 | 19.9 | 37 | 6.0 | 191 | 31.6 |
| | | 30-34 | 333 | 4 | 1.2 | 2 | 0.6 | 41 | 12.7 | 15 | 4.5 | 84 | 26.5 |
| | | 35+ | 149 | 1 | 0.7 | 1 | 0.7 | 8 | 5.5 | 4 | 2.7 | 31 | 21.5 |
| | **Years since diagnosis** | 5-9 | 264 | 2 | 0.8 | 1 | 0.4 | 79 | 30.9 | 15 | 5.7 | 108 | 42.4 |
| | | 10-14 | 832 | 4 | 0.5 | 3 | 0.4 | 203 | 24.8 | 48 | 5.8 | 303 | 37.2 |
| | | 15-19 | 772 | 3 | 0.4 | 2 | 0.3 | 187 | 24.7 | 38 | 5.0 | 262 | 34.8 |
| | | 20+ | 587 | 9 | 1.6 | 4 | 0.7 | 114 | 19.8 | 33 | 5.7 | 174 | 30.6 |
| | **Age at diagnosis** | <1 | 128 | 1 | 0.8 | . | . | 30 | 23.6 | 6 | 4.8 | 42 | 33.6 |
| | | 1-4 | 699 | 4 | 0.6 | 1 | 0.1 | 233 | 33.9 | 30 | 4.3 | 281 | 41.0 |
| | | 5-9 | 786 | 8 | 1.0 | 6 | 0.8 | 215 | 27.8 | 57 | 7.3 | 306 | 40.0 |
| | | 10-14 | 571 | 1 | 0.2 | 1 | 0.2 | 95 | 16.8 | 32 | 5.7 | 173 | 30.8 |
| | | 15-20 | 271 | 4 | 1.6 | 2 | 0.7 | 10 | 3.9 | 9 | 3.3 | 45 | 17.8 |
| | **Treatment** | Surgery only | 650 | 3 | 0.5 | 3 | 0.5 | 21 | 3.3 | 17 | 2.6 | 63 | 9.9 |
| | | Chemotherapy, no radiation | 191 | 2 | 1.1 | . | . | 22 | 11.6 | 4 | 2.1 | 48 | 25.7 |
| | | Radiation, no chemotherapy | 616 | 4 | 0.7 | 2 | 0.3 | 148 | 24.7 | 29 | 4.7 | 222 | 37.5 |
| | | Chemotherapy and radiation | 744 | 6 | 0.8 | 4 | 0.5 | 343 | 46.9 | 77 | 10.5 | 442 | 60.8 |
| | | Unknown | 254 | 3 | 1.2 | 1 | 0.4 | 49 | 19.5 | 7 | 2.8 | 72 | 28.7 |
| **Females** | **All cases** | | **2043** | **34** | **1.7** | **25** | **1.2** | **394** | **19.7** | **142** | **7.0** | **702** | **35.2** |
| | **Age at baseline** | <18 | 424 | 2 | 0.5 | 6 | 1.4 | 128 | 30.7 | 24 | 5.7 | 160 | 38.7 |
| | | 18-19 | 185 | 2 | 1.1 | 1 | 0.6 | 47 | 26.3 | 12 | 6.5 | 67 | 37.6 |
| | | 20-24 | 548 | 9 | 1.7 | 6 | 1.1 | 105 | 19.6 | 39 | 7.2 | 178 | 33.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | All cases | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 467 | 10 | 2.2 | 91 | 19.9 | 17 | 3.7 | 16 | 3.5 | 8 | 1.7 |
| | | 30-34 | 292 | 14 | 4.9 | 48 | 16.6 | 12 | 4.2 | 11 | 3.8 | 4 | 1.4 |
| | | 35+ | 127 | 4 | 3.2 | 23 | 18.5 | 1 | 0.8 | 6 | 4.8 | 6 | 4.8 |
| | **Years since diagnosis** | 5-9 | 200 | 5 | 2.5 | 35 | 17.7 | 1 | 0.5 | . | . | 1 | 0.5 |
| | | 10-14 | 708 | 9 | 1.3 | 119 | 17.1 | 11 | 1.6 | 15 | 2.1 | 6 | 0.9 |
| | | 15-19 | 644 | 17 | 2.7 | 123 | 19.3 | 15 | 2.4 | 17 | 2.7 | 5 | 0.8 |
| | | 20+ | 491 | 17 | 3.6 | 96 | 20.1 | 20 | 4.2 | 21 | 4.4 | 13 | 2.7 |
| | **Age at diagnosis** | <1 | 91 | 1 | 1.1 | 13 | 14.4 | . | . | . | . | 2 | 2.2 |
| | | 1-4 | 624 | 9 | 1.5 | 114 | 18.6 | 13 | 2.1 | 12 | 2.0 | 4 | 0.6 |
| | | 5-9 | 621 | 14 | 2.3 | 132 | 21.7 | 22 | 3.6 | 17 | 2.8 | 5 | 0.8 |
| | | 10-14 | 498 | 19 | 3.8 | 83 | 16.9 | 10 | 2.0 | 19 | 3.9 | 11 | 2.2 |
| | | 15-20 | 209 | 5 | 2.4 | 31 | 15.0 | 2 | 1.0 | 5 | 2.4 | 3 | 1.4 |
| | **Treatment** | Surgery only | 625 | 11 | 1.8 | 36 | 5.8 | 7 | 1.1 | 13 | 2.1 | 6 | 1.0 |
| | | Chemotherapy, no radiation | 164 | 1 | 0.6 | 19 | 11.7 | 2 | 1.2 | 4 | 2.5 | 4 | 2.5 |
| | | Radiation, no chemotherapy | 554 | 10 | 1.8 | 103 | 19.0 | 12 | 2.2 | 14 | 2.6 | 7 | 1.3 |
| | | Chemotherapy and radiation | 512 | 23 | 4.6 | 188 | 37.7 | 24 | 4.8 | 21 | 4.2 | 6 | 1.2 |
| | | Unknown | 188 | 3 | 1.6 | 27 | 14.5 | 2 | 1.1 | 1 | 0.5 | 2 | 1.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 467 | 11 | 2.4 | 4 | 0.9 | 85 | 18.7 | 38 | 8.2 | 172 | 37.6 |
| | | 30-34 | 292 | 4 | 1.4 | 3 | 1.0 | 26 | 9.1 | 21 | 7.2 | 87 | 30.4 |
| | | 35+ | 127 | 6 | 4.8 | 5 | 4.0 | 3 | 2.4 | 8 | 6.3 | 38 | 30.6 |
| | **Years since diagnosis** | 5-9 | 200 | 1 | 0.5 | 3 | 1.5 | 48 | 24.2 | 10 | 5.0 | 66 | 33.7 |
| | | 10-14 | 708 | 6 | 0.9 | 5 | 0.7 | 143 | 20.8 | 49 | 7.0 | 235 | 34.0 |
| | | 15-19 | 644 | 10 | 1.6 | 10 | 1.6 | 120 | 19.0 | 39 | 6.1 | 214 | 33.9 |
| | | 20+ | 491 | 17 | 3.5 | 7 | 1.4 | 83 | 17.4 | 44 | 9.1 | 187 | 39.4 |
| | **Age at diagnosis** | <1 | 91 | . | . | 1 | 1.1 | 25 | 28.1 | 7 | 7.8 | 33 | 37.1 |
| | | 1-4 | 624 | 10 | 1.6 | 6 | 1.0 | 154 | 25.2 | 47 | 7.6 | 229 | 37.9 |
| | | 5-9 | 621 | 8 | 1.3 | 8 | 1.3 | 163 | 27.0 | 43 | 7.0 | 238 | 39.3 |
| | | 10-14 | 498 | 11 | 2.2 | 5 | 1.0 | 42 | 8.6 | 34 | 6.9 | 153 | 31.2 |
| | | 15-20 | 209 | 5 | 2.4 | 5 | 2.4 | 10 | 4.9 | 11 | 5.3 | 49 | 23.8 |
| | **Treatment** | Surgery only | 625 | 4 | 0.6 | 4 | 0.6 | 12 | 1.9 | 15 | 2.4 | 76 | 12.4 |
| | | Chemotherapy, no radiation | 164 | 3 | 1.9 | 1 | 0.6 | 23 | 14.4 | 8 | 4.9 | 42 | 26.3 |
| | | Radiation, no chemotherapy | 554 | 10 | 1.8 | 6 | 1.1 | 124 | 23.1 | 40 | 7.3 | 210 | 39.2 |
| | | Chemotherapy and radiation | 512 | 16 | 3.2 | 12 | 2.4 | 208 | 41.9 | 67 | 13.3 | 320 | 64.1 |
| | | Unknown | 188 | 1 | 0.5 | 2 | 1.1 | 27 | 14.5 | 12 | 6.4 | 54 | 29.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2694** | **56** | **2.1** | **334** | **12.5** | **23** | **0.9** | **34** | **1.3** | **25** | **0.9** |
| | **Age at baseline** | <18 | 528 | 6 | 1.1 | 83 | 15.8 | 1 | 0.2 | 2 | 0.4 | 5 | 1.0 |
| | | 18-19 | 215 | 4 | 1.9 | 27 | 12.7 | 3 | 1.4 | 1 | 0.5 | . | . |
| | | 20-24 | 715 | 10 | 1.4 | 97 | 13.7 | 5 | 0.7 | 11 | 1.6 | 3 | 0.4 |
| | | 25-29 | 665 | 20 | 3.0 | 72 | 11.0 | 5 | 0.8 | 7 | 1.1 | 8 | 1.2 |
| | | 30-34 | 387 | 9 | 2.3 | 38 | 9.9 | 4 | 1.0 | 7 | 1.8 | 4 | 1.0 |
| | | 35+ | 184 | 7 | 3.9 | 17 | 9.4 | 5 | 2.8 | 6 | 3.3 | 5 | 2.7 |
| | **Years since diagnosis** | 5-9 | 238 | 6 | 2.5 | 38 | 16.0 | . | . | . | . | 1 | 0.4 |
| | | 10-14 | 906 | 9 | 1.0 | 107 | 11.9 | 4 | 0.4 | 4 | 0.4 | 9 | 1.0 |
| | | 15-19 | 831 | 20 | 2.4 | 98 | 11.9 | 7 | 0.9 | 13 | 1.6 | 4 | 0.5 |
| | | 20+ | 719 | 21 | 3.0 | 91 | 12.9 | 12 | 1.7 | 17 | 2.4 | 11 | 1.5 |
| | **Age at diagnosis** | <1 | 151 | 2 | 1.3 | 34 | 23.0 | . | . | . | . | 3 | 2.0 |
| | | 1-4 | 802 | 12 | 1.5 | 106 | 13.3 | 7 | 0.9 | 11 | 1.4 | 5 | 0.6 |
| | | 5-9 | 794 | 17 | 2.2 | 100 | 12.7 | 9 | 1.1 | 10 | 1.3 | 3 | 0.4 |
| | | 10-14 | 642 | 19 | 3.0 | 70 | 11.0 | 2 | 0.3 | 7 | 1.1 | 9 | 1.4 |
| | | 15-20 | 305 | 6 | 2.0 | 24 | 8.0 | 5 | 1.7 | 6 | 2.0 | 5 | 1.7 |
| | **Treatment** | Surgery only | 1049 | 18 | 1.7 | 43 | 4.1 | 7 | 0.7 | 10 | 1.0 | 9 | 0.9 |
| | | Chemotherapy, no radiation | 255 | 7 | 2.8 | 38 | 15.0 | 1 | 0.4 | 4 | 1.6 | 6 | 2.4 |
| | | Radiation, no chemotherapy | 730 | 16 | 2.2 | 110 | 15.2 | 6 | 0.8 | 7 | 1.0 | 5 | 0.7 |
| | | Chemotherapy and radiation | 374 | 9 | 2.5 | 111 | 30.3 | 6 | 1.6 | 10 | 2.7 | 3 | 0.8 |
| | | Unknown | 286 | 6 | 2.1 | 32 | 11.3 | 3 | 1.1 | 3 | 1.1 | 2 | 0.7 |
| **Males** | **All cases** | | **1409** | **30** | **2.1** | **173** | **12.4** | **8** | **0.6** | **13** | **0.9** | **7** | **0.5** |
| | **Age at baseline** | <18 | 279 | 5 | 1.8 | 50 | 17.9 | . | . | 2 | 0.7 | 3 | 1.1 |
| | | 18-19 | 109 | 2 | 1.8 | 13 | 12.0 | 1 | 0.9 | . | . | . | . |
| | | 20-24 | 355 | 4 | 1.1 | 51 | 14.5 | 1 | 0.3 | 4 | 1.1 | . | . |
| | | 25-29 | 372 | 12 | 3.3 | 37 | 10.0 | 1 | 0.3 | 3 | 0.8 | 1 | 0.3 |
| | | 30-34 | 196 | 3 | 1.5 | 18 | 9.2 | 1 | 0.5 | 2 | 1.0 | 2 | 1.0 |
| | | 35+ | 98 | 4 | 4.1 | 4 | 4.1 | 4 | 4.2 | 2 | 2.1 | 1 | 1.0 |
| | **Years since diagnosis** | 5-9 | 126 | 2 | 1.6 | 24 | 19.0 | . | . | . | . | . | . |
| | | 10-14 | 479 | 7 | 1.5 | 62 | 12.9 | 1 | 0.2 | 2 | 0.4 | 5 | 1.0 |
| | | 15-19 | 422 | 9 | 2.2 | 48 | 11.5 | 4 | 1.0 | 7 | 1.7 | 1 | 0.2 |
| | | 20+ | 382 | 12 | 3.2 | 39 | 10.3 | 3 | 0.8 | 4 | 1.1 | 1 | 0.3 |
| | **Age at diagnosis** | <1 | 86 | 1 | 1.2 | 23 | 27.4 | . | . | . | . | 1 | 1.2 |
| | | 1-4 | 404 | 6 | 1.5 | 53 | 13.2 | 1 | 0.2 | 5 | 1.2 | 1 | 0.2 |
| | | 5-9 | 422 | 11 | 2.6 | 54 | 12.9 | 2 | 0.5 | 4 | 1.0 | 1 | 0.2 |
| | | 10-14 | 329 | 10 | 3.0 | 35 | 10.6 | 1 | 0.3 | 2 | 0.6 | 1 | 0.3 |
| | | 15-20 | 168 | 2 | 1.2 | 8 | 4.8 | 4 | 2.4 | 2 | 1.2 | 3 | 1.8 |
| | **Treatment** | Surgery only | 525 | 7 | 1.3 | 16 | 3.1 | 1 | 0.2 | 1 | 0.2 | 3 | 0.6 |
| | | Chemotherapy, no radiation | 142 | 6 | 4.3 | 25 | 17.7 | . | . | 2 | 1.4 | 2 | 1.4 |
| | | Radiation, no chemotherapy | 371 | 8 | 2.2 | 56 | 15.2 | 4 | 1.1 | 5 | 1.4 | . | . |
| | | Chemotherapy and radiation | 212 | 4 | 1.9 | 62 | 29.8 | 1 | 0.5 | 3 | 1.4 | 1 | 0.5 |
| | | Unknown | 159 | 5 | 3.1 | 14 | 8.8 | 2 | 1.3 | 2 | 1.3 | 1 | 0.6 |
| **Females** | **All cases** | | **1285** | **26** | **2.0** | **161** | **12.7** | **15** | **1.2** | **21** | **1.7** | **18** | **1.4** |
| | **Age at baseline** | <18 | 249 | 1 | 0.4 | 33 | 13.5 | 1 | 0.4 | . | . | 2 | 0.8 |
| | | 18-19 | 106 | 2 | 1.9 | 14 | 13.3 | 2 | 1.9 | 1 | 1.0 | . | . |
| | | 20-24 | 360 | 6 | 1.7 | 46 | 12.8 | 4 | 1.1 | 7 | 2.0 | 3 | 0.8 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2694** | **29** | **1.1** | **25** | **0.9** | **383** | **14.5** | **134** | **5.0** | **681** | **26.0** |
| | **Age at baseline** | <18 | 528 | 3 | 0.6 | 5 | 1.0 | 131 | 25.0 | 21 | 4.0 | 172 | 33.0 |
| | | 18-19 | 215 | 2 | 1.0 | 2 | 0.9 | 38 | 18.4 | 14 | 6.5 | 59 | 28.8 |
| | | 20-24 | 715 | 5 | 0.7 | 5 | 0.7 | 110 | 15.6 | 35 | 5.0 | 181 | 25.9 |
| | | 25-29 | 665 | 11 | 1.7 | 6 | 0.9 | 77 | 11.8 | 44 | 6.7 | 163 | 25.2 |
| | | 30-34 | 387 | 3 | 0.8 | 4 | 1.0 | 21 | 5.6 | 12 | 3.1 | 69 | 18.5 |
| | | 35+ | 184 | 5 | 2.8 | 3 | 1.7 | 6 | 3.3 | 8 | 4.4 | 37 | 20.9 |
| | **Years since diagnosis** | 5-9 | 238 | 1 | 0.4 | 3 | 1.3 | 50 | 21.5 | 9 | 3.8 | 72 | 31.0 |
| | | 10-14 | 906 | 6 | 0.7 | 6 | 0.7 | 131 | 14.7 | 49 | 5.4 | 223 | 25.2 |
| | | 15-19 | 831 | 5 | 0.6 | 7 | 0.8 | 112 | 13.7 | 34 | 4.1 | 198 | 24.3 |
| | | 20+ | 719 | 17 | 2.4 | 9 | 1.3 | 90 | 12.9 | 42 | 5.9 | 188 | 27.2 |
| | **Age at diagnosis** | <1 | 151 | 1 | 0.7 | 1 | 0.7 | 43 | 29.1 | 10 | 6.8 | 59 | 40.1 |
| | | 1-4 | 802 | 8 | 1.0 | 4 | 0.5 | 162 | 20.6 | 41 | 5.2 | 234 | 29.9 |
| | | 5-9 | 794 | 9 | 1.1 | 10 | 1.3 | 123 | 15.8 | 40 | 5.1 | 201 | 26.0 |
| | | 10-14 | 642 | 6 | 0.9 | 6 | 0.9 | 46 | 7.2 | 31 | 4.9 | 138 | 21.9 |
| | | 15-20 | 305 | 5 | 1.7 | 4 | 1.3 | 9 | 3.1 | 12 | 4.0 | 49 | 16.9 |
| | **Treatment** | Surgery only | 1049 | 3 | 0.3 | 4 | 0.4 | 26 | 2.5 | 28 | 2.7 | 108 | 10.5 |
| | | Chemotherapy, no radiation | 255 | 4 | 1.6 | 1 | 0.4 | 35 | 13.9 | 10 | 4.0 | 70 | 28.0 |
| | | Radiation, no chemotherapy | 730 | 10 | 1.4 | 7 | 1.0 | 159 | 22.4 | 46 | 6.4 | 245 | 34.9 |
| | | Chemotherapy and radiation | 374 | 10 | 2.7 | 10 | 2.7 | 126 | 34.4 | 40 | 10.8 | 187 | 51.8 |
| | | Unknown | 286 | 2 | 0.7 | 3 | 1.1 | 37 | 13.1 | 10 | 3.5 | 71 | 25.2 |
| **Males** | **All cases** | | **1409** | **8** | **0.6** | **7** | **0.5** | **216** | **15.7** | **57** | **4.1** | **344** | **25.1** |
| | **Age at baseline** | <18 | 279 | 1 | 0.4 | 1 | 0.4 | 74 | 26.6 | 6 | 2.2 | 97 | 35.0 |
| | | 18-19 | 109 | . | . | 1 | 0.9 | 24 | 23.5 | 10 | 9.2 | 34 | 33.3 |
| | | 20-24 | 355 | . | . | 1 | 0.3 | 62 | 17.8 | 14 | 4.0 | 90 | 25.9 |
| | | 25-29 | 372 | 4 | 1.1 | 2 | 0.5 | 40 | 11.0 | 18 | 4.9 | 78 | 21.5 |
| | | 30-34 | 196 | 2 | 1.1 | 1 | 0.5 | 12 | 6.4 | 6 | 3.1 | 32 | 17.3 |
| | | 35+ | 98 | 1 | 1.0 | 1 | 1.0 | 4 | 4.2 | 3 | 3.1 | 13 | 13.8 |
| | **Years since diagnosis** | 5-9 | 126 | . | . | 1 | 0.8 | 29 | 23.8 | 5 | 4.0 | 43 | 35.2 |
| | | 10-14 | 479 | 2 | 0.4 | 2 | 0.4 | 78 | 16.6 | 22 | 4.6 | 123 | 26.3 |
| | | 15-19 | 422 | 1 | 0.2 | 1 | 0.2 | 63 | 15.3 | 15 | 3.6 | 101 | 24.6 |
| | | 20+ | 382 | 5 | 1.3 | 3 | 0.8 | 46 | 12.3 | 15 | 4.0 | 77 | 21.0 |
| | **Age at diagnosis** | <1 | 86 | 1 | 1.2 | . | . | 23 | 27.1 | 5 | 6.0 | 33 | 39.3 |
| | | 1-4 | 404 | 1 | 0.3 | . | . | 95 | 24.0 | 10 | 2.5 | 117 | 29.5 |
| | | 5-9 | 422 | 3 | 0.7 | 4 | 1.0 | 64 | 15.5 | 22 | 5.2 | 105 | 25.7 |
| | | 10-14 | 329 | 1 | 0.3 | 1 | 0.3 | 31 | 9.5 | 14 | 4.3 | 67 | 20.7 |
| | | 15-20 | 168 | 2 | 1.3 | 2 | 1.2 | 3 | 1.9 | 6 | 3.6 | 22 | 14.1 |
| | **Treatment** | Surgery only | 525 | 1 | 0.2 | 2 | 0.4 | 16 | 3.1 | 14 | 2.7 | 47 | 9.2 |
| | | Chemotherapy, no radiation | 142 | 1 | 0.7 | . | . | 19 | 13.4 | 3 | 2.1 | 39 | 27.7 |
| | | Radiation, no chemotherapy | 371 | 3 | 0.8 | 2 | 0.5 | 86 | 23.9 | 15 | 4.1 | 121 | 33.9 |
| | | Chemotherapy and radiation | 212 | 1 | 0.5 | 2 | 1.0 | 70 | 34.0 | 19 | 9.1 | 97 | 47.8 |
| | | Unknown | 159 | 2 | 1.3 | 1 | 0.6 | 25 | 16.0 | 6 | 3.8 | 40 | 25.6 |
| **Females** | **All cases** | | **1285** | **21** | **1.7** | **18** | **1.4** | **167** | **13.2** | **77** | **6.1** | **337** | **26.9** |
| | **Age at baseline** | <18 | 249 | 2 | 0.8 | 4 | 1.6 | 57 | 23.2 | 15 | 6.1 | 75 | 30.7 |
| | | 18-19 | 106 | 2 | 1.9 | 1 | 0.9 | 14 | 13.5 | 4 | 3.8 | 25 | 24.3 |
| | | 20-24 | 360 | 5 | 1.4 | 4 | 1.1 | 48 | 13.5 | 21 | 5.9 | 91 | 25.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 293 | 8 | 2.8 | 35 | 12.2 | 4 | 1.4 | 4 | 1.4 | 7 | 2.4 |
| | | 30-34 | 191 | 6 | 3.2 | 20 | 10.5 | 3 | 1.6 | 5 | 2.6 | 2 | 1.1 |
| | | 35+ | 86 | 3 | 3.6 | 13 | 15.7 | 1 | 1.2 | 4 | 4.7 | 4 | 4.7 |
| | **Years since diagnosis** | 5-9 | 112 | 4 | 3.6 | 14 | 12.6 | . | . | . | . | 1 | 0.9 |
| | | 10-14 | 427 | 2 | 0.5 | 45 | 10.7 | 3 | 0.7 | 2 | 0.5 | 4 | 0.9 |
| | | 15-19 | 409 | 11 | 2.7 | 50 | 12.3 | 3 | 0.7 | 6 | 1.5 | 3 | 0.7 |
| | | 20+ | 337 | 9 | 2.7 | 52 | 15.9 | 9 | 2.7 | 13 | 3.9 | 10 | 3.0 |
| | **Age at diagnosis** | <1 | 65 | 1 | 1.5 | 11 | 17.2 | . | . | . | . | 2 | 3.1 |
| | | 1-4 | 398 | 6 | 1.5 | 53 | 13.5 | 6 | 1.5 | 6 | 1.5 | 4 | 1.0 |
| | | 5-9 | 372 | 6 | 1.6 | 46 | 12.5 | 7 | 1.9 | 6 | 1.6 | 2 | 0.5 |
| | | 10-14 | 313 | 9 | 2.9 | 35 | 11.4 | 1 | 0.3 | 5 | 1.6 | 8 | 2.6 |
| | | 15-20 | 137 | 4 | 3.0 | 16 | 11.9 | 1 | 0.7 | 4 | 2.9 | 2 | 1.5 |
| | **Treatment** | Surgery only | 524 | 11 | 2.1 | 27 | 5.2 | 6 | 1.2 | 9 | 1.7 | 6 | 1.1 |
| | | Chemotherapy, no radiation | 113 | 1 | 0.9 | 13 | 11.6 | 1 | 0.9 | 2 | 1.8 | 4 | 3.6 |
| | | Radiation, no chemotherapy | 359 | 8 | 2.3 | 54 | 15.3 | 2 | 0.6 | 2 | 0.6 | 5 | 1.4 |
| | | Chemotherapy and radiation | 162 | 5 | 3.1 | 49 | 31.0 | 5 | 3.1 | 7 | 4.4 | 2 | 1.2 |
| | | Unknown | 127 | 1 | 0.8 | 18 | 14.4 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 293 | 7 | 2.4 | 4 | 1.4 | 37 | 13.0 | 26 | 9.0 | 85 | 29.8 |
| | | 30-34 | 191 | 1 | 0.5 | 3 | 1.6 | 9 | 4.8 | 6 | 3.2 | 37 | 19.8 |
| | | 35+ | 86 | 4 | 4.7 | 2 | 2.4 | 2 | 2.4 | 5 | 5.9 | 24 | 28.9 |
| | **Years since diagnosis** | 5-9 | 112 | 1 | 0.9 | 2 | 1.8 | 21 | 18.9 | 4 | 3.6 | 29 | 26.4 |
| | | 10-14 | 427 | 4 | 1.0 | 4 | 0.9 | 53 | 12.6 | 27 | 6.4 | 100 | 24.0 |
| | | 15-19 | 409 | 4 | 1.0 | 6 | 1.5 | 49 | 12.1 | 19 | 4.7 | 97 | 24.1 |
| | | 20+ | 337 | 12 | 3.6 | 6 | 1.8 | 44 | 13.5 | 27 | 8.1 | 111 | 34.3 |
| | **Age at diagnosis** | <1 | 65 | . | . | 1 | 1.5 | 20 | 31.7 | 5 | 7.8 | 26 | 41.3 |
| | | 1-4 | 398 | 7 | 1.8 | 4 | 1.0 | 67 | 17.1 | 31 | 7.9 | 117 | 30.2 |
| | | 5-9 | 372 | 6 | 1.6 | 6 | 1.6 | 59 | 16.2 | 18 | 4.9 | 96 | 26.4 |
| | | 10-14 | 313 | 5 | 1.6 | 5 | 1.6 | 15 | 4.9 | 17 | 5.5 | 71 | 23.2 |
| | | 15-20 | 137 | 3 | 2.2 | 2 | 1.5 | 6 | 4.5 | 6 | 4.4 | 27 | 20.1 |
| | **Treatment** | Surgery only | 524 | 2 | 0.4 | 2 | 0.4 | 10 | 1.9 | 14 | 2.7 | 61 | 11.9 |
| | | Chemotherapy, no radiation | 113 | 3 | 2.7 | 1 | 0.9 | 16 | 14.7 | 7 | 6.3 | 31 | 28.4 |
| | | Radiation, no chemotherapy | 359 | 7 | 2.0 | 5 | 1.4 | 73 | 20.9 | 31 | 8.8 | 124 | 35.8 |
| | | Chemotherapy and radiation | 162 | 9 | 5.6 | 8 | 4.9 | 56 | 35.0 | 21 | 13.0 | 90 | 57.0 |
| | | Unknown | 127 | . | . | 2 | 1.6 | 12 | 9.5 | 4 | 3.2 | 31 | 24.6 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1040** | **44** | **4.3** | **404** | **39.6** | **40** | **3.9** | **29** | **2.8** | **9** | **0.9** |
| | **Age at baseline** | <18 | 246 | 6 | 2.5 | 89 | 36.5 | 7 | 2.9 | 2 | 0.8 | 1 | 0.4 |
| | | 18-19 | 82 | 3 | 3.7 | 33 | 40.7 | 1 | 1.3 | 2 | 2.5 | 1 | 1.3 |
| | | 20-24 | 292 | 15 | 5.3 | 115 | 40.2 | 9 | 3.1 | 5 | 1.7 | 1 | 0.3 |
| | | 25-29 | 252 | 9 | 3.7 | 102 | 41.6 | 12 | 4.9 | 13 | 5.2 | 1 | 0.4 |
| | | 30-34 | 131 | 9 | 7.1 | 54 | 41.9 | 10 | 7.8 | 5 | 3.9 | 3 | 2.3 |
| | | 35+ | 37 | 2 | 5.6 | 11 | 30.6 | 1 | 2.9 | 2 | 5.7 | 2 | 5.6 |
| | **Years since diagnosis** | 5-9 | 124 | 1 | 0.8 | 41 | 33.6 | 1 | 0.8 | 1 | 0.8 | . | . |
| | | 10-14 | 355 | 18 | 5.2 | 140 | 39.8 | 11 | 3.2 | 7 | 2.0 | 2 | 0.6 |
| | | 15-19 | 344 | 11 | 3.3 | 140 | 41.8 | 15 | 4.5 | 13 | 3.8 | 2 | 0.6 |
| | | 20+ | 217 | 14 | 6.8 | 83 | 39.2 | 13 | 6.2 | 8 | 3.8 | 5 | 2.3 |
| | **Age at diagnosis** | <1 | 28 | . | . | 4 | 14.3 | . | . | . | . | . | . |
| | | 1-4 | 298 | 13 | 4.5 | 118 | 40.1 | 13 | 4.4 | 5 | 1.7 | 1 | 0.3 |
| | | 5-9 | 422 | 15 | 3.7 | 182 | 44.3 | 18 | 4.4 | 14 | 3.4 | 6 | 1.4 |
| | | 10-14 | 230 | 14 | 6.2 | 86 | 38.1 | 7 | 3.1 | 9 | 3.9 | 2 | 0.9 |
| | | 15-20 | 62 | 2 | 3.2 | 14 | 22.6 | 2 | 3.3 | 1 | 1.6 | . | . |
| | **Treatment** | Surgery only | 8 | . | . | 2 | 25.0 | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 53 | 2 | 3.9 | 6 | 11.3 | 1 | 1.9 | . | . | . | . |
| | | Radiation, no chemotherapy | 208 | 3 | 1.5 | 62 | 30.8 | 13 | 6.5 | 9 | 4.5 | . | . |
| | | Chemotherapy and radiation | 694 | 36 | 5.3 | 318 | 46.5 | 25 | 3.7 | 18 | 2.6 | 8 | 1.2 |
| | | Unknown | 77 | 3 | 3.9 | 16 | 21.3 | 1 | 1.3 | 2 | 2.6 | 1 | 1.3 |
| **Males** | **All cases** | | **631** | **28** | **4.5** | **247** | **39.8** | **16** | **2.6** | **11** | **1.8** | **4** | **0.6** |
| | **Age at baseline** | <18 | 147 | 5 | 3.5 | 55 | 37.7 | 4 | 2.7 | 1 | 0.7 | 1 | 0.7 |
| | | 18-19 | 47 | 1 | 2.1 | 19 | 40.4 | 1 | 2.1 | 1 | 2.1 | 1 | 2.2 |
| | | 20-24 | 185 | 11 | 6.0 | 77 | 42.3 | 4 | 2.2 | 2 | 1.1 | . | . |
| | | 25-29 | 157 | 7 | 4.6 | 58 | 38.2 | 3 | 2.0 | 5 | 3.2 | 1 | 0.6 |
| | | 30-34 | 73 | 3 | 4.2 | 32 | 43.8 | 3 | 4.2 | 1 | 1.4 | 1 | 1.4 |
| | | 35+ | 22 | 1 | 4.8 | 6 | 28.6 | 1 | 5.0 | 1 | 4.8 | . | . |
| | **Years since diagnosis** | 5-9 | 76 | . | . | 23 | 30.7 | . | . | 1 | 1.3 | . | . |
| | | 10-14 | 208 | 12 | 5.9 | 91 | 44.0 | 5 | 2.4 | 1 | 0.5 | 2 | 1.0 |
| | | 15-19 | 217 | 8 | 3.8 | 79 | 37.4 | 5 | 2.4 | 5 | 2.3 | . | . |
| | | 20+ | 130 | 8 | 6.3 | 54 | 42.2 | 6 | 4.7 | 4 | 3.1 | 2 | 1.5 |
| | **Age at diagnosis** | <1 | 16 | . | . | 3 | 18.8 | . | . | . | . | . | . |
| | | 1-4 | 180 | 12 | 6.8 | 70 | 39.1 | 8 | 4.5 | 4 | 2.2 | 1 | 0.6 |
| | | 5-9 | 266 | 9 | 3.5 | 116 | 44.6 | 6 | 2.3 | 5 | 1.9 | 3 | 1.1 |
| | | 10-14 | 132 | 6 | 4.7 | 51 | 39.5 | 1 | 0.8 | 1 | 0.8 | . | . |
| | | 15-20 | 37 | 1 | 2.7 | 7 | 18.9 | 1 | 2.8 | 1 | 2.7 | . | . |
| | **Treatment** | Surgery only | 5 | . | . | 2 | 40.0 | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 27 | 2 | 7.7 | 3 | 11.1 | 1 | 3.7 | . | . | . | . |
| | | Radiation, no chemotherapy | 116 | 2 | 1.8 | 30 | 26.5 | 4 | 3.5 | 1 | 0.9 | . | . |
| | | Chemotherapy and radiation | 436 | 22 | 5.1 | 201 | 46.6 | 11 | 2.6 | 8 | 1.9 | 4 | 0.9 |
| | | Unknown | 47 | 2 | 4.3 | 11 | 24.4 | . | . | 2 | 4.3 | . | . |
| **Females** | **All cases** | | **409** | **16** | **4.0** | **157** | **39.3** | **24** | **6.0** | **18** | **4.5** | **5** | **1.2** |
| | **Age at baseline** | <18 | 99 | 1 | 1.0 | 34 | 34.7 | 3 | 3.1 | 1 | 1.0 | . | . |
| | | 18-19 | 35 | 2 | 5.9 | 14 | 41.2 | . | . | 1 | 2.9 | . | . |
| | | 20-24 | 107 | 4 | 3.9 | 38 | 36.5 | 5 | 4.8 | 3 | 2.8 | 1 | 0.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem[2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1040** | **11** | **1.1** | **4** | **0.4** | **482** | **47.2** | **105** | **10.2** | **659** | **64.5** |
| | **Age at baseline** | <18 | 246 | 1 | 0.4 | 1 | 0.4 | 141 | 58.0 | 20 | 8.1 | 166 | 69.2 |
| | | 18-19 | 82 | . | . | . | . | 53 | 67.1 | 5 | 6.3 | 59 | 74.7 |
| | | 20-24 | 292 | 3 | 1.0 | 1 | 0.3 | 142 | 49.5 | 31 | 10.8 | 184 | 63.9 |
| | | 25-29 | 252 | 5 | 2.0 | . | . | 104 | 42.1 | 25 | 10.2 | 155 | 62.2 |
| | | 30-34 | 131 | 1 | 0.8 | 1 | 0.8 | 39 | 30.2 | 22 | 16.9 | 80 | 62.0 |
| | | 35+ | 37 | 1 | 2.8 | 1 | 2.7 | 3 | 8.1 | 2 | 5.4 | 15 | 40.5 |
| | **Years since diagnosis** | 5-9 | 124 | . | . | 1 | 0.8 | 59 | 48.0 | 11 | 8.9 | 75 | 61.5 |
| | | 10-14 | 355 | 1 | 0.3 | . | . | 173 | 49.9 | 32 | 9.1 | 231 | 66.2 |
| | | 15-19 | 344 | 5 | 1.5 | 2 | 0.6 | 160 | 47.3 | 29 | 8.6 | 217 | 64.4 |
| | | 20+ | 217 | 5 | 2.3 | 1 | 0.5 | 90 | 42.1 | 33 | 15.3 | 136 | 63.6 |
| | **Age at diagnosis** | <1 | 28 | . | . | . | . | 8 | 28.6 | 2 | 7.1 | 10 | 37.0 |
| | | 1-4 | 298 | 4 | 1.4 | . | . | 180 | 61.4 | 27 | 9.1 | 211 | 72.5 |
| | | 5-9 | 422 | 5 | 1.2 | 3 | 0.7 | 221 | 53.6 | 46 | 11.1 | 289 | 70.1 |
| | | 10-14 | 230 | 2 | 0.9 | . | . | 67 | 29.5 | 26 | 11.6 | 129 | 56.1 |
| | | 15-20 | 62 | . | . | 1 | 1.6 | 6 | 9.7 | 4 | 6.5 | 20 | 32.3 |
| | **Treatment** | Surgery only | 8 | 1 | 12.5 | . | . | 2 | 25.0 | . | . | 3 | 37.5 |
| | | Chemotherapy, no radiation | 53 | . | . | . | . | 8 | 15.1 | 1 | 1.9 | 12 | 23.1 |
| | | Radiation, no chemotherapy | 208 | . | . | 1 | 0.5 | 70 | 34.7 | 13 | 6.3 | 111 | 55.0 |
| | | Chemotherapy and radiation | 694 | 10 | 1.4 | 3 | 0.4 | 373 | 54.7 | 86 | 12.6 | 495 | 72.5 |
| | | Unknown | 77 | . | . | . | . | 29 | 37.7 | 5 | 6.5 | 38 | 49.4 |
| **Males** | **All cases** | | **631** | **5** | **0.8** | **2** | **0.3** | **312** | **49.9** | **63** | **10.1** | **400** | **64.3** |
| | **Age at baseline** | <18 | 147 | 1 | 0.7 | . | . | 85 | 58.2 | 12 | 8.2 | 102 | 70.8 |
| | | 18-19 | 47 | . | . | . | . | 31 | 67.4 | 3 | 6.5 | 33 | 71.7 |
| | | 20-24 | 185 | . | . | 1 | 0.5 | 100 | 54.3 | 22 | 12.0 | 123 | 67.2 |
| | | 25-29 | 157 | 4 | 2.6 | . | . | 70 | 45.2 | 17 | 11.1 | 93 | 60.0 |
| | | 30-34 | 73 | . | . | 1 | 1.4 | 24 | 33.3 | 9 | 12.3 | 41 | 56.9 |
| | | 35+ | 22 | . | . | . | . | 2 | 9.1 | . | . | 8 | 36.4 |
| | **Years since diagnosis** | 5-9 | 76 | . | . | . | . | 38 | 50.0 | 7 | 9.2 | 45 | 60.0 |
| | | 10-14 | 208 | 1 | 0.5 | . | . | 106 | 51.7 | 20 | 9.7 | 140 | 68.3 |
| | | 15-19 | 217 | 2 | 0.9 | 1 | 0.5 | 107 | 49.8 | 18 | 8.5 | 132 | 62.0 |
| | | 20+ | 130 | 2 | 1.5 | 1 | 0.8 | 61 | 47.3 | 18 | 13.8 | 83 | 64.3 |
| | **Age at diagnosis** | <1 | 16 | . | . | . | . | 5 | 31.3 | 1 | 6.3 | 6 | 40.0 |
| | | 1-4 | 180 | 2 | 1.1 | . | . | 114 | 63.7 | 17 | 9.4 | 132 | 74.2 |
| | | 5-9 | 266 | 3 | 1.1 | 2 | 0.8 | 144 | 55.0 | 30 | 11.5 | 181 | 69.6 |
| | | 10-14 | 132 | . | . | . | . | 47 | 35.9 | 14 | 10.9 | 73 | 55.3 |
| | | 15-20 | 37 | . | . | . | . | 2 | 5.4 | 1 | 2.7 | 8 | 21.6 |
| | **Treatment** | Surgery only | 5 | . | . | . | . | 2 | 40.0 | . | . | 2 | 40.0 |
| | | Chemotherapy, no radiation | 27 | . | . | . | . | 2 | 7.4 | 1 | 3.7 | 6 | 23.1 |
| | | Radiation, no chemotherapy | 116 | . | . | . | . | 39 | 33.9 | 8 | 6.9 | 57 | 50.4 |
| | | Chemotherapy and radiation | 436 | 5 | 1.2 | 2 | 0.5 | 251 | 58.2 | 53 | 12.4 | 312 | 72.4 |
| | | Unknown | 47 | . | . | . | . | 18 | 38.3 | 1 | 2.1 | 23 | 48.9 |
| **Females** | **All cases** | | **409** | **6** | **1.5** | **2** | **0.5** | **170** | **42.8** | **42** | **10.4** | **259** | **64.8** |
| | **Age at baseline** | <18 | 99 | . | . | 1 | 1.0 | 56 | 57.7 | 8 | 8.1 | 64 | 66.7 |
| | | 18-19 | 35 | . | . | . | . | 22 | 66.7 | 2 | 5.9 | 26 | 78.8 |
| | | 20-24 | 107 | 3 | 2.8 | . | . | 42 | 40.8 | 9 | 8.6 | 61 | 58.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1)[1] | | Underactive thyroid (E.2/E.2)[1] | | Thyroid nodules (E.3/E.3)[1] | | Thyroid enlargement (E.4/E.4)[1] | | Diabetes-diet (E.5/E.5)[1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 95 | 2 | 2.2 | 44 | 47.3 | 9 | 9.6 | 8 | 8.5 | . | . |
| | | 30-34 | 58 | 6 | 10.7 | 22 | 39.3 | 7 | 12.5 | 4 | 7.0 | 2 | 3.5 |
| | | 35+ | 15 | 1 | 6.7 | 5 | 33.3 | . | . | 1 | 7.1 | 2 | 14.3 |
| | **Years since diagnosis** | 5-9 | 48 | 1 | 2.1 | 18 | 38.3 | 1 | 2.1 | . | . | . | . |
| | | 10-14 | 147 | 6 | 4.2 | 49 | 33.8 | 6 | 4.2 | 6 | 4.1 | . | . |
| | | 15-19 | 127 | 3 | 2.4 | 61 | 49.2 | 10 | 8.1 | 8 | 6.4 | 2 | 1.6 |
| | | 20+ | 87 | 6 | 7.4 | 29 | 34.5 | 7 | 8.3 | 4 | 4.7 | 3 | 3.5 |
| | **Age at diagnosis** | <1 | 12 | . | . | 1 | 8.3 | . | . | . | . | . | . |
| | | 1-4 | 118 | 1 | 0.9 | 48 | 41.7 | 5 | 4.4 | 1 | 0.9 | . | . |
| | | 5-9 | 156 | 6 | 4.0 | 66 | 43.7 | 12 | 8.0 | 9 | 5.9 | 3 | 2.0 |
| | | 10-14 | 98 | 8 | 8.2 | 35 | 36.1 | 6 | 6.1 | 8 | 8.2 | 2 | 2.0 |
| | | 15-20 | 25 | 1 | 4.0 | 7 | 28.0 | 1 | 4.2 | . | . | . | . |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 26 | . | . | 3 | 11.5 | . | . | . | . | . | . |
| | | Radiation, no chemotherapy | 92 | 1 | 1.1 | 32 | 36.4 | 9 | 10.2 | 8 | 9.0 | . | . |
| | | Chemotherapy and radiation | 258 | 14 | 5.6 | 117 | 46.2 | 14 | 5.6 | 10 | 3.9 | 4 | 1.6 |
| | | Unknown | 30 | 1 | 3.3 | 5 | 16.7 | 1 | 3.3 | . | . | 1 | 3.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 95 | 1 | 1.1 | . | . | 34 | 37.0 | 8 | 8.6 | 62 | 66.0 |
| | | 30-34 | 58 | 1 | 1.8 | . | . | 15 | 26.3 | 13 | 22.8 | 39 | 68.4 |
| | | 35+ | 15 | 1 | 7.1 | 1 | 6.7 | 1 | 6.7 | 2 | 13.3 | 7 | 46.7 |
| | **Years since diagnosis** | 5-9 | 48 | . | . | 1 | 2.1 | 21 | 44.7 | 4 | 8.3 | 30 | 63.8 |
| | | 10-14 | 147 | . | . | . | . | 67 | 47.2 | 12 | 8.3 | 91 | 63.2 |
| | | 15-19 | 127 | 3 | 2.4 | 1 | 0.8 | 53 | 43.1 | 11 | 8.8 | 85 | 68.5 |
| | | 20+ | 87 | 3 | 3.5 | . | . | 29 | 34.1 | 15 | 17.6 | 53 | 62.4 |
| | **Age at diagnosis** | <1 | 12 | . | . | . | . | 3 | 25.0 | 1 | 8.3 | 4 | 33.3 |
| | | 1-4 | 118 | 2 | 1.7 | . | . | 66 | 57.9 | 10 | 8.5 | 79 | 69.9 |
| | | 5-9 | 156 | 2 | 1.3 | 1 | 0.7 | 77 | 51.3 | 16 | 10.5 | 108 | 71.1 |
| | | 10-14 | 98 | 2 | 2.1 | . | . | 20 | 20.8 | 12 | 12.5 | 56 | 57.1 |
| | | 15-20 | 25 | . | . | 1 | 4.0 | 4 | 16.0 | 3 | 12.0 | 12 | 48.0 |
| | **Treatment** | Surgery only | 3 | 1 | 33.3 | . | . | . | . | . | . | 1 | 33.3 |
| | | Chemotherapy, no radiation | 26 | . | . | . | . | 6 | 23.1 | . | . | 6 | 23.1 |
| | | Radiation, no chemotherapy | 92 | . | . | 1 | 1.1 | 31 | 35.6 | 5 | 5.6 | 54 | 60.7 |
| | | Chemotherapy and radiation | 258 | 5 | 2.0 | 1 | 0.4 | 122 | 48.6 | 33 | 13.0 | 183 | 72.6 |
| | | Unknown | 30 | . | . | . | . | 11 | 36.7 | 4 | 13.3 | 15 | 50.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **3111** | **150** | **4.9** | **901** | **29.2** | **277** | **9.0** | **226** | **7.4** | **43** | **1.4** |
| | **Age at baseline** | <18 | 61 | 1 | 1.7 | 17 | 28.8 | 1 | 1.7 | 4 | 6.8 | . | . |
| | | 18-19 | 61 | 2 | 3.4 | 8 | 13.3 | 5 | 8.2 | 5 | 8.2 | 1 | 1.6 |
| | | 20-24 | 375 | 17 | 4.5 | 60 | 16.0 | 21 | 5.6 | 20 | 5.3 | 1 | 0.3 |
| | | 25-29 | 798 | 25 | 3.2 | 209 | 26.4 | 46 | 5.8 | 51 | 6.5 | 11 | 1.4 |
| | | 30-34 | 951 | 59 | 6.3 | 292 | 31.1 | 86 | 9.2 | 65 | 7.0 | 18 | 1.9 |
| | | 35+ | 865 | 46 | 5.4 | 315 | 36.6 | 118 | 13.8 | 81 | 9.5 | 12 | 1.4 |
| | **Years since diagnosis** | 5-9 | 242 | 7 | 2.9 | 48 | 19.9 | 4 | 1.7 | 12 | 5.0 | 1 | 0.4 |
| | | 10-14 | 946 | 40 | 4.3 | 252 | 26.9 | 44 | 4.7 | 43 | 4.6 | 12 | 1.3 |
| | | 15-19 | 1008 | 55 | 5.5 | 316 | 31.6 | 94 | 9.4 | 76 | 7.7 | 14 | 1.4 |
| | | 20+ | 915 | 48 | 5.3 | 285 | 31.4 | 135 | 14.9 | 95 | 10.5 | 16 | 1.8 |
| | **Age at diagnosis** | 1-4 | 82 | 3 | 3.7 | 18 | 22.0 | 8 | 9.9 | 9 | 11.1 | 1 | 1.2 |
| | | 5-9 | 421 | 24 | 5.7 | 75 | 17.9 | 44 | 10.5 | 41 | 9.8 | 5 | 1.2 |
| | | 10-14 | 1120 | 48 | 4.4 | 286 | 25.9 | 109 | 9.8 | 89 | 8.1 | 17 | 1.5 |
| | | 15-20 | 1488 | 75 | 5.1 | 522 | 35.3 | 116 | 7.9 | 87 | 5.9 | 20 | 1.3 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 364 | 9 | 2.5 | 29 | 8.0 | 10 | 2.8 | 14 | 3.9 | 5 | 1.4 |
| | | Radiation, no chemotherapy | 652 | 40 | 6.2 | 246 | 38.1 | 85 | 13.2 | 59 | 9.2 | 4 | 0.6 |
| | | Chemotherapy and radiation | 1765 | 83 | 4.8 | 555 | 31.7 | 161 | 9.2 | 140 | 8.0 | 29 | 1.7 |
| | | Unknown | 328 | 18 | 5.6 | 71 | 21.8 | 21 | 6.4 | 13 | 4.0 | 5 | 1.5 |
| **Males** | **All cases** | | **1634** | **72** | **4.4** | **349** | **21.5** | **69** | **4.3** | **82** | **5.1** | **18** | **1.1** |
| | **Age at baseline** | <18 | 46 | 1 | 2.2 | 14 | 31.1 | 1 | 2.2 | 2 | 4.4 | . | . |
| | | 18-19 | 48 | 1 | 2.1 | 7 | 14.6 | 4 | 8.3 | 5 | 10.4 | . | . |
| | | 20-24 | 239 | 11 | 4.6 | 30 | 12.6 | 10 | 4.2 | 10 | 4.2 | 1 | 0.4 |
| | | 25-29 | 445 | 11 | 2.5 | 98 | 22.1 | 21 | 4.7 | 25 | 5.7 | 4 | 0.9 |
| | | 30-34 | 482 | 25 | 5.2 | 102 | 21.3 | 20 | 4.2 | 24 | 5.1 | 7 | 1.5 |
| | | 35+ | 374 | 23 | 6.2 | 98 | 26.3 | 13 | 3.5 | 16 | 4.3 | 6 | 1.6 |
| | **Years since diagnosis** | 5-9 | 138 | 2 | 1.5 | 21 | 15.3 | 3 | 2.2 | 4 | 2.9 | 1 | 0.7 |
| | | 10-14 | 491 | 17 | 3.5 | 107 | 21.8 | 13 | 2.7 | 20 | 4.1 | 4 | 0.8 |
| | | 15-19 | 537 | 28 | 5.2 | 121 | 22.6 | 23 | 4.3 | 27 | 5.1 | 6 | 1.1 |
| | | 20+ | 468 | 25 | 5.4 | 100 | 21.6 | 30 | 6.5 | 31 | 6.8 | 7 | 1.5 |
| | **Age at diagnosis** | 1-4 | 62 | 3 | 4.9 | 15 | 24.2 | 5 | 8.2 | 6 | 9.8 | 1 | 1.6 |
| | | 5-9 | 305 | 18 | 5.9 | 44 | 14.5 | 23 | 7.6 | 25 | 8.3 | 2 | 0.7 |
| | | 10-14 | 581 | 17 | 3.0 | 109 | 18.9 | 27 | 4.7 | 25 | 4.4 | 6 | 1.0 |
| | | 15-20 | 686 | 34 | 5.0 | 181 | 26.5 | 14 | 2.1 | 26 | 3.8 | 9 | 1.3 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 187 | 2 | 1.1 | 9 | 4.8 | 1 | 0.5 | 4 | 2.1 | 3 | 1.6 |
| | | Radiation, no chemotherapy | 336 | 19 | 5.7 | 98 | 29.4 | 24 | 7.3 | 19 | 5.8 | 1 | 0.3 |
| | | Chemotherapy and radiation | 915 | 40 | 4.4 | 216 | 23.7 | 39 | 4.3 | 54 | 6.0 | 12 | 1.3 |
| | | Unknown | 194 | 11 | 5.8 | 26 | 13.5 | 5 | 2.6 | 5 | 2.6 | 2 | 1.0 |
| **Females** | **All cases** | | **1477** | **78** | **5.4** | **552** | **37.8** | **208** | **14.2** | **144** | **9.9** | **25** | **1.7** |
| | **Age at baseline** | <18 | 15 | . | . | 3 | 21.4 | . | . | 2 | 14.3 | . | . |
| | | 18-19 | 13 | 1 | 8.3 | 1 | 8.3 | 1 | 7.7 | . | . | 1 | 7.7 |
| | | 20-24 | 136 | 6 | 4.4 | 30 | 22.2 | 11 | 8.1 | 10 | 7.4 | . | . |
| | | 25-29 | 353 | 14 | 4.0 | 111 | 31.8 | 25 | 7.2 | 26 | 7.5 | 7 | 2.0 |
| | | 30-34 | 469 | 34 | 7.4 | 190 | 41.2 | 66 | 14.3 | 41 | 8.9 | 11 | 2.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **3111** | **40** | **1.3** | **34** | **1.1** | **32** | **1.1** | **98** | **3.2** | **1284** | **42.3** |
| | **Age at baseline** | <18 | 61 | . | . | 1 | 1.7 | 6 | 10.0 | 1 | 1.7 | 24 | 40.7 |
| | | 18-19 | 61 | 1 | 1.7 | . | . | 2 | 3.4 | 2 | 3.3 | 17 | 28.8 |
| | | 20-24 | 375 | 1 | 0.3 | . | . | 9 | 2.5 | 10 | 2.7 | 107 | 29.5 |
| | | 25-29 | 798 | 5 | 0.7 | 7 | 0.9 | 6 | 0.8 | 19 | 2.4 | 275 | 35.5 |
| | | 30-34 | 951 | 15 | 1.6 | 14 | 1.5 | 6 | 0.7 | 33 | 3.5 | 421 | 45.4 |
| | | 35+ | 865 | 18 | 2.1 | 12 | 1.4 | 3 | 0.4 | 33 | 3.8 | 440 | 51.7 |
| | **Years since diagnosis** | 5-9 | 242 | 2 | 0.9 | . | . | 4 | 1.8 | 5 | 2.1 | 70 | 30.0 |
| | | 10-14 | 946 | 5 | 0.6 | 7 | 0.7 | 13 | 1.4 | 25 | 2.7 | 339 | 37.2 |
| | | 15-19 | 1008 | 10 | 1.0 | 13 | 1.3 | 7 | 0.7 | 32 | 3.2 | 448 | 45.6 |
| | | 20+ | 915 | 23 | 2.5 | 14 | 1.5 | 8 | 0.9 | 36 | 4.0 | 427 | 47.1 |
| | **Age at diagnosis** | 1-4 | 82 | 2 | 2.5 | 1 | 1.2 | 5 | 6.2 | 1 | 1.2 | 30 | 36.6 |
| | | 5-9 | 421 | 2 | 0.5 | 2 | 0.5 | 14 | 3.4 | 14 | 3.3 | 142 | 34.5 |
| | | 10-14 | 1120 | 14 | 1.3 | 16 | 1.4 | 9 | 0.8 | 42 | 3.8 | 436 | 40.0 |
| | | 15-20 | 1488 | 22 | 1.5 | 15 | 1.0 | 4 | 0.3 | 41 | 2.8 | 676 | 46.7 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 364 | 10 | 2.8 | 2 | 0.6 | 3 | 0.8 | 9 | 2.5 | 69 | 19.7 |
| | | Radiation, no chemotherapy | 652 | 7 | 1.2 | 7 | 1.1 | 2 | 0.3 | 9 | 1.4 | 335 | 53.3 |
| | | Chemotherapy and radiation | 1765 | 19 | 1.1 | 23 | 1.3 | 21 | 1.2 | 67 | 3.8 | 775 | 44.8 |
| | | Unknown | 328 | 4 | 1.2 | 2 | 0.6 | 6 | 1.9 | 13 | 4.0 | 105 | 32.4 |
| **Males** | **All cases** | | **1634** | **28** | **1.8** | **14** | **0.9** | **18** | **1.1** | **32** | **2.0** | **520** | **32.7** |
| | **Age at baseline** | <18 | 46 | . | . | . | . | 4 | 8.7 | 1 | 2.2 | 19 | 42.2 |
| | | 18-19 | 48 | 1 | 2.2 | . | . | 2 | 4.3 | 2 | 4.2 | 14 | 30.4 |
| | | 20-24 | 239 | 1 | 0.4 | . | . | 6 | 2.6 | 6 | 2.5 | 56 | 24.2 |
| | | 25-29 | 445 | 3 | 0.7 | 3 | 0.7 | 2 | 0.5 | 10 | 2.3 | 131 | 30.4 |
| | | 30-34 | 482 | 10 | 2.1 | 6 | 1.3 | 3 | 0.6 | 6 | 1.3 | 158 | 33.5 |
| | | 35+ | 374 | 13 | 3.5 | 5 | 1.3 | 1 | 0.3 | 7 | 1.9 | 142 | 38.7 |
| | **Years since diagnosis** | 5-9 | 138 | 1 | 0.8 | . | . | 3 | 2.3 | 2 | 1.4 | 33 | 25.4 |
| | | 10-14 | 491 | 4 | 0.8 | 3 | 0.6 | 7 | 1.5 | 12 | 2.5 | 146 | 30.7 |
| | | 15-19 | 537 | 7 | 1.3 | 6 | 1.1 | 4 | 0.8 | 9 | 1.7 | 184 | 35.2 |
| | | 20+ | 468 | 16 | 3.4 | 5 | 1.1 | 4 | 0.9 | 9 | 1.9 | 157 | 33.8 |
| | **Age at diagnosis** | 1-4 | 62 | 2 | 3.2 | . | . | 3 | 4.8 | 1 | 1.6 | 22 | 35.5 |
| | | 5-9 | 305 | 1 | 0.3 | . | . | 10 | 3.3 | 9 | 3.0 | 88 | 29.5 |
| | | 10-14 | 581 | 11 | 1.9 | 7 | 1.2 | 4 | 0.7 | 14 | 2.4 | 171 | 30.2 |
| | | 15-20 | 686 | 14 | 2.1 | 7 | 1.0 | 1 | 0.2 | 8 | 1.2 | 239 | 35.9 |
| | **Treatment** | Surgery only | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 187 | 7 | 3.9 | 2 | 1.1 | 2 | 1.1 | . | . | 22 | 12.2 |
| | | Radiation, no chemotherapy | 336 | 6 | 1.9 | 2 | 0.6 | 1 | 0.3 | 3 | 0.9 | 138 | 42.9 |
| | | Chemotherapy and radiation | 915 | 12 | 1.3 | 9 | 1.0 | 10 | 1.1 | 21 | 2.3 | 312 | 34.9 |
| | | Unknown | 194 | 3 | 1.6 | 1 | 0.5 | 5 | 2.6 | 8 | 4.1 | 48 | 25.0 |
| **Females** | **All cases** | | **1477** | **12** | **0.8** | **20** | **1.4** | **14** | **1.0** | **66** | **4.5** | **764** | **53.0** |
| | **Age at baseline** | <18 | 15 | . | . | 1 | 7.1 | 2 | 14.3 | . | . | 5 | 35.7 |
| | | 18-19 | 13 | . | . | . | . | . | . | . | . | 3 | 23.1 |
| | | 20-24 | 136 | . | . | . | . | 3 | 2.3 | 4 | 2.9 | 51 | 38.6 |
| | | 25-29 | 353 | 2 | 0.6 | 4 | 1.1 | 4 | 1.2 | 9 | 2.6 | 144 | 41.9 |
| | | 30-34 | 469 | 5 | 1.1 | 8 | 1.7 | 3 | 0.7 | 27 | 5.8 | 263 | 57.8 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 491 | 23 | 4.7 | 217 | 44.4 | 105 | 21.5 | 65 | 13.4 | 6 | 1.2 |
| | **Years since diagnosis** | 5-9 | 104 | 5 | 4.8 | 27 | 26.0 | 1 | 1.0 | 8 | 7.7 | . | . |
| | | 10-14 | 455 | 23 | 5.2 | 145 | 32.5 | 31 | 6.9 | 23 | 5.1 | 8 | 1.8 |
| | | 15-19 | 471 | 27 | 5.8 | 195 | 41.8 | 71 | 15.3 | 49 | 10.7 | 8 | 1.7 |
| | | 20+ | 447 | 23 | 5.2 | 185 | 41.7 | 105 | 23.6 | 64 | 14.4 | 9 | 2.0 |
| | **Age at diagnosis** | 1-4 | 20 | . | . | 3 | 15.0 | 3 | 15.0 | 3 | 15.0 | . | . |
| | | 5-9 | 116 | 6 | 5.3 | 31 | 27.2 | 21 | 18.4 | 16 | 13.9 | 3 | 2.6 |
| | | 10-14 | 539 | 31 | 5.9 | 177 | 33.4 | 82 | 15.4 | 64 | 12.1 | 11 | 2.1 |
| | | 15-20 | 802 | 41 | 5.2 | 341 | 42.8 | 102 | 12.9 | 61 | 7.7 | 11 | 1.4 |
| | **Treatment** | Chemotherapy, no radiation | 177 | 7 | 4.0 | 20 | 11.4 | 9 | 5.1 | 10 | 5.7 | 2 | 1.1 |
| | | Radiation, no chemotherapy | 316 | 21 | 6.7 | 148 | 47.3 | 61 | 19.5 | 40 | 12.9 | 3 | 1.0 |
| | | Chemotherapy and radiation | 850 | 43 | 5.2 | 339 | 40.5 | 122 | 14.6 | 86 | 10.3 | 17 | 2.0 |
| | | Unknown | 134 | 7 | 5.3 | 45 | 33.8 | 16 | 12.0 | 8 | 6.0 | 3 | 2.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 491 | 5 | 1.0 | 7 | 1.4 | 2 | 0.4 | 26 | 5.3 | 298 | 61.6 |
| | **Years since diagnosis** | 5-9 | 104 | 1 | 1.0 | . | . | 1 | 1.0 | 3 | 2.9 | 37 | 35.9 |
| | | 10-14 | 455 | 1 | 0.2 | 4 | 0.9 | 6 | 1.4 | 13 | 2.9 | 193 | 44.2 |
| | | 15-19 | 471 | 3 | 0.7 | 7 | 1.5 | 3 | 0.7 | 23 | 4.9 | 264 | 57.3 |
| | | 20+ | 447 | 7 | 1.6 | 9 | 2.0 | 4 | 0.9 | 27 | 6.1 | 270 | 61.2 |
| | **Age at diagnosis** | 1-4 | 20 | . | . | 1 | 5.0 | 2 | 10.5 | . | . | 8 | 40.0 |
| | | 5-9 | 116 | 1 | 0.9 | 2 | 1.7 | 4 | 3.5 | 5 | 4.3 | 54 | 47.4 |
| | | 10-14 | 539 | 3 | 0.6 | 9 | 1.7 | 5 | 1.0 | 28 | 5.2 | 265 | 50.5 |
| | | 15-20 | 802 | 8 | 1.0 | 8 | 1.0 | 3 | 0.4 | 33 | 4.1 | 437 | 55.8 |
| | **Treatment** | Chemotherapy, no radiation | 177 | 3 | 1.7 | . | . | 1 | 0.6 | 9 | 5.1 | 47 | 27.6 |
| | | Radiation, no chemotherapy | 316 | 1 | 0.3 | 5 | 1.6 | 1 | 0.3 | 6 | 1.9 | 197 | 64.4 |
| | | Chemotherapy and radiation | 850 | 7 | 0.8 | 14 | 1.7 | 11 | 1.3 | 46 | 5.5 | 463 | 55.5 |
| | | Unknown | 134 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 | 5 | 3.8 | 57 | 43.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2117** | **27** | **1.3** | **125** | **6.0** | **44** | **2.1** | **49** | **2.3** | **34** | **1.6** |
| | **Age at baseline** | <18 | 212 | 1 | 0.5 | 8 | 3.8 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 |
| | | 18-19 | 132 | 1 | 0.8 | 9 | 6.9 | 2 | 1.5 | 1 | 0.8 | . | . |
| | | 20-24 | 469 | 6 | 1.3 | 27 | 5.8 | 5 | 1.1 | 10 | 2.2 | 9 | 1.9 |
| | | 25-29 | 572 | 6 | 1.1 | 26 | 4.6 | 8 | 1.4 | 9 | 1.6 | 5 | 0.9 |
| | | 30-34 | 483 | 6 | 1.3 | 33 | 6.9 | 17 | 3.6 | 14 | 2.9 | 11 | 2.3 |
| | | 35+ | 249 | 7 | 2.8 | 22 | 8.9 | 11 | 4.4 | 14 | 5.6 | 8 | 3.3 |
| | **Years since diagnosis** | 5-9 | 144 | 1 | 0.7 | 3 | 2.1 | . | . | . | . | 1 | 0.7 |
| | | 10-14 | 671 | 7 | 1.1 | 31 | 4.7 | 10 | 1.5 | 8 | 1.2 | 8 | 1.2 |
| | | 15-19 | 730 | 9 | 1.2 | 50 | 6.9 | 14 | 1.9 | 22 | 3.0 | 10 | 1.4 |
| | | 20+ | 572 | 10 | 1.8 | 41 | 7.2 | 20 | 3.5 | 19 | 3.4 | 15 | 2.7 |
| | **Age at diagnosis** | <1 | 15 | . | . | . | . | 1 | 6.7 | . | . | . | . |
| | | 1-4 | 347 | 3 | 0.9 | 22 | 6.4 | 1 | 0.3 | 2 | 0.6 | 3 | 0.9 |
| | | 5-9 | 649 | 11 | 1.7 | 38 | 5.9 | 18 | 2.8 | 20 | 3.1 | 9 | 1.4 |
| | | 10-14 | 672 | 8 | 1.2 | 31 | 4.7 | 11 | 1.7 | 14 | 2.1 | 10 | 1.5 |
| | | 15-20 | 434 | 5 | 1.2 | 34 | 7.9 | 13 | 3.0 | 13 | 3.0 | 12 | 2.8 |
| | **Treatment** | Surgery only | 16 | . | . | . | . | . | . | 1 | 6.3 | . | . |
| | | Chemotherapy, no radiation | 1077 | 12 | 1.1 | 27 | 2.5 | 16 | 1.5 | 18 | 1.7 | 18 | 1.7 |
| | | Radiation, no chemotherapy | 38 | . | . | 5 | 13.2 | 1 | 2.6 | 1 | 2.6 | . | . |
| | | Chemotherapy and radiation | 767 | 11 | 1.4 | 82 | 10.8 | 24 | 3.2 | 23 | 3.0 | 13 | 1.7 |
| | | Unknown | 219 | 4 | 1.8 | 11 | 5.1 | 3 | 1.4 | 6 | 2.8 | 3 | 1.4 |
| **Males** | **All cases** | | **1437** | **14** | **1.0** | **66** | **4.6** | **13** | **0.9** | **17** | **1.2** | **15** | **1.1** |
| | **Age at baseline** | <18 | 146 | 1 | 0.7 | 6 | 4.1 | . | . | . | . | 1 | 0.7 |
| | | 18-19 | 97 | . | . | 6 | 6.3 | 1 | 1.0 | . | . | . | . |
| | | 20-24 | 304 | 3 | 1.0 | 13 | 4.3 | . | . | 1 | 0.3 | 3 | 1.0 |
| | | 25-29 | 407 | 5 | 1.2 | 13 | 3.2 | 2 | 0.5 | 6 | 1.5 | 1 | 0.2 |
| | | 30-34 | 319 | 2 | 0.6 | 13 | 4.1 | 5 | 1.6 | 4 | 1.3 | 6 | 1.9 |
| | | 35+ | 164 | 3 | 1.8 | 15 | 9.1 | 5 | 3.0 | 6 | 3.7 | 4 | 2.5 |
| | **Years since diagnosis** | 5-9 | 109 | 1 | 0.9 | 2 | 1.8 | . | . | . | . | 1 | 0.9 |
| | | 10-14 | 456 | 3 | 0.7 | 15 | 3.3 | 2 | 0.4 | 3 | 0.7 | 4 | 0.9 |
| | | 15-19 | 480 | 6 | 1.3 | 25 | 5.3 | 6 | 1.3 | 9 | 1.9 | 2 | 0.4 |
| | | 20+ | 392 | 4 | 1.0 | 24 | 6.2 | 5 | 1.3 | 5 | 1.3 | 8 | 2.1 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 235 | 2 | 0.9 | 15 | 6.4 | . | . | . | . | . | . |
| | | 5-9 | 451 | 4 | 0.9 | 18 | 4.0 | 5 | 1.1 | 5 | 1.1 | 4 | 0.9 |
| | | 10-14 | 462 | 4 | 0.9 | 17 | 3.7 | 2 | 0.4 | 6 | 1.3 | 5 | 1.1 |
| | | 15-20 | 284 | 4 | 1.4 | 16 | 5.7 | 6 | 2.1 | 6 | 2.1 | 6 | 2.1 |
| | **Treatment** | Surgery only | 13 | . | . | . | . | . | . | 1 | 7.7 | . | . |
| | | Chemotherapy, no radiation | 728 | 7 | 1.0 | 9 | 1.2 | 4 | 0.6 | 5 | 0.7 | 8 | 1.1 |
| | | Radiation, no chemotherapy | 28 | . | . | 5 | 17.9 | 1 | 3.6 | 1 | 3.6 | . | . |
| | | Chemotherapy and radiation | 511 | 5 | 1.0 | 44 | 8.7 | 8 | 1.6 | 9 | 1.8 | 6 | 1.2 |
| | | Unknown | 157 | 2 | 1.3 | 8 | 5.2 | . | . | 1 | 0.6 | 1 | 0.6 |
| **Females** | **All cases** | | **680** | **13** | **1.9** | **59** | **8.7** | **31** | **4.6** | **32** | **4.7** | **19** | **2.8** |
| | **Age at baseline** | <18 | 66 | . | . | 2 | 3.0 | 1 | 1.5 | 1 | 1.5 | . | . |
| | | 18-19 | 35 | 1 | 2.9 | 3 | 8.6 | 1 | 2.9 | 1 | 2.9 | . | . |
| | | 20-24 | 165 | 3 | 1.8 | 14 | 8.6 | 5 | 3.1 | 9 | 5.5 | 6 | 3.7 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2117** | **24** | **1.1** | **36** | **1.7** | **63** | **3.0** | **59** | **2.8** | **326** | **15.8** |
| | **Age at baseline** | <18 | 212 | . | . | 2 | 0.9 | 13 | 6.1 | 4 | 1.9 | 27 | 13.0 |
| | | 18-19 | 132 | . | . | 1 | 0.8 | 9 | 7.0 | 2 | 1.5 | 17 | 13.4 |
| | | 20-24 | 469 | 4 | 0.9 | 10 | 2.2 | 21 | 4.6 | 9 | 1.9 | 69 | 15.0 |
| | | 25-29 | 572 | 3 | 0.5 | 7 | 1.2 | 11 | 2.0 | 20 | 3.5 | 74 | 13.2 |
| | | 30-34 | 483 | 8 | 1.7 | 10 | 2.1 | 8 | 1.7 | 14 | 2.9 | 81 | 17.3 |
| | | 35+ | 249 | 9 | 3.7 | 6 | 2.4 | 1 | 0.4 | 10 | 4.0 | 58 | 23.9 |
| | **Years since diagnosis** | 5-9 | 144 | . | . | 2 | 1.4 | . | . | . | . | 7 | 5.0 |
| | | 10-14 | 671 | 4 | 0.6 | 12 | 1.8 | 18 | 2.7 | 19 | 2.9 | 89 | 13.7 |
| | | 15-19 | 730 | 7 | 1.0 | 10 | 1.4 | 30 | 4.2 | 26 | 3.6 | 126 | 17.6 |
| | | 20+ | 572 | 13 | 2.3 | 12 | 2.1 | 15 | 2.7 | 14 | 2.5 | 104 | 18.7 |
| | **Age at diagnosis** | <1 | 15 | . | . | . | . | 2 | 13.3 | . | . | 3 | 20.0 |
| | | 1-4 | 347 | 2 | 0.6 | 3 | 0.9 | 30 | 8.7 | 5 | 1.5 | 51 | 15.1 |
| | | 5-9 | 649 | 2 | 0.3 | 6 | 0.9 | 22 | 3.4 | 15 | 2.3 | 99 | 15.5 |
| | | 10-14 | 672 | 9 | 1.4 | 16 | 2.4 | 9 | 1.4 | 22 | 3.3 | 92 | 14.2 |
| | | 15-20 | 434 | 11 | 2.6 | 11 | 2.5 | . | . | 17 | 3.9 | 81 | 19.2 |
| | **Treatment** | Surgery only | 16 | . | . | . | . | . | . | . | . | 1 | 6.3 |
| | | Chemotherapy, no radiation | 1077 | 15 | 1.4 | 19 | 1.8 | 11 | 1.0 | 29 | 2.7 | 121 | 11.5 |
| | | Radiation, no chemotherapy | 38 | . | . | 1 | 2.6 | . | . | 3 | 7.9 | 10 | 27.8 |
| | | Chemotherapy and radiation | 767 | 8 | 1.1 | 13 | 1.7 | 47 | 6.3 | 22 | 2.9 | 163 | 22.0 |
| | | Unknown | 219 | 1 | 0.5 | 3 | 1.4 | 5 | 2.3 | 5 | 2.3 | 31 | 14.4 |
| **Males** | **All cases** | | **1437** | **13** | **0.9** | **20** | **1.4** | **41** | **2.9** | **30** | **2.1** | **176** | **12.6** |
| | **Age at baseline** | <18 | 146 | . | . | . | . | 9 | 6.2 | 3 | 2.1 | 17 | 12.1 |
| | | 18-19 | 97 | . | . | 1 | 1.0 | 4 | 4.3 | 2 | 2.1 | 10 | 10.8 |
| | | 20-24 | 304 | 2 | 0.7 | 3 | 1.0 | 16 | 5.3 | 4 | 1.3 | 33 | 11.0 |
| | | 25-29 | 407 | 1 | 0.2 | 4 | 1.0 | 7 | 1.8 | 10 | 2.5 | 42 | 10.6 |
| | | 30-34 | 319 | 6 | 1.9 | 9 | 2.8 | 5 | 1.6 | 7 | 2.2 | 43 | 14.0 |
| | | 35+ | 164 | 4 | 2.5 | 3 | 1.8 | . | . | 4 | 2.5 | 31 | 19.3 |
| | **Years since diagnosis** | 5-9 | 109 | . | . | . | . | . | . | . | . | 4 | 3.7 |
| | | 10-14 | 456 | 3 | 0.7 | 5 | 1.1 | 13 | 2.9 | 9 | 2.0 | 45 | 10.2 |
| | | 15-19 | 480 | 3 | 0.6 | 6 | 1.3 | 19 | 4.1 | 13 | 2.7 | 68 | 14.5 |
| | | 20+ | 392 | 7 | 1.8 | 9 | 2.3 | 9 | 2.3 | 8 | 2.1 | 59 | 15.5 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 235 | . | . | . | . | 21 | 9.0 | 4 | 1.7 | 31 | 13.7 |
| | | 5-9 | 451 | . | . | 4 | 0.9 | 13 | 2.9 | 9 | 2.0 | 52 | 11.7 |
| | | 10-14 | 462 | 8 | 1.8 | 10 | 2.2 | 7 | 1.6 | 12 | 2.6 | 53 | 11.9 |
| | | 15-20 | 284 | 5 | 1.8 | 6 | 2.1 | . | . | 5 | 1.8 | 40 | 14.5 |
| | **Treatment** | Surgery only | 13 | . | . | . | . | . | . | . | . | 1 | 7.7 |
| | | Chemotherapy, no radiation | 728 | 8 | 1.1 | 9 | 1.2 | 8 | 1.1 | 16 | 2.2 | 58 | 8.1 |
| | | Radiation, no chemotherapy | 28 | . | . | 1 | 3.6 | . | . | 1 | 3.6 | 8 | 29.6 |
| | | Chemotherapy and radiation | 511 | 4 | 0.8 | 8 | 1.6 | 30 | 6.1 | 11 | 2.2 | 91 | 18.5 |
| | | Unknown | 157 | 1 | 0.6 | 2 | 1.3 | 3 | 1.9 | 2 | 1.3 | 18 | 11.7 |
| **Females** | **All cases** | | **680** | **11** | **1.6** | **16** | **2.4** | **22** | **3.3** | **29** | **4.3** | **150** | **22.6** |
| | **Age at baseline** | <18 | 66 | . | . | 2 | 3.0 | 4 | 6.1 | 1 | 1.5 | 10 | 15.2 |
| | | 18-19 | 35 | . | . | . | . | 5 | 14.3 | . | . | 7 | 20.6 |
| | | 20-24 | 165 | 2 | 1.2 | 7 | 4.3 | 5 | 3.1 | 5 | 3.1 | 36 | 22.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1)[1] | | Underactive thyroid (E.2/E.2)[1] | | Thyroid nodules (E.3/E.3)[1] | | Thyroid enlargement (E.4/E.4)[1] | | Diabetes-diet (E.5/E.5)[1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 165 | 1 | 0.6 | 13 | 7.9 | 6 | 3.7 | 3 | 1.8 | 4 | 2.4 |
| | | 30-34 | 164 | 4 | 2.5 | 20 | 12.3 | 12 | 7.4 | 10 | 6.1 | 5 | 3.1 |
| | | 35+ | 85 | 4 | 4.8 | 7 | 8.3 | 6 | 7.1 | 8 | 9.5 | 4 | 4.8 |
| | **Years since diagnosis** | 5-9 | 35 | . | . | 1 | 2.9 | . | . | . | . | . | . |
| | | 10-14 | 215 | 4 | 1.9 | 16 | 7.5 | 8 | 3.8 | 5 | 2.3 | 4 | 1.9 |
| | | 15-19 | 250 | 3 | 1.2 | 25 | 10.0 | 8 | 3.2 | 13 | 5.2 | 8 | 3.2 |
| | | 20+ | 180 | 6 | 3.4 | 17 | 9.6 | 15 | 8.4 | 14 | 7.9 | 7 | 3.9 |
| | **Age at diagnosis** | <1 | 10 | . | . | . | . | 1 | 10.0 | . | . | . | . |
| | | 1-4 | 112 | 1 | 0.9 | 7 | 6.3 | 1 | 0.9 | 2 | 1.8 | 3 | 2.7 |
| | | 5-9 | 198 | 7 | 3.5 | 20 | 10.2 | 13 | 6.6 | 15 | 7.6 | 5 | 2.5 |
| | | 10-14 | 210 | 4 | 1.9 | 14 | 6.7 | 9 | 4.3 | 8 | 3.8 | 5 | 2.4 |
| | | 15-20 | 150 | 1 | 0.7 | 18 | 12.2 | 7 | 4.8 | 7 | 4.7 | 6 | 4.1 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 349 | 5 | 1.4 | 18 | 5.2 | 12 | 3.5 | 13 | 3.8 | 10 | 2.9 |
| | | Radiation, no chemotherapy | 10 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 256 | 6 | 2.4 | 38 | 15.0 | 16 | 6.3 | 14 | 5.5 | 7 | 2.8 |
| | | Unknown | 62 | 2 | 3.2 | 3 | 4.9 | 3 | 4.8 | 5 | 8.1 | 2 | 3.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 165 | 2 | 1.2 | 3 | 1.8 | 4 | 2.4 | 10 | 6.1 | 32 | 19.6 |
| | | 30-34 | 164 | 2 | 1.2 | 1 | 0.6 | 3 | 1.8 | 7 | 4.3 | 38 | 23.9 |
| | | 35+ | 85 | 5 | 6.0 | 3 | 3.6 | 1 | 1.2 | 6 | 7.1 | 27 | 32.9 |
| | **Years since diagnosis** | 5-9 | 35 | . | . | 2 | 5.7 | . | . | . | . | 3 | 9.1 |
| | | 10-14 | 215 | 1 | 0.5 | 7 | 3.3 | 5 | 2.4 | 10 | 4.7 | 44 | 20.9 |
| | | 15-19 | 250 | 4 | 1.6 | 4 | 1.6 | 11 | 4.4 | 13 | 5.3 | 58 | 23.7 |
| | | 20+ | 180 | 6 | 3.4 | 3 | 1.7 | 6 | 3.4 | 6 | 3.4 | 45 | 25.6 |
| | **Age at diagnosis** | <1 | 10 | . | . | . | . | 2 | 20.0 | . | . | 3 | 30.0 |
| | | 1-4 | 112 | 2 | 1.8 | 3 | 2.7 | 9 | 8.0 | 1 | 0.9 | 20 | 18.0 |
| | | 5-9 | 198 | 2 | 1.0 | 2 | 1.0 | 9 | 4.6 | 6 | 3.0 | 47 | 24.0 |
| | | 10-14 | 210 | 1 | 0.5 | 6 | 2.9 | 2 | 1.0 | 10 | 4.8 | 39 | 19.2 |
| | | 15-20 | 150 | 6 | 4.1 | 5 | 3.4 | . | . | 12 | 8.1 | 41 | 28.3 |
| | **Treatment** | Surgery only | 3 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 349 | 7 | 2.0 | 10 | 2.9 | 3 | 0.9 | 13 | 3.8 | 63 | 18.5 |
| | | Radiation, no chemotherapy | 10 | . | . | . | . | . | . | 2 | 20.0 | 2 | 22.2 |
| | | Chemotherapy and radiation | 256 | 4 | 1.6 | 5 | 2.0 | 17 | 6.8 | 11 | 4.3 | 72 | 28.8 |
| | | Unknown | 62 | . | . | 1 | 1.6 | 2 | 3.2 | 3 | 4.8 | 13 | 21.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2277** | **13** | **0.6** | **45** | **2.0** | **15** | **0.7** | **33** | **1.5** | **19** | **0.8** |
| | **Age at baseline** | <18 | 832 | 4 | 0.5 | 9 | 1.1 | 4 | 0.5 | 3 | 0.4 | 3 | 0.4 |
| | | 18-19 | 305 | 3 | 1.0 | 5 | 1.6 | 1 | 0.3 | 4 | 1.3 | . | . |
| | | 20-24 | 670 | 1 | 0.1 | 13 | 1.9 | 3 | 0.4 | 10 | 1.5 | 7 | 1.0 |
| | | 25-29 | 374 | 5 | 1.3 | 16 | 4.3 | 6 | 1.6 | 13 | 3.6 | 9 | 2.4 |
| | | 30-34 | 77 | . | . | 2 | 2.7 | 1 | 1.3 | 2 | 2.6 | . | . |
| | | 35+ | 19 | . | . | . | . | . | . | 1 | 5.3 | . | . |
| | **Years since diagnosis** | 5-9 | 176 | 1 | 0.6 | 1 | 0.6 | . | . | . | . | . | . |
| | | 10-14 | 739 | 4 | 0.5 | 12 | 1.6 | 5 | 0.7 | 5 | 0.7 | 3 | 0.4 |
| | | 15-19 | 759 | 4 | 0.5 | 11 | 1.5 | 3 | 0.4 | 12 | 1.6 | 4 | 0.5 |
| | | 20+ | 603 | 4 | 0.7 | 21 | 3.5 | 7 | 1.2 | 16 | 2.7 | 12 | 2.0 |
| | **Age at diagnosis** | <1 | 331 | 1 | 0.3 | 6 | 1.8 | . | . | 2 | 0.6 | 2 | 0.6 |
| | | 1-4 | 1396 | 5 | 0.4 | 23 | 1.7 | 10 | 0.7 | 19 | 1.4 | 13 | 0.9 |
| | | 5-9 | 468 | 7 | 1.5 | 14 | 3.0 | 5 | 1.1 | 9 | 1.9 | 3 | 0.6 |
| | | 10-14 | 59 | . | . | 2 | 3.4 | . | . | 2 | 3.4 | 1 | 1.7 |
| | | 15-20 | 23 | . | . | . | . | . | . | 1 | 4.3 | . | . |
| | **Treatment** | Surgery only | 35 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 873 | 3 | 0.3 | 9 | 1.0 | . | . | 5 | 0.6 | 5 | 0.6 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 1155 | 10 | 0.9 | 33 | 2.9 | 14 | 1.2 | 26 | 2.3 | 12 | 1.0 |
| | | Unknown | 210 | . | . | 3 | 1.4 | 1 | 0.5 | 2 | 1.0 | 2 | 1.0 |
| **Males** | **All cases** | | **1019** | **2** | **0.2** | **11** | **1.1** | **3** | **0.3** | **7** | **0.7** | **6** | **0.6** |
| | **Age at baseline** | <18 | 403 | 1 | 0.2 | 4 | 1.0 | 1 | 0.2 | 2 | 0.5 | 2 | 0.5 |
| | | 18-19 | 126 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 285 | . | . | 5 | 1.8 | . | . | 2 | 0.7 | 2 | 0.7 |
| | | 25-29 | 165 | 1 | 0.6 | 2 | 1.2 | 2 | 1.2 | 3 | 1.9 | 2 | 1.2 |
| | | 30-34 | 32 | . | . | . | . | . | . | . | . | . | . |
| | | 35+ | 8 | . | . | . | . | . | . | . | . | . | . |
| | **Years since diagnosis** | 5-9 | 79 | . | . | . | . | . | . | . | . | . | . |
| | | 10-14 | 333 | 1 | 0.3 | 4 | 1.2 | 1 | 0.3 | 2 | 0.6 | 1 | 0.3 |
| | | 15-19 | 334 | . | . | 3 | 0.9 | . | . | 1 | 0.3 | 2 | 0.6 |
| | | 20+ | 273 | 1 | 0.4 | 4 | 1.5 | 2 | 0.7 | 4 | 1.5 | 3 | 1.1 |
| | **Age at diagnosis** | <1 | 169 | 1 | 0.6 | 1 | 0.6 | . | . | 1 | 0.6 | 2 | 1.2 |
| | | 1-4 | 628 | . | . | 8 | 1.3 | 2 | 0.3 | 5 | 0.8 | 4 | 0.6 |
| | | 5-9 | 192 | 1 | 0.5 | 2 | 1.0 | 1 | 0.5 | 1 | 0.5 | . | . |
| | | 10-14 | 21 | . | . | . | . | . | . | . | . | . | . |
| | | 15-20 | 9 | . | . | . | . | . | . | . | . | . | . |
| | **Treatment** | Surgery only | 19 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 396 | 1 | 0.3 | . | . | . | . | . | . | 1 | 0.3 |
| | | Chemotherapy and radiation | 499 | 1 | 0.2 | 11 | 2.2 | 3 | 0.6 | 7 | 1.4 | 4 | 0.8 |
| | | Unknown | 105 | . | . | . | . | . | . | . | . | 1 | 1.0 |
| **Females** | **All cases** | | **1258** | **11** | **0.9** | **34** | **2.7** | **12** | **1.0** | **26** | **2.1** | **13** | **1.0** |
| | **Age at baseline** | <18 | 429 | 3 | 0.7 | 5 | 1.2 | 3 | 0.7 | 1 | 0.2 | 1 | 0.2 |
| | | 18-19 | 179 | 3 | 1.7 | 5 | 2.8 | 1 | 0.6 | 4 | 2.2 | . | . |
| | | 20-24 | 385 | 1 | 0.3 | 8 | 2.1 | 3 | 0.8 | 8 | 2.1 | 5 | 1.3 |
| | | 25-29 | 209 | 4 | 1.9 | 14 | 6.8 | 4 | 1.9 | 10 | 4.9 | 7 | 3.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2277** | **11** | **0.5** | **23** | **1.0** | **49** | **2.2** | **43** | **1.9** | **187** | **8.4** |
| | **Age at baseline** | <18 | 832 | 1 | 0.1 | 4 | 0.5 | 16 | 1.9 | 10 | 1.2 | 42 | 5.1 |
| | | 18-19 | 305 | . | . | 2 | 0.7 | 6 | 2.0 | 5 | 1.6 | 22 | 7.3 |
| | | 20-24 | 670 | 3 | 0.5 | 6 | 0.9 | 13 | 2.0 | 11 | 1.7 | 54 | 8.3 |
| | | 25-29 | 374 | 5 | 1.4 | 9 | 2.4 | 13 | 3.5 | 15 | 4.0 | 59 | 16.2 |
| | | 30-34 | 77 | 2 | 2.6 | 2 | 2.7 | . | . | 2 | 2.6 | 8 | 10.7 |
| | | 35+ | 19 | . | . | . | . | 1 | 5.6 | . | . | 2 | 11.1 |
| | **Years since diagnosis** | 5-9 | 176 | . | . | . | . | 2 | 1.1 | 1 | 0.6 | 3 | 1.7 |
| | | 10-14 | 739 | 1 | 0.1 | 5 | 0.7 | 16 | 2.2 | 11 | 1.5 | 50 | 6.9 |
| | | 15-19 | 759 | 2 | 0.3 | 7 | 0.9 | 15 | 2.0 | 12 | 1.6 | 55 | 7.4 |
| | | 20+ | 603 | 8 | 1.3 | 11 | 1.8 | 16 | 2.7 | 19 | 3.2 | 79 | 13.5 |
| | **Age at diagnosis** | <1 | 331 | . | . | 2 | 0.6 | 7 | 2.1 | 5 | 1.5 | 20 | 6.1 |
| | | 1-4 | 1396 | 8 | 0.6 | 15 | 1.1 | 27 | 2.0 | 25 | 1.8 | 109 | 8.0 |
| | | 5-9 | 468 | 3 | 0.6 | 6 | 1.3 | 14 | 3.0 | 12 | 2.6 | 51 | 11.2 |
| | | 10-14 | 59 | . | . | . | . | 1 | 1.7 | 1 | 1.7 | 6 | 10.2 |
| | | 15-20 | 23 | . | . | . | . | . | . | . | . | 1 | 4.5 |
| | **Treatment** | Surgery only | 35 | . | . | . | . | 2 | 5.9 | 1 | 2.9 | 3 | 8.8 |
| | | Chemotherapy, no radiation | 873 | . | . | 3 | 0.3 | 8 | 0.9 | 9 | 1.0 | 36 | 4.2 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 1155 | 10 | 0.9 | 18 | 1.6 | 35 | 3.1 | 30 | 2.6 | 135 | 11.9 |
| | | Unknown | 210 | 1 | 0.5 | 2 | 1.0 | 4 | 1.9 | 3 | 1.4 | 13 | 6.3 |
| **Males** | **All cases** | | **1019** | **3** | **0.3** | **8** | **0.8** | **16** | **1.6** | **9** | **0.9** | **51** | **5.1** |
| | **Age at baseline** | <18 | 403 | 1 | 0.2 | 2 | 0.5 | 6 | 1.5 | 3 | 0.7 | 17 | 4.3 |
| | | 18-19 | 126 | . | . | . | . | 1 | 0.8 | 2 | 1.6 | 3 | 2.4 |
| | | 20-24 | 285 | 1 | 0.4 | 2 | 0.7 | 5 | 1.8 | 2 | 0.7 | 15 | 5.4 |
| | | 25-29 | 165 | 1 | 0.6 | 4 | 2.4 | 4 | 2.5 | 1 | 0.6 | 15 | 9.5 |
| | | 30-34 | 32 | . | . | . | . | . | . | 1 | 3.1 | 1 | 3.2 |
| | | 35+ | 8 | . | . | . | . | . | . | . | . | . | . |
| | **Years since diagnosis** | 5-9 | 79 | . | . | . | . | . | . | . | . | . | . |
| | | 10-14 | 333 | 1 | 0.3 | 2 | 0.6 | 5 | 1.5 | 3 | 0.9 | 15 | 4.6 |
| | | 15-19 | 334 | 1 | 0.3 | 2 | 0.6 | 5 | 1.5 | 4 | 1.2 | 15 | 4.6 |
| | | 20+ | 273 | 1 | 0.4 | 4 | 1.5 | 6 | 2.2 | 2 | 0.7 | 21 | 8.0 |
| | **Age at diagnosis** | <1 | 169 | . | . | 1 | 0.6 | 3 | 1.8 | 2 | 1.2 | 10 | 6.0 |
| | | 1-4 | 628 | 3 | 0.5 | 4 | 0.6 | 10 | 1.6 | 5 | 0.8 | 31 | 5.0 |
| | | 5-9 | 192 | . | . | 3 | 1.6 | 3 | 1.6 | 2 | 1.0 | 10 | 5.3 |
| | | 10-14 | 21 | . | . | . | . | . | . | . | . | . | . |
| | | 15-20 | 9 | . | . | . | . | . | . | . | . | . | . |
| | **Treatment** | Surgery only | 19 | . | . | . | . | 2 | 10.5 | 1 | 5.3 | 3 | 15.8 |
| | | Chemotherapy, no radiation | 396 | . | . | 1 | 0.3 | 3 | 0.8 | 3 | 0.8 | 8 | 2.1 |
| | | Chemotherapy and radiation | 499 | 3 | 0.6 | 6 | 1.2 | 9 | 1.8 | 5 | 1.0 | 36 | 7.4 |
| | | Unknown | 105 | . | . | 1 | 1.0 | 2 | 1.9 | . | . | 4 | 3.9 |
| **Females** | **All cases** | | **1258** | **8** | **0.6** | **15** | **1.2** | **33** | **2.6** | **34** | **2.7** | **136** | **11.0** |
| | **Age at baseline** | <18 | 429 | . | . | 2 | 0.5 | 10 | 2.3 | 7 | 1.6 | 25 | 5.9 |
| | | 18-19 | 179 | . | . | 2 | 1.1 | 5 | 2.8 | 3 | 1.7 | 19 | 10.7 |
| | | 20-24 | 385 | 2 | 0.5 | 4 | 1.0 | 8 | 2.1 | 9 | 2.4 | 39 | 10.4 |
| | | 25-29 | 209 | 4 | 1.9 | 5 | 2.4 | 9 | 4.3 | 14 | 6.7 | 44 | 21.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 30-34 | 45 | . | . | 2 | 4.5 | 1 | 2.3 | 2 | 4.5 | . | . |
| | | 35+ | 11 | . | . | . | . | . | . | 1 | 9.1 | . | . |
| | **Years since diagnosis** | 5-9 | 97 | 1 | 1.0 | 1 | 1.0 | . | . | . | . | . | . |
| | | 10-14 | 406 | 3 | 0.7 | 8 | 2.0 | 4 | 1.0 | 3 | 0.7 | 2 | 0.5 |
| | | 15-19 | 425 | 4 | 0.9 | 8 | 1.9 | 3 | 0.7 | 11 | 2.6 | 2 | 0.5 |
| | | 20+ | 330 | 3 | 0.9 | 17 | 5.2 | 5 | 1.5 | 12 | 3.7 | 9 | 2.8 |
| | **Age at diagnosis** | <1 | 162 | . | . | 5 | 3.1 | . | . | 1 | 0.6 | . | . |
| | | 1-4 | 768 | 5 | 0.7 | 15 | 2.0 | 8 | 1.0 | 14 | 1.8 | 9 | 1.2 |
| | | 5-9 | 276 | 6 | 2.2 | 12 | 4.4 | 4 | 1.5 | 8 | 2.9 | 3 | 1.1 |
| | | 10-14 | 38 | . | . | 2 | 5.3 | . | . | 2 | 5.3 | 1 | 2.6 |
| | | 15-20 | 14 | . | . | . | . | . | . | 1 | 7.1 | . | . |
| | **Treatment** | Surgery only | 16 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 477 | 2 | 0.4 | 9 | 1.9 | . | . | 5 | 1.1 | 4 | 0.8 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 656 | 9 | 1.4 | 22 | 3.4 | 11 | 1.7 | 19 | 2.9 | 8 | 1.2 |
| | | Unknown | 105 | . | . | 3 | 2.9 | 1 | 1.0 | 2 | 1.9 | 1 | 1.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 30-34 | 45 | 2 | 4.5 | 2 | 4.7 | . | . | 1 | 2.3 | 7 | 15.9 |
| | | 35+ | 11 | . | . | . | . | 1 | 10.0 | . | . | 2 | 20.0 |
| | **Years since diagnosis** | 5-9 | 97 | . | . | . | . | 2 | 2.1 | 1 | 1.0 | 3 | 3.1 |
| | | 10-14 | 406 | . | . | 3 | 0.7 | 11 | 2.7 | 8 | 2.0 | 35 | 8.7 |
| | | 15-19 | 425 | 1 | 0.2 | 5 | 1.2 | 10 | 2.4 | 8 | 1.9 | 40 | 9.6 |
| | | 20+ | 330 | 7 | 2.2 | 7 | 2.2 | 10 | 3.1 | 17 | 5.2 | 58 | 18.1 |
| | **Age at diagnosis** | <1 | 162 | . | . | 1 | 0.6 | 4 | 2.5 | 3 | 1.9 | 10 | 6.2 |
| | | 1-4 | 768 | 5 | 0.7 | 11 | 1.4 | 17 | 2.2 | 20 | 2.6 | 78 | 10.3 |
| | | 5-9 | 276 | 3 | 1.1 | 3 | 1.1 | 11 | 4.0 | 10 | 3.7 | 41 | 15.2 |
| | | 10-14 | 38 | . | . | . | . | 1 | 2.6 | 1 | 2.6 | 6 | 15.8 |
| | | 15-20 | 14 | . | . | . | . | . | . | . | . | 1 | 7.7 |
| | **Treatment** | Surgery only | 16 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 477 | . | . | 2 | 0.4 | 5 | 1.1 | 6 | 1.3 | 28 | 5.9 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 656 | 7 | 1.1 | 12 | 1.8 | 26 | 4.0 | 25 | 3.8 | 99 | 15.4 |
| | | Unknown | 105 | 1 | 1.0 | 1 | 1.0 | 2 | 1.9 | 3 | 2.9 | 9 | 8.8 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1954** | **22** | **1.1** | **99** | **5.1** | **37** | **1.9** | **36** | **1.9** | **25** | **1.3** |
| | **Age at baseline** | <18 | 957 | 4 | 0.4 | 35 | 3.7 | 9 | 0.9 | 11 | 1.2 | 3 | 0.3 |
| | | 18-19 | 237 | 3 | 1.3 | 12 | 5.1 | . | . | 2 | 0.8 | 2 | 0.8 |
| | | 20-24 | 544 | 9 | 1.7 | 26 | 4.8 | 14 | 2.6 | 13 | 2.4 | 14 | 2.6 |
| | | 25-29 | 172 | 5 | 2.9 | 18 | 10.6 | 9 | 5.3 | 7 | 4.1 | 2 | 1.2 |
| | | 30-34 | 36 | 1 | 2.8 | 6 | 17.1 | 5 | 13.9 | 2 | 5.6 | 4 | 11.1 |
| | | 35+ | 8 | . | . | 2 | 25.0 | . | . | 1 | 12.5 | . | . |
| | **Years since diagnosis** | 5-9 | 160 | . | . | 5 | 3.1 | . | . | 1 | 0.6 | . | . |
| | | 10-14 | 610 | 4 | 0.7 | 29 | 4.8 | 5 | 0.8 | 8 | 1.3 | 3 | 0.5 |
| | | 15-19 | 639 | 6 | 0.9 | 30 | 4.7 | 11 | 1.7 | 12 | 1.9 | 7 | 1.1 |
| | | 20+ | 545 | 12 | 2.2 | 35 | 6.5 | 21 | 3.9 | 15 | 2.8 | 15 | 2.8 |
| | **Age at diagnosis** | <1 | 993 | 8 | 0.8 | 22 | 2.2 | 10 | 1.0 | 11 | 1.1 | 8 | 0.8 |
| | | 1-4 | 764 | 12 | 1.6 | 55 | 7.3 | 22 | 2.9 | 18 | 2.4 | 11 | 1.4 |
| | | 5-9 | 148 | 2 | 1.4 | 14 | 9.5 | 4 | 2.7 | 5 | 3.4 | 5 | 3.4 |
| | | 10-14 | 30 | . | . | 7 | 23.3 | . | . | 2 | 6.9 | . | . |
| | | 15-20 | 19 | . | . | 1 | 5.3 | 1 | 5.3 | . | . | 1 | 5.3 |
| | **Treatment** | Surgery only | 548 | 2 | 0.4 | 6 | 1.1 | 2 | 0.4 | 5 | 0.9 | 4 | 0.7 |
| | | Chemotherapy, no radiation | 562 | 6 | 1.1 | 16 | 2.9 | 8 | 1.4 | 7 | 1.3 | 6 | 1.1 |
| | | Radiation, no chemotherapy | 138 | . | . | 5 | 3.6 | 1 | 0.7 | 3 | 2.2 | . | . |
| | | Chemotherapy and radiation | 532 | 11 | 2.1 | 66 | 12.5 | 21 | 4.0 | 16 | 3.0 | 14 | 2.6 |
| | | Unknown | 174 | 3 | 1.7 | 6 | 3.5 | 5 | 2.9 | 5 | 2.9 | 1 | 0.6 |
| **Males** | **All cases** | | **953** | **9** | **0.9** | **43** | **4.5** | **10** | **1.1** | **13** | **1.4** | **16** | **1.7** |
| | **Age at baseline** | <18 | 479 | 3 | 0.6 | 16 | 3.4 | 3 | 0.6 | 6 | 1.3 | 3 | 0.6 |
| | | 18-19 | 104 | 2 | 1.9 | 9 | 8.7 | . | . | 1 | 1.0 | 1 | 1.0 |
| | | 20-24 | 275 | 3 | 1.1 | 8 | 2.9 | 3 | 1.1 | 4 | 1.5 | 8 | 2.9 |
| | | 25-29 | 78 | 1 | 1.3 | 7 | 9.1 | 3 | 3.9 | 1 | 1.3 | 2 | 2.6 |
| | | 30-34 | 14 | . | . | 1 | 7.1 | 1 | 7.1 | . | . | 2 | 14.3 |
| | | 35+ | 3 | . | . | 2 | 66.7 | . | . | 1 | 33.3 | . | . |
| | **Years since diagnosis** | 5-9 | 75 | . | . | 2 | 2.7 | . | . | 1 | 1.3 | . | . |
| | | 10-14 | 304 | 3 | 1.0 | 15 | 5.0 | 2 | 0.7 | 5 | 1.7 | 2 | 0.7 |
| | | 15-19 | 308 | 4 | 1.3 | 13 | 4.2 | 3 | 1.0 | 4 | 1.3 | 5 | 1.6 |
| | | 20+ | 266 | 2 | 0.8 | 13 | 4.9 | 5 | 1.9 | 3 | 1.1 | 9 | 3.4 |
| | **Age at diagnosis** | <1 | 516 | 3 | 0.6 | 11 | 2.1 | 3 | 0.6 | 5 | 1.0 | 5 | 1.0 |
| | | 1-4 | 344 | 4 | 1.2 | 23 | 6.7 | 6 | 1.8 | 4 | 1.2 | 8 | 2.3 |
| | | 5-9 | 74 | 2 | 2.7 | 6 | 8.2 | 1 | 1.4 | 2 | 2.7 | 3 | 4.1 |
| | | 10-14 | 13 | . | . | 2 | 15.4 | . | . | 2 | 16.7 | . | . |
| | | 15-20 | 6 | . | . | 1 | 16.7 | . | . | . | . | . | . |
| | **Treatment** | Surgery only | 263 | 1 | 0.4 | 1 | 0.4 | . | . | 1 | 0.4 | 3 | 1.1 |
| | | Chemotherapy, no radiation | 279 | 2 | 0.7 | 7 | 2.5 | 2 | 0.7 | 2 | 0.7 | 3 | 1.1 |
| | | Radiation, no chemotherapy | 62 | . | . | 1 | 1.6 | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 259 | 5 | 1.9 | 31 | 12.0 | 7 | 2.7 | 7 | 2.7 | 10 | 3.9 |
| | | Unknown | 90 | 1 | 1.1 | 3 | 3.3 | 1 | 1.1 | 3 | 3.3 | . | . |
| **Females** | **All cases** | | **1001** | **13** | **1.3** | **56** | **5.6** | **27** | **2.7** | **23** | **2.3** | **9** | **0.9** |
| | **Age at baseline** | <18 | 478 | 1 | 0.2 | 19 | 4.0 | 6 | 1.3 | 5 | 1.1 | . | . |
| | | 18-19 | 133 | 1 | 0.8 | 3 | 2.3 | . | . | 1 | 0.8 | 1 | 0.8 |
| | | 20-24 | 269 | 6 | 2.2 | 18 | 6.8 | 11 | 4.1 | 9 | 3.4 | 6 | 2.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1954** | **20** | **1.0** | **26** | **1.3** | **125** | **6.5** | **55** | **2.8** | **285** | **14.9** |
| | **Age at baseline** | <18 | 957 | 3 | 0.3 | 6 | 0.6 | 60 | 6.3 | 19 | 2.0 | 105 | 11.1 |
| | | 18-19 | 237 | 1 | 0.4 | 4 | 1.7 | 11 | 4.7 | 7 | 3.0 | 32 | 13.8 |
| | | 20-24 | 544 | 10 | 1.9 | 11 | 2.0 | 35 | 6.6 | 21 | 3.9 | 93 | 17.5 |
| | | 25-29 | 172 | 4 | 2.4 | 3 | 1.7 | 16 | 9.6 | 6 | 3.5 | 42 | 25.1 |
| | | 30-34 | 36 | 2 | 5.9 | 2 | 5.6 | 3 | 8.8 | 2 | 5.6 | 11 | 32.4 |
| | | 35+ | 8 | . | . | . | . | . | . | . | . | 2 | 25.0 |
| | **Years since diagnosis** | 5-9 | 160 | . | . | 1 | 0.6 | 11 | 6.9 | 8 | 5.0 | 21 | 13.4 |
| | | 10-14 | 610 | 1 | 0.2 | 6 | 1.0 | 42 | 7.0 | 12 | 2.0 | 78 | 13.0 |
| | | 15-19 | 639 | 8 | 1.3 | 7 | 1.1 | 38 | 6.0 | 18 | 2.8 | 88 | 14.1 |
| | | 20+ | 545 | 11 | 2.1 | 12 | 2.2 | 34 | 6.4 | 17 | 3.1 | 98 | 18.4 |
| | **Age at diagnosis** | <1 | 993 | 3 | 0.3 | 6 | 0.6 | 20 | 2.0 | 12 | 1.2 | 84 | 8.6 |
| | | 1-4 | 764 | 11 | 1.5 | 15 | 2.0 | 83 | 11.0 | 33 | 4.4 | 148 | 19.8 |
| | | 5-9 | 148 | 6 | 4.1 | 4 | 2.7 | 20 | 13.7 | 10 | 6.8 | 41 | 28.3 |
| | | 10-14 | 30 | . | . | . | . | 2 | 7.1 | . | . | 8 | 28.6 |
| | | 15-20 | 19 | . | . | 1 | 5.3 | . | . | . | . | 4 | 22.2 |
| | **Treatment** | Surgery only | 548 | 3 | 0.6 | 2 | 0.4 | 3 | 0.6 | 2 | 0.4 | 21 | 3.9 |
| | | Chemotherapy, no radiation | 562 | 2 | 0.4 | 3 | 0.5 | 18 | 3.2 | 11 | 2.0 | 56 | 10.1 |
| | | Radiation, no chemotherapy | 138 | . | . | 1 | 0.7 | 6 | 4.7 | 2 | 1.5 | 13 | 10.4 |
| | | Chemotherapy and radiation | 532 | 15 | 2.8 | 16 | 3.0 | 92 | 17.5 | 38 | 7.2 | 177 | 33.8 |
| | | Unknown | 174 | . | . | 4 | 2.3 | 6 | 3.5 | 2 | 1.1 | 18 | 10.5 |
| **Males** | **All cases** | | **953** | **14** | **1.5** | **16** | **1.7** | **58** | **6.2** | **19** | **2.0** | **125** | **13.4** |
| | **Age at baseline** | <18 | 479 | 2 | 0.4 | 3 | 0.6 | 33 | 6.9 | 9 | 1.9 | 55 | 11.7 |
| | | 18-19 | 104 | . | . | 3 | 2.9 | 6 | 5.8 | 2 | 1.9 | 16 | 15.7 |
| | | 20-24 | 275 | 6 | 2.2 | 8 | 2.9 | 12 | 4.5 | 7 | 2.6 | 34 | 12.7 |
| | | 25-29 | 78 | 4 | 5.3 | 1 | 1.3 | 6 | 8.0 | 1 | 1.3 | 16 | 21.3 |
| | | 30-34 | 14 | 2 | 15.4 | 1 | 7.1 | 1 | 7.7 | . | . | 2 | 15.4 |
| | | 35+ | 3 | . | . | . | . | . | . | . | . | 2 | 66.7 |
| | **Years since diagnosis** | 5-9 | 75 | . | . | . | . | 7 | 9.5 | 5 | 6.7 | 12 | 16.2 |
| | | 10-14 | 304 | 1 | 0.3 | 4 | 1.3 | 21 | 7.0 | 4 | 1.3 | 38 | 12.7 |
| | | 15-19 | 308 | 3 | 1.0 | 5 | 1.6 | 20 | 6.6 | 7 | 2.3 | 40 | 13.4 |
| | | 20+ | 266 | 10 | 3.8 | 7 | 2.6 | 10 | 3.8 | 3 | 1.1 | 35 | 13.5 |
| | **Age at diagnosis** | <1 | 516 | 3 | 0.6 | 5 | 1.0 | 12 | 2.4 | 5 | 1.0 | 40 | 7.9 |
| | | 1-4 | 344 | 6 | 1.8 | 8 | 2.3 | 32 | 9.4 | 9 | 2.6 | 59 | 17.5 |
| | | 5-9 | 74 | 5 | 6.9 | 3 | 4.1 | 13 | 18.1 | 5 | 6.8 | 23 | 32.4 |
| | | 10-14 | 13 | . | . | . | . | 1 | 9.1 | . | . | 2 | 18.2 |
| | | 15-20 | 6 | . | . | . | . | . | . | . | . | 1 | 16.7 |
| | **Treatment** | Surgery only | 263 | 2 | 0.8 | 2 | 0.8 | 2 | 0.8 | . | . | 8 | 3.1 |
| | | Chemotherapy, no radiation | 279 | 2 | 0.7 | 2 | 0.7 | 12 | 4.3 | 4 | 1.4 | 28 | 10.2 |
| | | Radiation, no chemotherapy | 62 | . | . | . | . | . | . | . | . | 1 | 1.8 |
| | | Chemotherapy and radiation | 259 | 10 | 3.9 | 11 | 4.3 | 40 | 15.6 | 14 | 5.4 | 80 | 31.4 |
| | | Unknown | 90 | . | . | 1 | 1.1 | 4 | 4.4 | 1 | 1.1 | 8 | 8.9 |
| **Females** | **All cases** | | **1001** | **6** | **0.6** | **10** | **1.0** | **67** | **6.8** | **36** | **3.6** | **160** | **16.3** |
| | **Age at baseline** | <18 | 478 | 1 | 0.2 | 3 | 0.6 | 27 | 5.7 | 10 | 2.1 | 50 | 10.6 |
| | | 18-19 | 133 | 1 | 0.8 | 1 | 0.8 | 5 | 3.8 | 5 | 3.8 | 16 | 12.3 |
| | | 20-24 | 269 | 4 | 1.5 | 3 | 1.1 | 23 | 8.7 | 14 | 5.2 | 59 | 22.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 94 | 4 | 4.3 | 11 | 11.8 | 6 | 6.4 | 6 | 6.4 | . | . |
| | | 30-34 | 22 | 1 | 4.5 | 5 | 23.8 | 4 | 18.2 | 2 | 9.1 | 2 | 9.1 |
| | | 35+ | 5 | . | . | . | . | . | . | . | . | . | . |
| | **Years since diagnosis** | 5-9 | 85 | . | . | 3 | 3.5 | . | . | . | . | . | . |
| | | 10-14 | 306 | 1 | 0.3 | 14 | 4.6 | 3 | 1.0 | 3 | 1.0 | 1 | 0.3 |
| | | 15-19 | 331 | 2 | 0.6 | 17 | 5.2 | 8 | 2.4 | 8 | 2.4 | 2 | 0.6 |
| | | 20+ | 279 | 10 | 3.6 | 22 | 8.0 | 16 | 5.8 | 12 | 4.3 | 6 | 2.2 |
| | **Age at diagnosis** | <1 | 477 | 5 | 1.1 | 11 | 2.3 | 7 | 1.5 | 6 | 1.3 | 3 | 0.6 |
| | | 1-4 | 420 | 8 | 1.9 | 32 | 7.7 | 16 | 3.8 | 14 | 3.3 | 3 | 0.7 |
| | | 5-9 | 74 | . | . | 8 | 10.8 | 3 | 4.1 | 3 | 4.1 | 2 | 2.7 |
| | | 10-14 | 17 | . | . | 5 | 29.4 | . | . | . | . | . | . |
| | | 15-20 | 13 | . | . | . | . | 1 | 7.7 | . | . | 1 | 7.7 |
| | **Treatment** | Surgery only | 285 | 1 | 0.4 | 5 | 1.8 | 2 | 0.7 | 4 | 1.4 | 1 | 0.4 |
| | | Chemotherapy, no radiation | 283 | 4 | 1.4 | 9 | 3.2 | 6 | 2.1 | 5 | 1.8 | 3 | 1.1 |
| | | Radiation, no chemotherapy | 76 | . | . | 4 | 5.3 | 1 | 1.4 | 3 | 4.0 | . | . |
| | | Chemotherapy and radiation | 273 | 6 | 2.2 | 35 | 13.0 | 14 | 5.1 | 9 | 3.3 | 4 | 1.5 |
| | | Unknown | 84 | 2 | 2.4 | 3 | 3.6 | 4 | 4.8 | 2 | 2.4 | 1 | 1.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 94 | . | . | 2 | 2.1 | 10 | 10.9 | 5 | 5.3 | 26 | 28.3 |
| | | 30-34 | 22 | . | . | 1 | 4.5 | 2 | 9.5 | 2 | 9.1 | 9 | 42.9 |
| | | 35+ | 5 | . | . | . | . | . | . | . | . | . | . |
| | **Years since diagnosis** | 5-9 | 85 | . | . | 1 | 1.2 | 4 | 4.7 | 3 | 3.6 | 9 | 10.8 |
| | | 10-14 | 306 | . | . | 2 | 0.7 | 21 | 6.9 | 8 | 2.6 | 40 | 13.2 |
| | | 15-19 | 331 | 5 | 1.5 | 2 | 0.6 | 18 | 5.5 | 11 | 3.3 | 48 | 14.8 |
| | | 20+ | 279 | 1 | 0.4 | 5 | 1.8 | 24 | 8.8 | 14 | 5.1 | 63 | 23.2 |
| | **Age at diagnosis** | <1 | 477 | . | . | 1 | 0.2 | 8 | 1.7 | 7 | 1.5 | 44 | 9.4 |
| | | 1-4 | 420 | 5 | 1.2 | 7 | 1.7 | 51 | 12.3 | 24 | 5.7 | 89 | 21.8 |
| | | 5-9 | 74 | 1 | 1.4 | 1 | 1.4 | 7 | 9.5 | 5 | 6.8 | 18 | 24.3 |
| | | 10-14 | 17 | . | . | . | . | 1 | 5.9 | . | . | 6 | 35.3 |
| | | 15-20 | 13 | . | . | 1 | 7.7 | . | . | . | . | 3 | 25.0 |
| | **Treatment** | Surgery only | 285 | 1 | 0.4 | . | . | 1 | 0.4 | 2 | 0.7 | 13 | 4.6 |
| | | Chemotherapy, no radiation | 283 | . | . | 1 | 0.4 | 6 | 2.1 | 7 | 2.5 | 28 | 10.0 |
| | | Radiation, no chemotherapy | 76 | . | . | 1 | 1.3 | 6 | 8.3 | 2 | 2.7 | 12 | 17.1 |
| | | Chemotherapy and radiation | 273 | 5 | 1.9 | 5 | 1.8 | 52 | 19.3 | 24 | 8.9 | 97 | 36.2 |
| | | Unknown | 84 | . | . | 3 | 3.6 | 2 | 2.4 | 1 | 1.2 | 10 | 12.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1760** | **25** | **1.4** | **133** | **7.6** | **25** | **1.4** | **34** | **1.9** | **13** | **0.7** |
| | **Age at baseline** | <18 | 341 | 4 | 1.2 | 20 | 5.9 | 3 | 0.9 | 6 | 1.8 | . | . |
| | | 18-19 | 125 | 1 | 0.8 | 10 | 8.2 | 3 | 2.5 | . | . | 1 | 0.8 |
| | | 20-24 | 425 | 3 | 0.7 | 33 | 7.8 | 6 | 1.4 | 11 | 2.6 | 1 | 0.2 |
| | | 25-29 | 393 | 8 | 2.1 | 36 | 9.2 | 6 | 1.5 | 8 | 2.0 | 5 | 1.3 |
| | | 30-34 | 299 | 9 | 3.0 | 26 | 8.8 | 6 | 2.0 | 5 | 1.7 | 2 | 0.7 |
| | | 35+ | 177 | . | . | 8 | 4.5 | 1 | 0.6 | 4 | 2.3 | 4 | 2.3 |
| | **Years since diagnosis** | 5-9 | 182 | 2 | 1.1 | 7 | 3.8 | . | . | . | . | 1 | 0.5 |
| | | 10-14 | 521 | 7 | 1.4 | 40 | 7.7 | 7 | 1.4 | 10 | 1.9 | 2 | 0.4 |
| | | 15-19 | 541 | 10 | 1.9 | 32 | 6.0 | 6 | 1.1 | 9 | 1.7 | 5 | 0.9 |
| | | 20+ | 516 | 6 | 1.2 | 54 | 10.5 | 12 | 2.3 | 15 | 2.9 | 5 | 1.0 |
| | **Age at diagnosis** | <1 | 124 | . | . | 3 | 2.4 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 |
| | | 1-4 | 562 | 8 | 1.4 | 49 | 8.8 | 11 | 2.0 | 15 | 2.7 | 1 | 0.2 |
| | | 5-9 | 397 | 3 | 0.8 | 40 | 10.2 | 8 | 2.0 | 7 | 1.8 | 2 | 0.5 |
| | | 10-14 | 348 | 9 | 2.6 | 28 | 8.1 | 3 | 0.9 | 5 | 1.4 | 2 | 0.6 |
| | | 15-20 | 329 | 5 | 1.5 | 13 | 4.0 | 2 | 0.6 | 6 | 1.8 | 7 | 2.1 |
| | **Treatment** | Surgery only | 171 | 1 | 0.6 | 2 | 1.2 | . | . | 1 | 0.6 | 1 | 0.6 |
| | | Chemotherapy, no radiation | 361 | 2 | 0.6 | 5 | 1.4 | 2 | 0.6 | 2 | 0.6 | 3 | 0.8 |
| | | Radiation, no chemotherapy | 63 | 2 | 3.2 | 3 | 4.8 | 2 | 3.2 | . | . | . | . |
| | | Chemotherapy and radiation | 974 | 18 | 1.9 | 116 | 12.0 | 20 | 2.1 | 30 | 3.1 | 6 | 0.6 |
| | | Unknown | 191 | 2 | 1.1 | 7 | 3.7 | 1 | 0.5 | 1 | 0.5 | 3 | 1.6 |
| **Males** | **All cases** | | **951** | **11** | **1.2** | **56** | **5.9** | **9** | **1.0** | **12** | **1.3** | **5** | **0.5** |
| | **Age at baseline** | <18 | 192 | 3 | 1.6 | 9 | 4.7 | 2 | 1.0 | 2 | 1.0 | . | . |
| | | 18-19 | 66 | . | . | 4 | 6.3 | 3 | 4.8 | . | . | 1 | 1.5 |
| | | 20-24 | 242 | 1 | 0.4 | 16 | 6.6 | 3 | 1.3 | 5 | 2.1 | . | . |
| | | 25-29 | 208 | 2 | 1.0 | 16 | 7.7 | . | . | 3 | 1.4 | 1 | 0.5 |
| | | 30-34 | 159 | 5 | 3.1 | 10 | 6.3 | 1 | 0.6 | 1 | 0.6 | 1 | 0.6 |
| | | 35+ | 84 | . | . | 1 | 1.2 | . | . | 1 | 1.2 | 2 | 2.4 |
| | **Years since diagnosis** | 5-9 | 100 | 1 | 1.0 | 3 | 3.0 | . | . | . | . | . | . |
| | | 10-14 | 288 | 5 | 1.7 | 18 | 6.3 | 6 | 2.1 | 5 | 1.7 | 1 | 0.3 |
| | | 15-19 | 282 | 3 | 1.1 | 14 | 5.0 | 2 | 0.7 | 3 | 1.1 | 2 | 0.7 |
| | | 20+ | 281 | 2 | 0.7 | 21 | 7.5 | 1 | 0.4 | 4 | 1.4 | 2 | 0.7 |
| | **Age at diagnosis** | <1 | 52 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 331 | 4 | 1.2 | 27 | 8.2 | 5 | 1.5 | 6 | 1.8 | 1 | 0.3 |
| | | 5-9 | 225 | . | . | 13 | 5.8 | 4 | 1.8 | 2 | 0.9 | . | . |
| | | 10-14 | 186 | 4 | 2.2 | 14 | 7.6 | . | . | 2 | 1.1 | 1 | 0.5 |
| | | 15-20 | 157 | 3 | 1.9 | 2 | 1.3 | . | . | 2 | 1.3 | 3 | 1.9 |
| | **Treatment** | Surgery only | 74 | 1 | 1.4 | . | . | . | . | . | . | 1 | 1.4 |
| | | Chemotherapy, no radiation | 212 | 1 | 0.5 | 2 | 0.9 | . | . | . | . | 1 | 0.5 |
| | | Radiation, no chemotherapy | 32 | 1 | 3.1 | . | . | 1 | 3.1 | . | . | . | . |
| | | Chemotherapy and radiation | 524 | 7 | 1.4 | 53 | 10.2 | 8 | 1.5 | 12 | 2.3 | 3 | 0.6 |
| | | Unknown | 109 | 1 | 0.9 | 1 | 0.9 | . | . | . | . | . | . |
| **Females** | **All cases** | | **809** | **14** | **1.7** | **77** | **9.6** | **16** | **2.0** | **22** | **2.7** | **8** | **1.0** |
| | **Age at baseline** | <18 | 149 | 1 | 0.7 | 11 | 7.4 | 1 | 0.7 | 4 | 2.7 | . | . |
| | | 18-19 | 59 | 1 | 1.7 | 6 | 10.3 | . | . | . | . | . | . |
| | | 20-24 | 183 | 2 | 1.1 | 17 | 9.4 | 3 | 1.7 | 6 | 3.3 | 1 | 0.6 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1760** | **3** | **0.2** | **13** | **0.7** | **176** | **10.2** | **72** | **4.1** | **348** | **20.2** |
| | **Age at baseline** | <18 | 341 | . | . | 1 | 0.3 | 52 | 15.2 | 14 | 4.1 | 69 | 20.5 |
| | | 18-19 | 125 | . | . | . | . | 17 | 14.0 | 6 | 4.9 | 28 | 23.1 |
| | | 20-24 | 425 | . | . | 1 | 0.2 | 53 | 12.8 | 19 | 4.5 | 88 | 21.4 |
| | | 25-29 | 393 | 1 | 0.3 | 6 | 1.5 | 43 | 11.2 | 20 | 5.1 | 90 | 23.5 |
| | | 30-34 | 299 | . | . | 3 | 1.0 | 10 | 3.4 | 6 | 2.0 | 51 | 17.3 |
| | | 35+ | 177 | 2 | 1.1 | 2 | 1.1 | 1 | 0.6 | 7 | 4.0 | 22 | 12.7 |
| | **Years since diagnosis** | 5-9 | 182 | . | . | 1 | 0.6 | 18 | 10.2 | 8 | 4.4 | 30 | 17.0 |
| | | 10-14 | 521 | . | . | 5 | 1.0 | 63 | 12.3 | 24 | 4.7 | 110 | 21.5 |
| | | 15-19 | 541 | 1 | 0.2 | 2 | 0.4 | 46 | 8.7 | 22 | 4.1 | 99 | 18.8 |
| | | 20+ | 516 | 2 | 0.4 | 5 | 1.0 | 49 | 9.6 | 18 | 3.5 | 109 | 21.6 |
| | **Age at diagnosis** | <1 | 124 | . | . | 1 | 0.8 | 6 | 5.0 | 2 | 1.6 | 11 | 9.2 |
| | | 1-4 | 562 | . | . | 1 | 0.2 | 89 | 16.1 | 25 | 4.5 | 131 | 23.8 |
| | | 5-9 | 397 | . | . | 3 | 0.8 | 59 | 15.0 | 21 | 5.4 | 99 | 25.5 |
| | | 10-14 | 348 | 1 | 0.3 | 3 | 0.9 | 19 | 5.6 | 14 | 4.0 | 67 | 19.6 |
| | | 15-20 | 329 | 2 | 0.6 | 5 | 1.5 | 3 | 0.9 | 10 | 3.1 | 40 | 12.5 |
| | **Treatment** | Surgery only | 171 | 1 | 0.6 | . | . | 2 | 1.2 | 1 | 0.6 | 8 | 4.8 |
| | | Chemotherapy, no radiation | 361 | . | . | 2 | 0.6 | 2 | 0.6 | 5 | 1.4 | 17 | 4.8 |
| | | Radiation, no chemotherapy | 63 | . | . | 2 | 3.2 | 1 | 1.7 | 1 | 1.6 | 9 | 14.8 |
| | | Chemotherapy and radiation | 974 | 1 | 0.1 | 6 | 0.6 | 158 | 16.5 | 53 | 5.5 | 281 | 29.5 |
| | | Unknown | 191 | 1 | 0.5 | 3 | 1.6 | 13 | 6.8 | 12 | 6.3 | 33 | 17.5 |
| **Males** | **All cases** | | **951** | **1** | **0.1** | **5** | **0.5** | **100** | **10.7** | **30** | **3.2** | **167** | **18.0** |
| | **Age at baseline** | <18 | 192 | . | . | 1 | 0.5 | 29 | 15.1 | 7 | 3.6 | 36 | 18.8 |
| | | 18-19 | 66 | . | . | . | . | 10 | 15.6 | 3 | 4.5 | 15 | 23.1 |
| | | 20-24 | 242 | . | . | 1 | 0.4 | 26 | 11.1 | 9 | 3.8 | 45 | 19.3 |
| | | 25-29 | 208 | . | . | 3 | 1.5 | 29 | 14.1 | 8 | 3.9 | 44 | 21.6 |
| | | 30-34 | 159 | . | . | . | . | 6 | 3.8 | 1 | 0.6 | 21 | 13.5 |
| | | 35+ | 84 | 1 | 1.2 | . | . | . | . | 2 | 2.4 | 6 | 7.4 |
| | **Years since diagnosis** | 5-9 | 100 | . | . | 1 | 1.0 | 11 | 11.6 | 6 | 6.0 | 18 | 18.8 |
| | | 10-14 | 288 | . | . | 3 | 1.0 | 37 | 12.9 | 9 | 3.1 | 59 | 20.6 |
| | | 15-19 | 282 | . | . | 1 | 0.4 | 23 | 8.4 | 9 | 3.2 | 43 | 15.8 |
| | | 20+ | 281 | 1 | 0.4 | . | . | 29 | 10.4 | 6 | 2.2 | 47 | 17.1 |
| | **Age at diagnosis** | <1 | 52 | . | . | . | . | 4 | 7.8 | 1 | 1.9 | 5 | 9.8 |
| | | 1-4 | 331 | . | . | 1 | 0.3 | 48 | 14.7 | 13 | 4.0 | 67 | 20.6 |
| | | 5-9 | 225 | . | . | 1 | 0.4 | 30 | 13.4 | 6 | 2.7 | 44 | 19.9 |
| | | 10-14 | 186 | . | . | 2 | 1.1 | 16 | 8.8 | 7 | 3.8 | 37 | 20.4 |
| | | 15-20 | 157 | 1 | 0.7 | 1 | 0.6 | 2 | 1.3 | 3 | 1.9 | 14 | 9.3 |
| | **Treatment** | Surgery only | 74 | 1 | 1.4 | . | . | 2 | 2.9 | . | . | 4 | 5.8 |
| | | Chemotherapy, no radiation | 212 | . | . | . | . | 2 | 1.0 | 2 | 1.0 | 7 | 3.4 |
| | | Radiation, no chemotherapy | 32 | . | . | 1 | 3.1 | . | . | 1 | 3.1 | 3 | 9.7 |
| | | Chemotherapy and radiation | 524 | . | . | 3 | 0.6 | 87 | 16.9 | 24 | 4.6 | 139 | 26.9 |
| | | Unknown | 109 | . | . | 1 | 0.9 | 9 | 8.3 | 3 | 2.8 | 14 | 13.1 |
| **Females** | **All cases** | | **809** | **2** | **0.3** | **8** | **1.0** | **76** | **9.6** | **42** | **5.2** | **181** | **22.9** |
| | **Age at baseline** | <18 | 149 | . | . | . | . | 23 | 15.4 | 7 | 4.7 | 33 | 22.8 |
| | | 18-19 | 59 | . | . | . | . | 7 | 12.3 | 3 | 5.3 | 13 | 23.2 |
| | | 20-24 | 183 | . | . | . | . | 27 | 15.1 | 10 | 5.5 | 43 | 24.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | All cases | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 185 | 6 | 3.3 | 20 | 10.8 | 6 | 3.2 | 5 | 2.7 | 4 | 2.2 |
| | | 30-34 | 140 | 4 | 2.9 | 16 | 11.5 | 5 | 3.6 | 4 | 2.9 | 1 | 0.7 |
| | | 35+ | 93 | . | . | 7 | 7.5 | 1 | 1.1 | 3 | 3.2 | 2 | 2.2 |
| | **Years since diagnosis** | 5-9 | 82 | 1 | 1.2 | 4 | 4.9 | . | . | . | . | 1 | 1.2 |
| | | 10-14 | 233 | 2 | 0.9 | 22 | 9.5 | 1 | 0.4 | 5 | 2.2 | 1 | 0.4 |
| | | 15-19 | 259 | 7 | 2.7 | 18 | 7.0 | 4 | 1.6 | 6 | 2.3 | 3 | 1.2 |
| | | 20+ | 235 | 4 | 1.7 | 33 | 14.2 | 11 | 4.7 | 11 | 4.7 | 3 | 1.3 |
| | **Age at diagnosis** | <1 | 72 | . | . | 3 | 4.2 | 1 | 1.4 | 1 | 1.4 | 1 | 1.4 |
| | | 1-4 | 231 | 4 | 1.7 | 22 | 9.6 | 6 | 2.6 | 9 | 3.9 | . | . |
| | | 5-9 | 172 | 3 | 1.8 | 27 | 15.9 | 4 | 2.4 | 5 | 2.9 | 2 | 1.2 |
| | | 10-14 | 162 | 5 | 3.1 | 14 | 8.6 | 3 | 1.9 | 3 | 1.9 | 1 | 0.6 |
| | | 15-20 | 172 | 2 | 1.2 | 11 | 6.4 | 2 | 1.2 | 4 | 2.3 | 4 | 2.3 |
| | **Treatment** | Surgery only | 97 | . | . | 2 | 2.1 | . | . | 1 | 1.0 | . | . |
| | | Chemotherapy, no radiation | 149 | 1 | 0.7 | 3 | 2.0 | 2 | 1.4 | 2 | 1.4 | 2 | 1.4 |
| | | Radiation, no chemotherapy | 31 | 1 | 3.2 | 3 | 9.7 | 1 | 3.2 | . | . | . | . |
| | | Chemotherapy and radiation | 450 | 11 | 2.5 | 63 | 14.1 | 12 | 2.7 | 18 | 4.0 | 3 | 0.7 |
| | | Unknown | 82 | 1 | 1.2 | 6 | 7.3 | 1 | 1.2 | 1 | 1.2 | 3 | 3.7 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 185 | 1 | 0.6 | 3 | 1.6 | 14 | 7.9 | 12 | 6.5 | 46 | 25.7 |
| | | 30-34 | 140 | . | . | 3 | 2.1 | 4 | 2.9 | 5 | 3.6 | 30 | 21.6 |
| | | 35+ | 93 | 1 | 1.1 | 2 | 2.2 | 1 | 1.1 | 5 | 5.4 | 16 | 17.4 |
| | **Years since diagnosis** | 5-9 | 82 | . | . | . | . | 7 | 8.6 | 2 | 2.4 | 12 | 15.0 |
| | | 10-14 | 233 | . | . | 2 | 0.9 | 26 | 11.4 | 15 | 6.5 | 51 | 22.6 |
| | | 15-19 | 259 | 1 | 0.4 | 1 | 0.4 | 23 | 9.1 | 13 | 5.1 | 56 | 22.0 |
| | | 20+ | 235 | 1 | 0.4 | 5 | 2.1 | 20 | 8.7 | 12 | 5.1 | 62 | 27.0 |
| | **Age at diagnosis** | <1 | 72 | . | . | 1 | 1.4 | 2 | 2.9 | 1 | 1.4 | 6 | 8.7 |
| | | 1-4 | 231 | . | . | . | . | 41 | 18.1 | 12 | 5.2 | 64 | 28.6 |
| | | 5-9 | 172 | . | . | 2 | 1.2 | 29 | 17.2 | 15 | 8.8 | 55 | 32.9 |
| | | 10-14 | 162 | 1 | 0.6 | 1 | 0.6 | 3 | 1.9 | 7 | 4.3 | 30 | 18.8 |
| | | 15-20 | 172 | 1 | 0.6 | 4 | 2.3 | 1 | 0.6 | 7 | 4.1 | 26 | 15.3 |
| | **Treatment** | Surgery only | 97 | . | . | . | . | . | . | 1 | 1.0 | 4 | 4.2 |
| | | Chemotherapy, no radiation | 149 | . | . | 2 | 1.4 | . | . | 3 | 2.0 | 10 | 6.8 |
| | | Radiation, no chemotherapy | 31 | . | . | 1 | 3.2 | 1 | 3.6 | . | . | 6 | 20.0 |
| | | Chemotherapy and radiation | 450 | 1 | 0.2 | 3 | 0.7 | 71 | 16.1 | 29 | 6.5 | 142 | 32.6 |
| | | Unknown | 82 | 1 | 1.2 | 2 | 2.4 | 4 | 4.9 | 9 | 11.0 | 19 | 23.2 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2100** | **22** | **1.1** | **71** | **3.4** | **34** | **1.6** | **37** | **1.8** | **21** | **1.0** |
| | **Age at baseline** | <18 | 96 | . | . | 2 | 2.1 | . | . | . | . | . | . |
| | | 18-19 | 72 | . | . | . | . | . | . | 1 | 1.4 | . | . |
| | | 20-24 | 389 | 2 | 0.5 | 12 | 3.1 | 5 | 1.3 | 5 | 1.3 | 4 | 1.0 |
| | | 25-29 | 568 | 5 | 0.9 | 17 | 3.0 | 6 | 1.1 | 11 | 2.0 | 3 | 0.5 |
| | | 30-34 | 567 | 8 | 1.4 | 25 | 4.4 | 11 | 1.9 | 9 | 1.6 | 7 | 1.2 |
| | | 35+ | 408 | 7 | 1.7 | 15 | 3.7 | 12 | 2.9 | 11 | 2.7 | 7 | 1.7 |
| | **Years since diagnosis** | 5-9 | 243 | 1 | 0.4 | 5 | 2.1 | . | . | 3 | 1.2 | . | . |
| | | 10-14 | 681 | 6 | 0.9 | 23 | 3.4 | 7 | 1.0 | 10 | 1.5 | 7 | 1.0 |
| | | 15-19 | 677 | 7 | 1.0 | 21 | 3.1 | 12 | 1.8 | 12 | 1.8 | 6 | 0.9 |
| | | 20+ | 499 | 8 | 1.6 | 22 | 4.4 | 15 | 3.0 | 12 | 2.4 | 8 | 1.6 |
| | **Age at diagnosis** | <1 | 9 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 88 | 1 | 1.2 | 5 | 5.9 | 3 | 3.5 | 1 | 1.2 | . | . |
| | | 5-9 | 369 | . | . | 10 | 2.7 | 4 | 1.1 | 5 | 1.4 | 3 | 0.8 |
| | | 10-14 | 842 | 13 | 1.5 | 28 | 3.3 | 13 | 1.5 | 13 | 1.6 | 10 | 1.2 |
| | | 15-20 | 792 | 8 | 1.0 | 28 | 3.5 | 14 | 1.8 | 18 | 2.3 | 8 | 1.0 |
| | **Treatment** | Surgery only | 119 | 2 | 1.7 | 2 | 1.7 | 1 | 0.8 | 2 | 1.7 | 1 | 0.8 |
| | | Chemotherapy, no radiation | 1191 | 13 | 1.1 | 38 | 3.2 | 21 | 1.8 | 27 | 2.3 | 16 | 1.4 |
| | | Radiation, no chemotherapy | 17 | . | . | 2 | 11.8 | 1 | 5.9 | 1 | 5.9 | . | . |
| | | Chemotherapy and radiation | 582 | 5 | 0.9 | 24 | 4.1 | 8 | 1.4 | 5 | 0.9 | 3 | 0.5 |
| | | Unknown | 191 | 2 | 1.0 | 5 | 2.6 | 3 | 1.6 | 2 | 1.0 | 1 | 0.5 |
| **Males** | **All cases** | | **1086** | **10** | **0.9** | **15** | **1.4** | **10** | **0.9** | **11** | **1.0** | **5** | **0.5** |
| | **Age at baseline** | <18 | 48 | . | . | 1 | 2.1 | . | . | . | . | . | . |
| | | 18-19 | 36 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 194 | 1 | 0.5 | 1 | 0.5 | 2 | 1.0 | 1 | 0.5 | . | . |
| | | 25-29 | 299 | 2 | 0.7 | 6 | 2.0 | 3 | 1.0 | 4 | 1.4 | . | . |
| | | 30-34 | 284 | 4 | 1.4 | 5 | 1.8 | 1 | 0.4 | 3 | 1.1 | 3 | 1.1 |
| | | 35+ | 225 | 3 | 1.3 | 2 | 0.9 | 4 | 1.8 | 3 | 1.3 | 2 | 0.9 |
| | **Years since diagnosis** | 5-9 | 133 | . | . | 1 | 0.8 | . | . | 1 | 0.8 | . | . |
| | | 10-14 | 349 | 4 | 1.1 | 5 | 1.4 | 3 | 0.9 | 4 | 1.2 | 1 | 0.3 |
| | | 15-19 | 349 | 2 | 0.6 | 5 | 1.4 | 2 | 0.6 | 3 | 0.9 | 2 | 0.6 |
| | | 20+ | 255 | 4 | 1.6 | 4 | 1.6 | 5 | 2.0 | 3 | 1.2 | 2 | 0.8 |
| | **Age at diagnosis** | <1 | 4 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 47 | 1 | 2.2 | 2 | 4.3 | 2 | 4.3 | . | . | . | . |
| | | 5-9 | 189 | . | . | 3 | 1.6 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 |
| | | 10-14 | 403 | 3 | 0.7 | 4 | 1.0 | 2 | 0.5 | 3 | 0.7 | . | . |
| | | 15-20 | 443 | 6 | 1.4 | 6 | 1.4 | 5 | 1.1 | 7 | 1.6 | 4 | 0.9 |
| | **Treatment** | Surgery only | 48 | 2 | 4.2 | 1 | 2.1 | 1 | 2.1 | 2 | 4.3 | . | . |
| | | Chemotherapy, no radiation | 612 | 5 | 0.8 | 7 | 1.1 | 4 | 0.7 | 7 | 1.2 | 5 | 0.8 |
| | | Radiation, no chemotherapy | 9 | . | . | 2 | 22.2 | 1 | 11.1 | 1 | 11.1 | . | . |
| | | Chemotherapy and radiation | 297 | 2 | 0.7 | 4 | 1.4 | 3 | 1.0 | 1 | 0.3 | . | . |
| | | Unknown | 120 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 | . | . | . | . |
| **Females** | **All cases** | | **1014** | **12** | **1.2** | **56** | **5.6** | **24** | **2.4** | **26** | **2.6** | **16** | **1.6** |
| | **Age at baseline** | <18 | 48 | . | . | 1 | 2.1 | . | . | . | . | . | . |
| | | 18-19 | 36 | . | . | . | . | . | . | 1 | 2.8 | . | . |
| | | 20-24 | 195 | 1 | 0.5 | 11 | 5.7 | 3 | 1.5 | 4 | 2.1 | 4 | 2.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **2100** | **19** | **0.9** | **19** | **0.9** | **26** | **1.3** | **123** | **5.9** | **279** | **13.7** |
| | **Age at baseline** | <18 | 96 | . | . | 1 | 1.1 | 5 | 5.3 | 5 | 5.3 | 12 | 12.6 |
| | | 18-19 | 72 | . | . | . | . | 2 | 2.8 | 3 | 4.2 | 5 | 7.1 |
| | | 20-24 | 389 | 3 | 0.8 | 2 | 0.5 | 9 | 2.4 | 26 | 6.7 | 49 | 13.0 |
| | | 25-29 | 568 | 2 | 0.4 | 4 | 0.7 | 4 | 0.7 | 30 | 5.3 | 67 | 12.2 |
| | | 30-34 | 567 | 8 | 1.4 | 7 | 1.2 | 4 | 0.7 | 37 | 6.6 | 87 | 15.8 |
| | | 35+ | 408 | 6 | 1.5 | 5 | 1.2 | 2 | 0.5 | 22 | 5.4 | 59 | 14.6 |
| | **Years since diagnosis** | 5-9 | 243 | 1 | 0.4 | 1 | 0.4 | 3 | 1.3 | 10 | 4.1 | 20 | 8.6 |
| | | 10-14 | 681 | 4 | 0.6 | 5 | 0.7 | 9 | 1.3 | 38 | 5.6 | 86 | 13.0 |
| | | 15-19 | 677 | 9 | 1.3 | 7 | 1.0 | 7 | 1.0 | 37 | 5.5 | 86 | 13.0 |
| | | 20+ | 499 | 5 | 1.0 | 6 | 1.2 | 7 | 1.4 | 38 | 7.7 | 87 | 17.9 |
| | **Age at diagnosis** | <1 | 9 | . | . | . | . | 2 | 22.2 | 1 | 11.1 | 2 | 22.2 |
| | | 1-4 | 88 | . | . | . | . | 6 | 7.1 | 6 | 7.1 | 17 | 20.0 |
| | | 5-9 | 369 | 2 | 0.5 | 2 | 0.5 | 8 | 2.2 | 26 | 7.1 | 45 | 12.5 |
| | | 10-14 | 842 | 10 | 1.2 | 9 | 1.1 | 8 | 1.0 | 49 | 5.8 | 113 | 13.8 |
| | | 15-20 | 792 | 7 | 0.9 | 8 | 1.0 | 2 | 0.3 | 41 | 5.2 | 102 | 13.3 |
| | **Treatment** | Surgery only | 119 | . | . | 3 | 2.5 | . | . | 2 | 1.7 | 9 | 7.9 |
| | | Chemotherapy, no radiation | 1191 | 17 | 1.5 | 12 | 1.0 | 5 | 0.4 | 63 | 5.3 | 151 | 13.1 |
| | | Radiation, no chemotherapy | 17 | . | . | . | . | 1 | 5.9 | . | . | 3 | 17.6 |
| | | Chemotherapy and radiation | 582 | 2 | 0.4 | 4 | 0.7 | 17 | 3.0 | 52 | 8.9 | 97 | 17.1 |
| | | Unknown | 191 | . | . | . | . | 3 | 1.6 | 6 | 3.1 | 19 | 9.9 |
| **Males** | **All cases** | | **1086** | **4** | **0.4** | **9** | **0.8** | **11** | **1.0** | **40** | **3.7** | **96** | **9.1** |
| | **Age at baseline** | <18 | 48 | . | . | 1 | 2.1 | 3 | 6.3 | 2 | 4.2 | 7 | 14.6 |
| | | 18-19 | 36 | . | . | . | . | . | . | 2 | 5.6 | 2 | 5.7 |
| | | 20-24 | 194 | . | . | 1 | 0.5 | 2 | 1.1 | 6 | 3.1 | 13 | 6.9 |
| | | 25-29 | 299 | . | . | 1 | 0.3 | 2 | 0.7 | 11 | 3.7 | 26 | 9.1 |
| | | 30-34 | 284 | 2 | 0.7 | 2 | 0.7 | 3 | 1.1 | 10 | 3.6 | 25 | 9.0 |
| | | 35+ | 225 | 2 | 0.9 | 4 | 1.8 | 1 | 0.4 | 9 | 4.0 | 23 | 10.3 |
| | **Years since diagnosis** | 5-9 | 133 | . | . | 1 | 0.8 | 1 | 0.8 | 3 | 2.3 | 7 | 5.6 |
| | | 10-14 | 349 | . | . | 2 | 0.6 | 3 | 0.9 | 13 | 3.7 | 31 | 9.2 |
| | | 15-19 | 349 | 3 | 0.9 | 2 | 0.6 | 4 | 1.2 | 11 | 3.2 | 29 | 8.5 |
| | | 20+ | 255 | 1 | 0.4 | 4 | 1.6 | 3 | 1.2 | 13 | 5.1 | 29 | 11.6 |
| | **Age at diagnosis** | <1 | 4 | . | . | . | . | 1 | 25.0 | . | . | 1 | 25.0 |
| | | 1-4 | 47 | . | . | . | . | 2 | 4.3 | 3 | 6.5 | 8 | 17.4 |
| | | 5-9 | 189 | 1 | 0.5 | . | . | 4 | 2.1 | 7 | 3.7 | 15 | 8.2 |
| | | 10-14 | 403 | 1 | 0.3 | 4 | 1.0 | 2 | 0.5 | 15 | 3.7 | 30 | 7.6 |
| | | 15-20 | 443 | 2 | 0.5 | 5 | 1.1 | 2 | 0.5 | 15 | 3.4 | 42 | 9.8 |
| | **Treatment** | Surgery only | 48 | . | . | 2 | 4.2 | . | . | 2 | 4.2 | 7 | 14.9 |
| | | Chemotherapy, no radiation | 612 | 4 | 0.7 | 4 | 0.7 | 3 | 0.5 | 19 | 3.1 | 48 | 8.1 |
| | | Radiation, no chemotherapy | 9 | . | . | . | . | 1 | 11.1 | . | . | 3 | 33.3 |
| | | Chemotherapy and radiation | 297 | . | . | 3 | 1.0 | 6 | 2.1 | 16 | 5.4 | 32 | 11.2 |
| | | Unknown | 120 | . | . | . | . | 1 | 0.8 | 3 | 2.5 | 6 | 5.0 |
| **Females** | **All cases** | | **1014** | **15** | **1.5** | **10** | **1.0** | **15** | **1.5** | **83** | **8.2** | **183** | **18.5** |
| | **Age at baseline** | <18 | 48 | . | . | . | . | 2 | 4.3 | 3 | 6.4 | 5 | 10.6 |
| | | 18-19 | 36 | . | . | . | . | 2 | 5.6 | 1 | 2.8 | 3 | 8.6 |
| | | 20-24 | 195 | 3 | 1.6 | 1 | 0.5 | 7 | 3.6 | 20 | 10.3 | 36 | 18.9 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 269 | 3 | 1.1 | 11 | 4.1 | 3 | 1.1 | 7 | 2.6 | 3 | 1.1 |
| | | 30-34 | 283 | 4 | 1.4 | 20 | 7.1 | 10 | 3.5 | 6 | 2.1 | 4 | 1.4 |
| | | 35+ | 183 | 4 | 2.2 | 13 | 7.1 | 8 | 4.4 | 8 | 4.4 | 5 | 2.7 |
| | **Years since diagnosis** | 5-9 | 110 | 1 | 0.9 | 4 | 3.6 | . | . | 2 | 1.8 | . | . |
| | | 10-14 | 332 | 2 | 0.6 | 18 | 5.5 | 4 | 1.2 | 6 | 1.8 | 6 | 1.8 |
| | | 15-19 | 328 | 5 | 1.5 | 16 | 4.9 | 10 | 3.0 | 9 | 2.8 | 4 | 1.2 |
| | | 20+ | 244 | 4 | 1.6 | 18 | 7.4 | 10 | 4.1 | 9 | 3.7 | 6 | 2.5 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 41 | . | . | 3 | 7.7 | 1 | 2.6 | 1 | 2.6 | . | . |
| | | 5-9 | 180 | . | . | 7 | 3.9 | 3 | 1.7 | 4 | 2.2 | 2 | 1.1 |
| | | 10-14 | 439 | 10 | 2.3 | 24 | 5.5 | 11 | 2.5 | 10 | 2.3 | 10 | 2.3 |
| | | 15-20 | 349 | 2 | 0.6 | 22 | 6.3 | 9 | 2.6 | 11 | 3.2 | 4 | 1.2 |
| | **Treatment** | Surgery only | 71 | . | . | 1 | 1.4 | . | . | . | . | 1 | 1.4 |
| | | Chemotherapy, no radiation | 579 | 8 | 1.4 | 31 | 5.4 | 17 | 3.0 | 20 | 3.5 | 11 | 1.9 |
| | | Radiation, no chemotherapy | 8 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 285 | 3 | 1.1 | 20 | 7.0 | 5 | 1.8 | 4 | 1.4 | 3 | 1.1 |
| | | Unknown | 71 | 1 | 1.4 | 4 | 5.6 | 2 | 2.8 | 2 | 2.8 | 1 | 1.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 25-29 | 269 | 2 | 0.8 | 3 | 1.1 | 2 | 0.8 | 19 | 7.1 | 41 | 15.6 |
| | | 30-34 | 283 | 6 | 2.2 | 5 | 1.8 | 1 | 0.4 | 27 | 9.6 | 62 | 22.8 |
| | | 35+ | 183 | 4 | 2.2 | 1 | 0.5 | 1 | 0.6 | 13 | 7.1 | 36 | 20.0 |
| | **Years since diagnosis** | 5-9 | 110 | 1 | 0.9 | . | . | 2 | 1.9 | 7 | 6.4 | 13 | 12.1 |
| | | 10-14 | 332 | 4 | 1.2 | 3 | 0.9 | 6 | 1.8 | 25 | 7.6 | 55 | 17.0 |
| | | 15-19 | 328 | 6 | 1.9 | 5 | 1.5 | 3 | 0.9 | 26 | 8.0 | 57 | 17.8 |
| | | 20+ | 244 | 4 | 1.7 | 2 | 0.8 | 4 | 1.7 | 25 | 10.3 | 58 | 24.6 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | 1 | 20.0 | 1 | 20.0 | 1 | 20.0 |
| | | 1-4 | 41 | . | . | . | . | 4 | 10.3 | 3 | 7.7 | 9 | 23.1 |
| | | 5-9 | 180 | 1 | 0.6 | 2 | 1.1 | 4 | 2.2 | 19 | 10.6 | 30 | 16.9 |
| | | 10-14 | 439 | 9 | 2.1 | 5 | 1.1 | 6 | 1.4 | 34 | 7.8 | 83 | 19.4 |
| | | 15-20 | 349 | 5 | 1.5 | 3 | 0.9 | . | . | 26 | 7.5 | 60 | 17.7 |
| | **Treatment** | Surgery only | 71 | . | . | 1 | 1.4 | . | . | . | . | 2 | 3.0 |
| | | Chemotherapy, no radiation | 579 | 13 | 2.3 | 8 | 1.4 | 2 | 0.4 | 44 | 7.7 | 103 | 18.4 |
| | | Radiation, no chemotherapy | 8 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 285 | 2 | 0.7 | 1 | 0.4 | 11 | 3.9 | 36 | 12.6 | 65 | 23.2 |
| | | Unknown | 71 | . | . | . | . | 2 | 2.8 | 3 | 4.2 | 13 | 18.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **738** | **8** | **1.1** | **28** | **3.8** | **12** | **1.6** | **9** | **1.2** | **3** | **0.4** |
| | **Age at baseline** | <18 | 61 | . | . | . | . | . | . | . | . | . | . |
| | | 18-19 | 36 | . | . | . | . | . | . | 1 | 2.8 | . | . |
| | | 20-24 | 170 | 1 | 0.6 | 5 | 3.0 | 3 | 1.8 | 2 | 1.2 | 2 | 1.2 |
| | | 25-29 | 204 | 3 | 1.5 | 5 | 2.5 | 2 | 1.0 | 2 | 1.0 | . | . |
| | | 30-34 | 164 | 3 | 1.8 | 13 | 7.9 | 1 | 0.6 | 1 | 0.6 | . | . |
| | | 35+ | 103 | 1 | 1.0 | 5 | 4.9 | 6 | 5.8 | 3 | 2.9 | 1 | 1.0 |
| | **Years since diagnosis** | 5-9 | 104 | . | . | 1 | 1.0 | . | . | 2 | 1.9 | . | . |
| | | 10-14 | 247 | 3 | 1.2 | 6 | 2.4 | 1 | 0.4 | 1 | 0.4 | 2 | 0.8 |
| | | 15-19 | 223 | 4 | 1.8 | 9 | 4.0 | 5 | 2.2 | 3 | 1.3 | . | . |
| | | 20+ | 164 | 1 | 0.6 | 12 | 7.4 | 6 | 3.7 | 3 | 1.9 | 1 | 0.6 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 54 | . | . | 2 | 3.8 | 2 | 3.8 | 1 | 1.9 | . | . |
| | | 5-9 | 183 | . | . | 6 | 3.3 | 3 | 1.6 | 2 | 1.1 | 1 | 0.5 |
| | | 10-14 | 278 | 6 | 2.2 | 9 | 3.2 | 2 | 0.7 | 2 | 0.7 | 1 | 0.4 |
| | | 15-20 | 218 | 2 | 0.9 | 11 | 5.1 | 5 | 2.3 | 4 | 1.8 | 1 | 0.5 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 210 | 1 | 0.5 | 7 | 3.4 | 3 | 1.4 | 3 | 1.4 | 1 | 0.5 |
| | | Radiation, no chemotherapy | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 463 | 5 | 1.1 | 19 | 4.1 | 7 | 1.5 | 5 | 1.1 | 2 | 0.4 |
| | | Unknown | 62 | 2 | 3.2 | 2 | 3.2 | 2 | 3.2 | 1 | 1.6 | . | . |
| **Males** | **All cases** | | **386** | **4** | **1.0** | **6** | **1.6** | **4** | **1.0** | **2** | **0.5** | **1** | **0.3** |
| | **Age at baseline** | <18 | 27 | . | . | . | . | . | . | . | . | . | . |
| | | 18-19 | 20 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 88 | 1 | 1.1 | . | . | 1 | 1.1 | . | . | . | . |
| | | 25-29 | 105 | . | . | 2 | 1.9 | 1 | 1.0 | 1 | 1.0 | . | . |
| | | 30-34 | 90 | 2 | 2.2 | 3 | 3.3 | . | . | 1 | 1.1 | . | . |
| | | 35+ | 56 | 1 | 1.8 | 1 | 1.8 | 2 | 3.6 | . | . | 1 | 1.8 |
| | **Years since diagnosis** | 5-9 | 56 | . | . | . | . | . | . | 1 | 1.8 | . | . |
| | | 10-14 | 121 | 1 | 0.8 | . | . | . | . | 1 | 0.8 | . | . |
| | | 15-19 | 123 | 2 | 1.6 | 3 | 2.4 | 2 | 1.6 | . | . | . | . |
| | | 20+ | 86 | 1 | 1.2 | 3 | 3.6 | 2 | 2.4 | . | . | 1 | 1.2 |
| | **Age at diagnosis** | <1 | 2 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 29 | . | . | . | . | 1 | 3.6 | . | . | . | . |
| | | 5-9 | 91 | . | . | 3 | 3.3 | 1 | 1.1 | . | . | . | . |
| | | 10-14 | 147 | 3 | 2.0 | 1 | 0.7 | 1 | 0.7 | . | . | . | . |
| | | 15-20 | 117 | 1 | 0.9 | 2 | 1.7 | 1 | 0.9 | 2 | 1.7 | 1 | 0.9 |
| | **Treatment** | Chemotherapy, no radiation | 111 | 1 | 0.9 | 2 | 1.8 | . | . | 1 | 0.9 | 1 | 0.9 |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 237 | 2 | 0.8 | 4 | 1.7 | 3 | 1.3 | 1 | 0.4 | . | . |
| | | Unknown | 37 | 1 | 2.7 | . | . | 1 | 2.7 | . | . | . | . |
| **Females** | **All cases** | | **352** | **4** | **1.1** | **22** | **6.3** | **8** | **2.3** | **7** | **2.0** | **2** | **0.6** |
| | **Age at baseline** | <18 | 34 | . | . | . | . | . | . | . | . | . | . |
| | | 18-19 | 16 | . | . | . | . | . | . | 1 | 6.3 | . | . |
| | | 20-24 | 82 | . | . | 5 | 6.2 | 2 | 2.5 | 2 | 2.5 | 2 | 2.4 |
| | | 25-29 | 99 | 3 | 3.0 | 3 | 3.0 | 1 | 1.0 | 1 | 1.0 | . | . |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **738** | **3** | **0.4** | **5** | **0.7** | **15** | **2.1** | **50** | **6.8** | **108** | **15.0** |
| | **Age at baseline** | <18 | 61 | . | . | . | . | 4 | 6.7 | 3 | 5.0 | 6 | 10.0 |
| | | 18-19 | 36 | . | . | . | . | 1 | 2.8 | 2 | 5.6 | 3 | 8.6 |
| | | 20-24 | 170 | . | . | 1 | 0.6 | 6 | 3.6 | 12 | 7.1 | 25 | 15.0 |
| | | 25-29 | 204 | 1 | 0.5 | 1 | 0.5 | 1 | 0.5 | 14 | 6.9 | 27 | 13.7 |
| | | 30-34 | 164 | 2 | 1.3 | 1 | 0.6 | 3 | 1.9 | 13 | 8.0 | 30 | 19.0 |
| | | 35+ | 103 | . | . | 2 | 1.9 | . | . | 6 | 5.8 | 17 | 16.7 |
| | **Years since diagnosis** | 5-9 | 104 | . | . | . | . | 3 | 2.9 | 4 | 3.8 | 9 | 8.8 |
| | | 10-14 | 247 | 1 | 0.4 | 2 | 0.8 | 6 | 2.5 | 16 | 6.5 | 33 | 13.8 |
| | | 15-19 | 223 | 2 | 0.9 | 1 | 0.4 | 2 | 0.9 | 13 | 5.9 | 29 | 13.4 |
| | | 20+ | 164 | . | . | 2 | 1.2 | 4 | 2.5 | 17 | 10.4 | 37 | 23.0 |
| | **Age at diagnosis** | <1 | 5 | . | . | . | . | 1 | 20.0 | 1 | 20.0 | 1 | 20.0 |
| | | 1-4 | 54 | . | . | . | . | 3 | 5.8 | 4 | 7.7 | 10 | 19.2 |
| | | 5-9 | 183 | . | . | . | . | 6 | 3.3 | 16 | 8.7 | 27 | 15.1 |
| | | 10-14 | 278 | 1 | 0.4 | 2 | 0.7 | 5 | 1.8 | 18 | 6.5 | 40 | 14.7 |
| | | 15-20 | 218 | 2 | 0.9 | 3 | 1.4 | . | . | 11 | 5.1 | 30 | 14.2 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 210 | 2 | 1.0 | 3 | 1.4 | . | . | 5 | 2.4 | 18 | 8.9 |
| | | Radiation, no chemotherapy | 2 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 463 | 1 | 0.2 | 2 | 0.4 | 13 | 2.9 | 42 | 9.1 | 80 | 17.7 |
| | | Unknown | 62 | . | . | . | . | 2 | 3.2 | 3 | 4.8 | 10 | 16.1 |
| **Males** | **All cases** | | **386** | **.** | **.** | **4** | **1.0** | **5** | **1.3** | **14** | **3.6** | **36** | **9.6** |
| | **Age at baseline** | <18 | 27 | . | . | . | . | 2 | 7.4 | 1 | 3.7 | 3 | 11.1 |
| | | 18-19 | 20 | . | . | . | . | . | . | 1 | 5.0 | 1 | 5.0 |
| | | 20-24 | 88 | . | . | 1 | 1.1 | 1 | 1.1 | 2 | 2.3 | 6 | 6.8 |
| | | 25-29 | 105 | . | . | 1 | 1.0 | . | . | 5 | 4.8 | 9 | 9.1 |
| | | 30-34 | 90 | . | . | . | . | 2 | 2.2 | 3 | 3.4 | 10 | 11.5 |
| | | 35+ | 56 | . | . | 2 | 3.6 | . | . | 2 | 3.6 | 7 | 12.7 |
| | **Years since diagnosis** | 5-9 | 56 | . | . | . | . | 1 | 1.8 | 1 | 1.8 | 3 | 5.5 |
| | | 10-14 | 121 | . | . | 2 | 1.7 | 1 | 0.8 | 3 | 2.5 | 8 | 6.8 |
| | | 15-19 | 123 | . | . | . | . | 1 | 0.8 | 5 | 4.1 | 12 | 10.1 |
| | | 20+ | 86 | . | . | 2 | 2.4 | 2 | 2.4 | 5 | 5.9 | 13 | 15.5 |
| | **Age at diagnosis** | <1 | 2 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 29 | . | . | . | . | 1 | 3.6 | 2 | 7.1 | 4 | 14.3 |
| | | 5-9 | 91 | . | . | . | . | 3 | 3.3 | 4 | 4.4 | 9 | 10.1 |
| | | 10-14 | 147 | . | . | 1 | 0.7 | 1 | 0.7 | 7 | 4.8 | 14 | 9.7 |
| | | 15-20 | 117 | . | . | 3 | 2.6 | . | . | 1 | 0.9 | 9 | 8.0 |
| | **Treatment** | Chemotherapy, no radiation | 111 | . | . | 2 | 1.8 | . | . | . | . | 6 | 5.6 |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 237 | . | . | 2 | 0.8 | 5 | 2.2 | 13 | 5.5 | 27 | 11.7 |
| | | Unknown | 37 | . | . | . | . | . | . | 1 | 2.7 | 3 | 8.1 |
| **Females** | **All cases** | | **352** | **3** | **0.9** | **1** | **0.3** | **10** | **2.9** | **36** | **10.3** | **72** | **21.0** |
| | **Age at baseline** | <18 | 34 | . | . | . | . | 2 | 6.1 | 2 | 6.1 | 3 | 9.1 |
| | | 18-19 | 16 | . | . | . | . | 1 | 6.3 | 1 | 6.3 | 2 | 13.3 |
| | | 20-24 | 82 | . | . | . | . | 5 | 6.2 | 10 | 12.2 | 19 | 24.1 |
| | | 25-29 | 99 | 1 | 1.0 | . | . | 1 | 1.0 | 9 | 9.1 | 18 | 18.4 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 30-34 | 74 | 1 | 1.4 | 10 | 13.5 | 1 | 1.4 | . | . | . | . |
| | | 35+ | 47 | . | . | 4 | 8.5 | 4 | 8.5 | 3 | 6.4 | . | . |
| | **Years since diagnosis** | 5-9 | 48 | . | . | 1 | 2.1 | . | . | 1 | 2.1 | . | . |
| | | 10-14 | 126 | 2 | 1.6 | 6 | 4.8 | 1 | 0.8 | . | . | 2 | 1.6 |
| | | 15-19 | 100 | 2 | 2.0 | 6 | 6.0 | 3 | 3.0 | 3 | 3.0 | . | . |
| | | 20+ | 78 | . | . | 9 | 11.5 | 4 | 5.1 | 3 | 3.8 | . | . |
| | **Age at diagnosis** | <1 | 3 | . | . | . | . | . | . | . | . | . | . |
| | | 1-4 | 25 | . | . | 2 | 8.3 | 1 | 4.2 | 1 | 4.2 | . | . |
| | | 5-9 | 92 | . | . | 3 | 3.3 | 2 | 2.2 | 2 | 2.2 | 1 | 1.1 |
| | | 10-14 | 131 | 3 | 2.3 | 8 | 6.1 | 1 | 0.8 | 2 | 1.6 | 1 | 0.8 |
| | | 15-20 | 101 | 1 | 1.0 | 9 | 8.9 | 4 | 4.0 | 2 | 2.0 | . | . |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 99 | . | . | 5 | 5.2 | 3 | 3.1 | 2 | 2.1 | . | . |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 226 | 3 | 1.3 | 15 | 6.6 | 4 | 1.8 | 4 | 1.8 | 2 | 0.9 |
| | | Unknown | 25 | 1 | 4.0 | 2 | 8.0 | 1 | 4.0 | 1 | 4.0 | . | . |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 30-34 | 74 | 2 | 2.8 | 1 | 1.4 | 1 | 1.4 | 10 | 13.5 | 20 | 28.2 |
| | | 35+ | 47 | . | . | . | . | . | . | 4 | 8.5 | 10 | 21.3 |
| | **Years since diagnosis** | 5-9 | 48 | . | . | . | . | 2 | 4.3 | 3 | 6.3 | 6 | 12.8 |
| | | 10-14 | 126 | 1 | 0.8 | . | . | 5 | 4.0 | 13 | 10.4 | 25 | 20.7 |
| | | 15-19 | 100 | 2 | 2.0 | 1 | 1.0 | 1 | 1.0 | 8 | 8.0 | 17 | 17.3 |
| | | 20+ | 78 | . | . | . | . | 2 | 2.6 | 12 | 15.4 | 24 | 31.2 |
| | **Age at diagnosis** | <1 | 3 | . | . | . | . | 1 | 33.3 | 1 | 33.3 | 1 | 33.3 |
| | | 1-4 | 25 | . | . | . | . | 2 | 8.3 | 2 | 8.3 | 6 | 25.0 |
| | | 5-9 | 92 | . | . | . | . | 3 | 3.3 | 12 | 13.0 | 18 | 20.0 |
| | | 10-14 | 131 | 1 | 0.8 | 1 | 0.8 | 4 | 3.1 | 11 | 8.4 | 26 | 20.3 |
| | | 15-20 | 101 | 2 | 2.0 | . | . | . | . | 10 | 9.9 | 21 | 21.4 |
| | **Treatment** | Surgery only | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy, no radiation | 99 | 2 | 2.1 | 1 | 1.0 | . | . | 5 | 5.1 | 12 | 12.6 |
| | | Radiation, no chemotherapy | 1 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 226 | 1 | 0.5 | . | . | 8 | 3.6 | 29 | 12.8 | 53 | 24.0 |
| | | Unknown | 25 | . | . | . | . | 2 | 8.0 | 2 | 8.0 | 7 | 28.0 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1259** | **14** | **1.1** | **35** | **2.8** | **21** | **1.7** | **27** | **2.2** | **17** | **1.4** |
| | **Age at baseline** | <18 | 29 | . | . | 1 | 3.4 | . | . | . | . | . | . |
| | | 18-19 | 30 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 199 | 1 | 0.5 | 5 | 2.5 | 2 | 1.0 | 3 | 1.5 | 1 | 0.5 |
| | | 25-29 | 344 | 2 | 0.6 | 10 | 2.9 | 4 | 1.2 | 9 | 2.6 | 3 | 0.9 |
| | | 30-34 | 374 | 5 | 1.3 | 10 | 2.7 | 9 | 2.4 | 7 | 1.9 | 7 | 1.9 |
| | | 35+ | 283 | 6 | 2.1 | 9 | 3.2 | 6 | 2.1 | 8 | 2.8 | 6 | 2.1 |
| | **Years since diagnosis** | 5-9 | 132 | 1 | 0.8 | 2 | 1.5 | . | . | 1 | 0.8 | . | . |
| | | 10-14 | 397 | 3 | 0.8 | 15 | 3.8 | 5 | 1.3 | 8 | 2.0 | 5 | 1.3 |
| | | 15-19 | 423 | 3 | 0.7 | 10 | 2.4 | 7 | 1.7 | 9 | 2.1 | 5 | 1.2 |
| | | 20+ | 307 | 7 | 2.3 | 8 | 2.6 | 9 | 2.9 | 9 | 2.9 | 7 | 2.3 |
| | **Age at diagnosis** | 1-4 | 25 | 1 | 4.2 | 1 | 4.2 | 1 | 4.2 | . | . | . | . |
| | | 5-9 | 168 | . | . | 3 | 1.8 | 1 | 0.6 | 3 | 1.8 | 1 | 0.6 |
| | | 10-14 | 534 | 7 | 1.3 | 17 | 3.2 | 11 | 2.1 | 11 | 2.1 | 9 | 1.7 |
| | | 15-20 | 532 | 6 | 1.1 | 14 | 2.6 | 8 | 1.5 | 13 | 2.4 | 7 | 1.3 |
| | **Treatment** | Surgery only | 86 | 2 | 2.3 | . | . | 1 | 1.2 | 2 | 2.3 | 1 | 1.2 |
| | | Chemotherapy, no radiation | 957 | 12 | 1.3 | 30 | 3.2 | 18 | 1.9 | 23 | 2.4 | 15 | 1.6 |
| | | Radiation, no chemotherapy | 10 | . | . | 1 | 10.0 | 1 | 10.0 | 1 | 10.0 | . | . |
| | | Chemotherapy and radiation | 83 | . | . | 1 | 1.2 | . | . | . | . | . | . |
| | | Unknown | 123 | . | . | 3 | 2.4 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 |
| **Males** | **All cases** | | **648** | **6** | **0.9** | **7** | **1.1** | **6** | **0.9** | **8** | **1.2** | **4** | **0.6** |
| | **Age at baseline** | <18 | 20 | . | . | 1 | 5.0 | . | . | . | . | . | . |
| | | 18-19 | 12 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 95 | . | . | 1 | 1.1 | 1 | 1.1 | 1 | 1.1 | . | . |
| | | 25-29 | 183 | 2 | 1.1 | 3 | 1.6 | 2 | 1.1 | 3 | 1.7 | . | . |
| | | 30-34 | 179 | 2 | 1.1 | 1 | 0.6 | 1 | 0.6 | 1 | 0.6 | 3 | 1.7 |
| | | 35+ | 159 | 2 | 1.3 | 1 | 0.6 | 2 | 1.3 | 3 | 1.9 | 1 | 0.6 |
| | **Years since diagnosis** | 5-9 | 74 | . | . | 1 | 1.4 | . | . | . | . | . | . |
| | | 10-14 | 209 | 3 | 1.4 | 4 | 1.9 | 3 | 1.4 | 2 | 1.0 | 1 | 0.5 |
| | | 15-19 | 211 | . | . | 2 | 0.9 | . | . | 3 | 1.4 | 2 | 1.0 |
| | | 20+ | 154 | 3 | 2.0 | . | . | 3 | 1.9 | 3 | 1.9 | 1 | 0.6 |
| | **Age at diagnosis** | 1-4 | 14 | 1 | 7.1 | 1 | 7.1 | 1 | 7.1 | . | . | . | . |
| | | 5-9 | 84 | . | . | . | . | . | . | 1 | 1.2 | 1 | 1.2 |
| | | 10-14 | 246 | . | . | 3 | 1.2 | 1 | 0.4 | 3 | 1.2 | . | . |
| | | 15-20 | 304 | 5 | 1.7 | 3 | 1.0 | 4 | 1.3 | 4 | 1.3 | 3 | 1.0 |
| | **Treatment** | Surgery only | 30 | 2 | 6.7 | . | . | 1 | 3.3 | 2 | 6.7 | . | . |
| | | Chemotherapy, no radiation | 489 | 4 | 0.8 | 5 | 1.0 | 4 | 0.8 | 5 | 1.0 | 4 | 0.8 |
| | | Radiation, no chemotherapy | 6 | . | . | 1 | 16.7 | 1 | 16.7 | 1 | 16.7 | . | . |
| | | Chemotherapy and radiation | 44 | . | . | . | . | . | . | . | . | . | . |
| | | Unknown | 79 | . | . | 1 | 1.3 | . | . | . | . | . | . |
| **Females** | **All cases** | | **611** | **8** | **1.3** | **28** | **4.6** | **15** | **2.5** | **19** | **3.1** | **13** | **2.1** |
| | **Age at baseline** | <18 | 9 | . | . | . | . | . | . | . | . | . | . |
| | | 18-19 | 18 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 104 | 1 | 1.0 | 4 | 3.9 | 1 | 1.0 | 2 | 1.9 | 1 | 1.0 |
| | | 25-29 | 161 | . | . | 7 | 4.4 | 2 | 1.3 | 6 | 3.8 | 3 | 1.9 |
| | | 30-34 | 195 | 3 | 1.5 | 9 | 4.7 | 8 | 4.1 | 6 | 3.1 | 4 | 2.1 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| **Both sexes** | **All cases** | | **1259** | **15** | **1.2** | **13** | **1.0** | **7** | **0.6** | **67** | **5.4** | **154** | **12.6** |
| | **Age at baseline** | <18 | 29 | . | . | 1 | 3.4 | . | . | 2 | 6.9 | 4 | 13.8 |
| | | 18-19 | 30 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 199 | 2 | 1.0 | . | . | 2 | 1.0 | 14 | 7.0 | 22 | 11.5 |
| | | 25-29 | 344 | 1 | 0.3 | 3 | 0.9 | 2 | 0.6 | 16 | 4.7 | 38 | 11.4 |
| | | 30-34 | 374 | 6 | 1.6 | 6 | 1.6 | 1 | 0.3 | 22 | 5.9 | 52 | 14.3 |
| | | 35+ | 283 | 6 | 2.1 | 3 | 1.1 | 2 | 0.7 | 13 | 4.6 | 38 | 13.6 |
| | **Years since diagnosis** | 5-9 | 132 | 1 | 0.8 | 1 | 0.8 | . | . | 6 | 4.5 | 9 | 7.3 |
| | | 10-14 | 397 | 3 | 0.8 | 3 | 0.8 | 2 | 0.5 | 20 | 5.1 | 47 | 12.1 |
| | | 15-19 | 423 | 6 | 1.4 | 5 | 1.2 | 3 | 0.7 | 23 | 5.5 | 53 | 12.8 |
| | | 20+ | 307 | 5 | 1.6 | 4 | 1.3 | 2 | 0.7 | 18 | 5.9 | 45 | 15.1 |
| | **Age at diagnosis** | 1-4 | 25 | . | . | . | . | 1 | 4.2 | 1 | 4.2 | 3 | 12.5 |
| | | 5-9 | 168 | 1 | 0.6 | 1 | 0.6 | 1 | 0.6 | 10 | 6.0 | 17 | 10.3 |
| | | 10-14 | 534 | 9 | 1.7 | 7 | 1.3 | 3 | 0.6 | 30 | 5.6 | 70 | 13.5 |
| | | 15-20 | 532 | 5 | 1.0 | 5 | 0.9 | 2 | 0.4 | 26 | 4.9 | 64 | 12.3 |
| | **Treatment** | Surgery only | 86 | . | . | 3 | 3.5 | . | . | 2 | 2.3 | 7 | 8.4 |
| | | Chemotherapy, no radiation | 957 | 15 | 1.6 | 9 | 0.9 | 5 | 0.5 | 58 | 6.1 | 131 | 14.1 |
| | | Radiation, no chemotherapy | 10 | . | . | . | . | . | . | . | . | 2 | 20.0 |
| | | Chemotherapy and radiation | 83 | . | . | 1 | 1.2 | 1 | 1.2 | 4 | 4.8 | 5 | 6.2 |
| | | Unknown | 123 | . | . | . | . | 1 | 0.8 | 3 | 2.4 | 9 | 7.3 |
| **Males** | **All cases** | | **648** | **4** | **0.6** | **5** | **0.8** | **4** | **0.6** | **23** | **3.6** | **53** | **8.4** |
| | **Age at baseline** | <18 | 20 | . | . | 1 | 5.0 | . | . | 1 | 5.0 | 3 | 15.0 |
| | | 18-19 | 12 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 95 | . | . | . | . | 1 | 1.1 | 4 | 4.2 | 7 | 7.8 |
| | | 25-29 | 183 | . | . | . | . | 1 | 0.6 | 6 | 3.3 | 16 | 9.0 |
| | | 30-34 | 179 | 2 | 1.1 | 2 | 1.1 | 1 | 0.6 | 7 | 4.0 | 13 | 7.4 |
| | | 35+ | 159 | 2 | 1.3 | 2 | 1.3 | 1 | 0.6 | 5 | 3.1 | 14 | 8.8 |
| | **Years since diagnosis** | 5-9 | 74 | . | . | 1 | 1.4 | . | . | 2 | 2.7 | 4 | 5.9 |
| | | 10-14 | 209 | . | . | . | . | 1 | 0.5 | 9 | 4.3 | 19 | 9.4 |
| | | 15-19 | 211 | 3 | 1.4 | 2 | 0.9 | 3 | 1.4 | 6 | 2.8 | 17 | 8.2 |
| | | 20+ | 154 | 1 | 0.6 | 2 | 1.3 | . | . | 6 | 3.9 | 13 | 8.5 |
| | **Age at diagnosis** | 1-4 | 14 | . | . | . | . | . | . | . | . | 2 | 14.3 |
| | | 5-9 | 84 | 1 | 1.2 | . | . | 1 | 1.2 | 3 | 3.6 | 6 | 7.3 |
| | | 10-14 | 246 | 1 | 0.4 | 3 | 1.2 | 1 | 0.4 | 8 | 3.3 | 16 | 6.7 |
| | | 15-20 | 304 | 2 | 0.7 | 2 | 0.7 | 2 | 0.7 | 12 | 4.0 | 29 | 9.8 |
| | **Treatment** | Surgery only | 30 | . | . | 2 | 6.7 | . | . | 2 | 6.7 | 6 | 20.0 |
| | | Chemotherapy, no radiation | 489 | 4 | 0.8 | 2 | 0.4 | 3 | 0.6 | 19 | 3.9 | 41 | 8.6 |
| | | Radiation, no chemotherapy | 6 | . | . | . | . | . | . | . | . | 2 | 33.3 |
| | | Chemotherapy and radiation | 44 | . | . | 1 | 2.3 | . | . | . | . | 1 | 2.4 |
| | | Unknown | 79 | . | . | . | . | 1 | 1.3 | 2 | 2.5 | 3 | 3.8 |
| **Females** | **All cases** | | **611** | **11** | **1.8** | **8** | **1.3** | **3** | **0.5** | **44** | **7.3** | **101** | **17.0** |
| | **Age at baseline** | <18 | 9 | . | . | . | . | . | . | 1 | 11.1 | 1 | 11.1 |
| | | 18-19 | 18 | . | . | . | . | . | . | . | . | . | . |
| | | 20-24 | 104 | 2 | 2.0 | . | . | 1 | 1.0 | 10 | 9.6 | 15 | 14.7 |
| | | 25-29 | 161 | 1 | 0.6 | 3 | 1.9 | 1 | 0.6 | 10 | 6.3 | 22 | 14.1 |
| | | 30-34 | 195 | 4 | 2.1 | 4 | 2.1 | . | . | 15 | 7.8 | 39 | 20.7 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Overactive thyroid (E.1/E.1) [1] | | Underactive thyroid (E.2/E.2) [1] | | Thyroid nodules (E.3/E.3) [1] | | Thyroid enlargement (E.4/E.4) [1] | | Diabetes-diet (E.5/E.5) [1] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 124 | 4 | 3.2 | 8 | 6.5 | 4 | 3.2 | 5 | 4.0 | 5 | 4.1 |
| | **Years since diagnosis** | 5-9 | 58 | 1 | 1.7 | 1 | 1.7 | . | . | 1 | 1.7 | . | . |
| | | 10-14 | 188 | . | . | 11 | 5.9 | 2 | 1.1 | 6 | 3.2 | 4 | 2.1 |
| | | 15-19 | 212 | 3 | 1.4 | 8 | 3.8 | 7 | 3.3 | 6 | 2.9 | 3 | 1.4 |
| | | 20+ | 153 | 4 | 2.6 | 8 | 5.3 | 6 | 3.9 | 6 | 3.9 | 6 | 4.0 |
| | **Age at diagnosis** | 1-4 | 11 | . | . | . | . | . | . | . | . | . | . |
| | | 5-9 | 84 | . | . | 3 | 3.6 | 1 | 1.2 | 2 | 2.4 | . | . |
| | | 10-14 | 288 | 7 | 2.4 | 14 | 4.9 | 10 | 3.5 | 8 | 2.8 | 9 | 3.1 |
| | | 15-20 | 228 | 1 | 0.4 | 11 | 4.8 | 4 | 1.8 | 9 | 4.0 | 4 | 1.8 |
| | **Treatment** | Surgery only | 56 | . | . | . | . | . | . | . | . | 1 | 1.8 |
| | | Chemotherapy, no radiation | 468 | 8 | 1.7 | 25 | 5.4 | 14 | 3.0 | 18 | 3.9 | 11 | 2.4 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 39 | . | . | 1 | 2.6 | . | . | . | . | . | . |
| | | Unknown | 44 | . | . | 2 | 4.5 | 1 | 2.3 | 1 | 2.3 | 1 | 2.3 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*

| | | | | Diabetes-pills (E.6/E.6) [1] | | Diabetes-insulin (E.7/E.7) [1] | | Growth hormone deficiency (E.8/E.8) [1] | | Osteoporosis (E.10/E.10) [1] | | Any hormonal problem [2] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | All cases | N | % | N | % | N | % | N | % | N | % |
| | | 35+ | 124 | 4 | 3.2 | 1 | 0.8 | 1 | 0.8 | 8 | 6.5 | 24 | 19.8 |
| | **Years since diagnosis** | 5-9 | 58 | 1 | 1.8 | . | . | . | . | 4 | 6.9 | 5 | 8.9 |
| | | 10-14 | 188 | 3 | 1.6 | 3 | 1.6 | 1 | 0.5 | 11 | 5.9 | 28 | 15.1 |
| | | 15-19 | 212 | 3 | 1.4 | 3 | 1.4 | . | . | 17 | 8.1 | 36 | 17.4 |
| | | 20+ | 153 | 4 | 2.6 | 2 | 1.3 | 2 | 1.4 | 12 | 7.9 | 32 | 21.9 |
| | **Age at diagnosis** | 1-4 | 11 | . | . | . | . | 1 | 10.0 | 1 | 10.0 | 1 | 10.0 |
| | | 5-9 | 84 | . | . | 1 | 1.2 | . | . | 7 | 8.4 | 11 | 13.3 |
| | | 10-14 | 288 | 8 | 2.8 | 4 | 1.4 | 2 | 0.7 | 22 | 7.7 | 54 | 19.4 |
| | | 15-20 | 228 | 3 | 1.3 | 3 | 1.3 | . | . | 14 | 6.2 | 35 | 15.8 |
| | **Treatment** | Surgery only | 56 | . | . | 1 | 1.8 | . | . | . | . | 1 | 1.9 |
| | | Chemotherapy, no radiation | 468 | 11 | 2.4 | 7 | 1.5 | 2 | 0.4 | 39 | 8.4 | 90 | 19.8 |
| | | Radiation, no chemotherapy | 4 | . | . | . | . | . | . | . | . | . | . |
| | | Chemotherapy and radiation | 39 | . | . | . | . | 1 | 2.6 | 4 | 10.3 | 4 | 10.3 |
| | | Unknown | 44 | . | . | . | . | . | . | 1 | 2.3 | 6 | 13.6 |

*CCSS data from March 2026 data freeze*
*[1] N and % based on response of 'Yes'*
*[2] 'Any hormonal problem' is based on a response of 'Yes' to one or more of the listed hormonal problems*
*n=10 participants with no baseline information are not included*